Quarterly Report

0001553350-20-000420.txt : 20200512 0001553350-20-000420.hdr.sgml : 20200512 20200512123950 ACCESSION NUMBER: 0001553350-20-000420 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 54 CONFORMED PERIOD OF REPORT: 20200331 FILED AS OF DATE: 20200512 DATE AS OF CHANGE: 20200512 FILER: COMPANY DATA: COMPANY CONFORMED NAME: EVOLUTIONARY GENOMICS, INC. CENTRAL INDEX KEY: 0000884363 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 264369698 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-54129 FILM NUMBER: 20868249 BUSINESS ADDRESS: STREET 1: 1026 ANACONDA DRIVE CITY: CASTLE ROCK STATE: CO ZIP: 80108 BUSINESS PHONE: (720) 900-8666 MAIL ADDRESS: STREET 1: 1026 ANACONDA DRIVE CITY: CASTLE ROCK STATE: CO ZIP: 80108 FORMER COMPANY: FORMER CONFORMED NAME: Fona, Inc. DATE OF NAME CHANGE: 20100907 FORMER COMPANY: FORMER CONFORMED NAME: PHONE A HOME CORP DATE OF NAME CHANGE: 19930708 FORMER COMPANY: FORMER CONFORMED NAME: FONAHOME CORP DATE OF NAME CHANGE: 19930328 10-Q 1 fnam_10q.htm QUARTERLY REPORT Quarterly Report

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

———————

FORM 10-Q

———————

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2020

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM __________ TO __________

Commission File Number: 000-54129

——————————

EVOLUTIONARY GENOMICS, INC.

(Exact name of registrant as specified in its charter)


Nevada		26-4369698
(State of other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

1026 Anaconda Drive, Castle Rock, CO		80108
(Address of principal executive offices)		(Zip Code)

(720) 900-8666

(Registrant's telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
N/A	N/A	N/A

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes þ No ¨

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes þ No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.


Large accelerated filer ¨		Accelerated filer ¨
Non-accelerated filer þ		Smaller reporting company þ
		Emerging growth company ¨

If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Indicate by checkmark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No þ

As of March 31, 2020, the Registrant had 5,881,898 shares of common stock, $.001 par value, 577,063 shares of Series A-1 preferred stock, $.001 par value and 102,860 shares of Series A-2 preferred stock, $.001 par value outstanding. The Registrant’s common stock trades on the OTC Markets under the trading symbol “FNAM”.

EVOLUTIONARY GENOMICS, INC.

INDEX


	Page Number

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements	1

Condensed and Consolidated Balance Sheets as of March 31, 2020 (unaudited) and December 31, 2019	2

Condensed and Consolidated Statements of Operations, Three Months ended March 31, 2020 and 2019 (unaudited)	3

Condensed and Consolidated Statements of Stockholders’ Equity for the Quarterly Periods Ended March 31, 2020 and 2019 (unaudited)	4

Condensed and Consolidated Statements of Cash Flows, Three Months ended March 31, 2020 and 2019 (unaudited)	5

Notes to Condensed and Consolidated Financial Statements	6

Item 2. Management's Discussion and Analysis of Financial Conditions and Results of Operations	14

Item 3. Quantitative and Qualitative Disclosures about Market Risk	20

Item 4. Controls and Procedures	20

PART II. OTHER INFORMATION

Item 1. Legal Proceedings	21

Item 1A. Risk Factors	21

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds	21

Item 3. Defaults Upon Senior Securities	21

Item 4. Mine Safety Disclosures.	21

Item 5. Other Information	21

Item 6. Exhibits	21

PART I. FINANCIAL STATEMENTS

ITEM 1.

FINANCIAL STATEMENTS

The accompanying financial statements have been prepared by Evolutionary Genomics, Inc., without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (SEC). In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position of the Company as of March 31, 2020 and for the quarterly periods ended March 31, 2020 and 2019 have been made. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. It is suggested that these condensed and consolidated financial statements be read in conjunction with the financial statements and notes thereto included in the Company’s December 31, 2019 audited financial statements. The results of operations for these interim periods are not necessarily indicative of the results for the entire year.

Evolutionary Genomics, Inc. and Subsidiary

Condensed and Consolidated Balance Sheets


	March 31,			December 31,
	2020			2019
	(unaudited)
ASSETS

Current assets
Cash	$	10,653		$	45,441
Accounts receivable		—			6,845
Investments		29,694			41,694
Prepaid expenses		15,270			24,183
Total current assets		55,617			118,163

Non-current assets
Property and equipment, net		79,353			88,882
Intangible assets, net		4,034,941			4,035,592
Total non-current assets		4,114,294			4,124,474
Total assets	$	4,169,911		$	4,242,637

LIABILITIES AND STOCKHOLDERS' (DEFICIT) EQUITY

Current liabilities
Accounts payable and accrued expenses	$	133,575		$	19,415
Total current liabilities		133,575			19,415

Long-term liabilities
Deferred tax liability		987,353			987,353
Total liabilities		1,120,928			1,006,768
Commitments and contingencies
Preferred Stock subject to possible redemption, $0.001 par value,
20,000,000 authorized at March 31, 2020 and December 31, 2019
Series A-1 Convertible Preferred Stock, $0.001 par value; 600,000
shares authorized, 577,063 shares issued and outstanding at
March 31, 2020 and December 31, 2019; liquidation
preference at March 31, 2020 of $4,013,819		3,029,579			3,029,579
Series A-2 Convertible Preferred Stock, $0.001 par value; 200,000
shares authorized, 102,860 shares issued and outstanding at
March 31, 202 and December 31, 2019; liquidation
preference at March 31, 2020 of $577,827		540,015			540,015
Total preferred stock subject to possible redemption		3,569,594			3,569,594
Stockholders' equity
Preferred Stock		1,022,052			950,661
Common Stock, $0.001 par value; 780,000,000 shares authorized,
5,881,898 shares issued and outstanding at March 31, 2020 and December 31, 2019		5,882			5,882
Additional paid-in capital		12,064,940			12,081,401
Accumulated deficit		(13,613,485	)		(13,371,669	)
Total stockholders' (deficit) equity		(520,611	)		(333,725	)
Total liabilities and stockholders' (deficit) equity	$	4,169,911		$	4,242,637

The accompanying notes are an integral part of the consolidated financial statements.

Evolutionary Genomics, Inc. and Subsidiary

Condensed and Consolidated Statements of Operations

For the Three Months ended March 31, 2020 and 2019

(unaudited)


	2020			2019

Grant revenue	$	12,500		$	32,366

Operating expenses
Research and development		93,222			131,684
Salaries and benefits		92,430			54,779
General and administrative		56,665			58,254
Total operating expenses		242,317			244,717

Operating (loss)		(229,817	)		(212,351	)

Other income (expenses):
Investment income		1			11
Unrealized gain (loss) on investments		(12,000	)		11,943
Total other income (expenses)		(11,999	)		11,954
Loss before income taxes		(241,816	)		(200,397	)
Income taxes		—			—
Net loss		(241,816	)		(200,397	)
Preferred stock dividend		(71,391	)		(60,591	)
Net loss attributable to common stockholders	$	(313,207	)	$	(260,988	)

Net loss per common share, basic and diluted	$	(0.05	)	$	(0.04	)

Weighted average common shares outstanding, basic and diluted		5,881,898			5,881,898

The accompanying notes are an integral part of the consolidated financial statements.

Evolutionary Genomics, Inc. and Subsidiary

Condensed and Consolidated Statement of Stockholders' Equity


	Three Months Ended March 31, 2020
	Common Stock				Preferred		Additional			Accumulated			Stockholders'
	Shares		Amount		Dividend		Paid-In Capital			Deficit			(Deficit) Equity

Balance, December 31, 2019		5,881,898	$	5,882	$	950,661	$	12,081,401		$	(13,371,669	)	$	(333,725	)
Stock compensation		—		—		—		54,930			—			54,930
Preferred stock dividends		—		—		71,391		(71,391	)		—			—
Net loss		—		—		—		—			(241,816	)		(241,816	)
Balance, March 31, 2020		5,881,898	$	5,882	$	1,022,052	$	12,064,940		$	(13,613,485	)	$	(520,611	)


	Three Months Ended March 31, 2019
	Common Stock				Preferred		Additional			Accumulated			Stockholders'
	Shares		Amount		Dividend		Paid-In Capital			Deficit			Equity

Balance, December 31, 2018		5,881,898	$	5,882	$	681,282	$	12,294,952		$	(12,578,529	)	$	403,587
Stock compensation		—		—		—		17,278			—			17,278
Preferred stock dividends		—		—		60,591		(60,591	)		—			—
Net loss		—		—		—		—			(200,397	)		(200,397	)
Balance, March 31, 2019		5,881,898	$	5,882	$	741,873	$	12,251,639		$	(12,778,926	)	$	220,468

The accompanying notes are an integral part of the consolidated financial statements.

Evolutionary Genomics, Inc. and Subsidiary

Condensed and Consolidated Statements of Cash Flows

For the Three Months ended March 31, 2020 and 2019

(unaudited)


	2020			2019
Cash flows from operating activities:
Net loss	$	(241,816	)	$	(200,397	)
Adjustments to reconcile net loss to net
cash flows from operating activities
Depreciation and amortization		10,180			10,180
Stock-based compensation		54,930			17,278
Unrealized (gain) loss on investments		12,000			(11,943	)
Deferred income taxes		—			—
Changes in operating assets and liabilities:
Accounts receivable		6,845			8,073
Prepaid expenses		8,913			(3,644	)
Accounts payable and accrued expenses		114,160			56,374
Cash flows from operating activities		(34,788	)		(124,079	)

Cash flows from investing activities:
Cash flows from investing activities		—			—

Cash flows from financing activities:
Proceeds from issuance of preferred stock		—			—
Cash flows from financing activities		—			—

Net change in cash		(34,788	)		(124,079	)

Cash, beginning of period		45,441			131,406

Cash, end of period	$	10,653		$	7,327

Supplemental cash flow information
Preferred stock dividend accrual	$	71,391		$	60,591

The accompanying notes are an integral part of the consolidated financial statements.

EVOLUTIONARY GENOMICS, INC. AND SUBSIDIARY

NOTES TO CONDENSED AND CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2020 AND 2019 (Unaudited)

Note 1: Business Activity

Evolutionary Genomics, Inc. (the “Company,” “We,” or “Our”) has developed a technology platform, the Adapted Traits Platform (“ATP”), to identify commercially valuable genes that control important traits in animals and plants. We are using the ATP to identify genes to improve crop plant traits such as yield, sugar content, biomass, drought tolerance, and pest/disease resistance. Our platform identifies key genes that have changed successfully to impart new or improved traits.

The Company performs its research on behalf of governmental organizations, non-profit foundations, and commercial entities and receives revenue from grants and commercial research contracts. These grants/contracts contain fixed-fee arrangements and may also have licensing provisions upon effective commercialization of research results. Successful commercialization may take many years to produce license royalty payments. Ownership of intellectual property developed in research projects varies from the Company retaining no rights to intellectual property, to joint ownership, to the Company retaining all rights.

During 2014, the Company purchased 75.16% of the outstanding stock of Fona, Inc., (“Fona”) a public shell company. Since Fona was a public shell company which did not constitute a business and the purchase was done in contemplation of a reverse merger, the Company accounted for the payment as a distribution to Fona shareholders. The Company also entered into an Agreement and Plan of Merger (the “Merger”), which was consummated on October 19, 2015. As a result of the Merger, Evolutionary Genomics, Inc. became a wholly owned subsidiary of Fona. For accounting purposes, the merger was treated as a reverse acquisition with Evolutionary Genomics, Inc. as the acquirer and Fona as the acquired party. Subsequent to the Merger, Fona was renamed Evolutionary Genomics, Inc. and our subsidiary was renamed from Evolutionary Genomics, Inc. to EG Crop Science, Inc.

Note 2: Summary of Significant Accounting Policies

Principals of Consolidation: These condensed and consolidated financial statements include the accounts of Evolutionary Genomics, Inc. and its wholly owned subsidiary. All material intercompany transactions and balances have been eliminated.

Use of Estimates: The preparation of condensed and consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed and consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ materially from those estimates.

Cash: The Company considers all highly liquid investments purchased with an original or remaining maturity of three months or less when purchased to be cash.

Investments: The Company’s short-term investments are comprised of equity securities and are carried at their fair value based on the quoted market prices of the securities at March 31, 2020 and December 31, 2019. Net realized and unrealized gains and losses on investments are included in net earnings. For purposes of determining realized gains and losses, the cost of securities sold is based on specific identification.

Property and Equipment: Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is provided for by the straight-line method over three- to seven-year estimated useful lives of software, furniture and fixtures and equipment. Maintenance and repairs are expensed as incurred; major renewals and betterments that extend the useful lives of property and equipment are capitalized. When property and equipment are sold or retired, the related cost and accumulated depreciation are removed from the accounts and any gain or loss is recognized.

EVOLUTIONARY GENOMICS, INC. AND SUBSIDIARY

NOTES TO CONDENSED AND CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2020 AND 2019 (Unaudited)

Long-Lived Assets: The long-lived assets held and used by the Company are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. In the event that facts and circumstances indicate that the cost of any long-lived assets may be impaired, an evaluation of recoverability is performed. An impairment is considered to exist if the total estimated undiscounted cash flows are less than the carrying amount of the asset. An impairment loss is measured and recorded to the extent that the carrying amount of the asset exceeds its estimated fair value. No asset impairment was recorded during the three months ended March 31, 2020 and 2019.

Intangible Assets: Intangible assets include acquired research in progress and patents on the Company’s core technology for gene identification. Patents are amortized over their expected useful life of 20 years using the straight-line method. Acquired research in progress is an indefinite-lived intangible asset until the development is complete at which time the useful life of the asset will be assigned. Costs incurred to renew intangible assets are expensed in the period incurred, while costs incurred to extend the lives of patents are capitalized and amortized over the remaining useful life of the asset. Intangible assets held and used by the Company are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. In the event that facts and circumstances indicate that the cost of any intangible assets may be impaired, an evaluation of recoverability is performed. An impairment is considered to exist if the total estimated undiscounted cash flows are less than the carrying amount of the asset. No impairment was recorded during the three months ended March 31, 2020 and 2019. Realization of this asset is dependent upon the successful completion of the Company’s research and development efforts.

Revenue Recognition: In May 2014, the FASB issued new guidance related to revenue recognition, which outlines a comprehensive revenue recognition model and supersedes most current revenue recognition guidance. The new guidance requires a company to recognize revenue as control of goods or services transfers to a customer at an amount that reflects the expected consideration to be received in exchange for those goods or services. It defines a five-step approach for recognizing revenue, which may require a company to use more judgment and make more estimates than under the current guidance. The Company adopted this standard on January 1, 2018 using the modified-retrospective method and it did not have a material impact on the condensed and consolidated financial statements.

Grant revenue, which is not within the scope of Topic 606, consists of funding under cost reimbursement programs primarily from federal and non-profit foundation sources for qualified research and development activities performed by us, and as such, are not based on estimates that are susceptible to change. Such amounts are invoiced and recorded as revenue as grant-funded activities are performed.

Income Taxes: Deferred tax assets and liabilities are recognized for the expected tax consequences of temporary differences between the tax bases of assets and liabilities and their reported amounts. Management regularly assesses the likelihood that deferred tax assets will be recovered from future taxable income, and to the extent management believes that it is more likely than not that a deferred tax asset will not be realized, a valuation allowance is established. When a valuation allowance is established, increased or decreased, an income tax charge or benefit is included in the condensed and consolidated financial statements and net deferred tax assets are adjusted accordingly. As of March 31, 2020 and December 31, 2019, a full valuation allowance has been established on the net deferred tax asset.

Under the Income Tax topic of the ASC, in order to recognize an uncertain tax benefit, the taxpayer must be more likely than not of sustaining the position, and the measurement of the benefit is calculated as the largest amount that is more than 50% likely to be realized upon resolution of the benefit. The Company has no accruals for uncertain tax benefits.

Stock-Based Compensation: The Company accounts for stock option awards in accordance with ASC 718. The estimated grant-date fair value of stock-based awards is expensed over the requisite service period, which is typically equivalent to the vesting term of the award.

The Company’s accounting policy for equity instruments issued to consultants and vendors in exchange for goods and services received follows the provisions of ASC Topic 718. Accordingly, the measurement date for the fair value of the equity instruments issued is determined at the earlier of (i) the date at which a commitment for performance by the consultant or vendor is reached or (ii) the date at which the consultant or vendor’s performance is complete. In the case of equity instruments issued to consultants, the fair value of the equity instrument is recognized over the term of the consulting agreement.

EVOLUTIONARY GENOMICS, INC. AND SUBSIDIARY

NOTES TO CONDENSED AND CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2020 AND 2019 (Unaudited)

Research and Development: Research and development costs are expensed as incurred. In instances where we enter into agreements with third parties for research and development activities, we may prepay for services at the initiation of the contract. We record the prepayment as a prepaid asset and amortize the asset into research and development expense over the period of time the contracted research and development services are performed.

Net Loss Per Common Share: Basic net (loss) income per common share excludes any dilutive effects of equity instruments. We compute basic net (loss) income per common share using the weighted average number of common shares outstanding during the period. We compute diluted net (loss) income per common share using the weighted average number of common shares and common stock equivalents outstanding during the period. For the three months ended March 31, 2020, common stock equivalents including 679,923 shares of convertible preferred stock, options for 1,081,667 shares of common stock and warrants for 110,856 shares of common stock were excluded because their effect was anti-dilutive. For the three months ended March 31, 2019, common stock equivalents including 577,063 shares of convertible preferred stock, options for 566,667 shares of common stock and warrants for 110,884 shares of common stock were excluded because their effect was anti-dilutive.

Subsequent Events: The Company has evaluated all subsequent events through the date of this filing. On April 17, 2020, the Company received $71,268 in funding from the SBA under their Paycheck Protection Program and we expect that most, if not all of this funding will be forgiven.

Note 3: New Accounting Standards

Recently Issued Accounting Standards

In June 2016, the FASB issued ASU 2016-13, “Financial Instruments – Credit Losses: Measurement of Credit Losses on Financial Instruments,” which requires entities to estimate all expected credit losses for certain types of financial instruments, including trade receivables, held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. The updated guidance also expands the disclosure requirements to enable users of financial statements to understand the entity’s assumptions, models and methods for estimating expected credit losses over the entire contractual term of the instrument from the date of initial recognition of that instrument. This guidance is effective for fiscal years beginning after December 15, 2020, including interim periods within that reporting period and did not have an impact on the Company’s condensed and consolidated financial statements.

Note 4: Fair Value Measurements

The Company complies with the provisions of ASC 820, in measuring fair value and in disclosing fair value measurements at the measurement date. ASC 820 defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements required under other accounting pronouncements. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value measurements also reflect the assumptions market participants would use in pricing an asset or liability based on the best information available. Assumptions include the risks inherent in a particular valuation technique (such as a pricing model) and/or the risks inherent in the inputs to the model.

ASC 820 provides three levels of the fair value hierarchy as described below:

Level 1 Inputs – Quoted prices (unadjusted) in active markets for identical assets or liabilities.

Level 2 Inputs – Observable market-based inputs, other than quoted prices in active markets for identical assets or liabilities.

Level 3 Inputs – Unobservable inputs that are supported by little or no market activity.

When determining the fair value measurements for assets or liabilities required or permitted to be recorded at and/or marked to fair value, the Company considers the principal or most advantageous market in which it would transact and considers assumptions that market participants would use when pricing the asset or liability. When possible, the Company looks to active and observable markets to price identical assets. When identical assets are not traded in active markets, the Company looks to market observable data for similar assets.

EVOLUTIONARY GENOMICS, INC. AND SUBSIDIARY

NOTES TO CONDENSED AND CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2020 AND 2019 (Unaudited)

The following table presents the Company’s financial assets that were accounted for at fair value on a recurring basis as of March 31, 2020 and December 31, 2019, by level within the fair value hierarchy:


	Total		Quoted Prices in Active Markets for Identical Items (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Balance at December 31, 2019
Investments	$	41,694	$	41,694	$	—	$	—
	$	41,694	$	41,694	$	—	$	—
Balance at March 31, 2020
Investments	$	29,694	$	29,694	$	—	$	—
	$	29,694	$	29,694	$	—	$	—

For the Company’s Level 1 measures, which represent common stock in publicly traded companies, fair value is based on the last closing trade occurring on, or closest to, the respective period end date. The carrying value of financial instruments, including cash, receivables, accounts payable and accrued expenses, approximates their fair value at March 31, 2020 and December 31, 2019 due to the relatively short-term nature of these instruments.

Note 5: Property and Equipment

Property and equipment is comprised of the following:


	March 31,			December 31,
	2020			2019
Equipment	$	432,499		$	432,499
Software		63,179			63,179
Furniture and fixtures		7,987			7,987
		503,665			503,665
Accumulated depreciation		(424,312	)		(414,783	)
Property and equipment, net	$	79,353		$	88,882

Depreciation expense for the three months ended March 31, 2020 and 2019 was $9,529 and $9,529, respectively.

EVOLUTIONARY GENOMICS, INC. AND SUBSIDIARY

NOTES TO CONDENSED AND CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2020 AND 2019 (Unaudited)

Note 6: Intangible Assets

Intangible assets are comprised of the following:


	March 31,			December 31,
	2020			2019
Acquired research in progress - indefinite lived	$	4,016,596		$	4,016,596
Patents		52,045			52,045
Accumulated amortization		(33,700	)		(33,049	)
Intangible assets, net	$	4,034,941		$	4,035,592

The Company expects to recognize $2,602 of amortization expense related to its patents during each of the next five years and the remaining $5,335 thereafter. Amortization expense for the patents during the three months ended March 31, 2020 and 2019 was $651 and $650, respectively.

In its merger completed on October 19, 2015, the Company acquired research in progress. The value of the acquired research in progress was based upon several factors including, evaluation of other intangible assets, the purchase price, estimated future cash flows, and the amounts expended on the research to date. Acquired research in progress is an indefinite lived intangible asset until the development phase is complete, at which time a useful life of the asset will be determined. The research in progress was the identification and validation of genes to provide pest and disease resistance to plants performed by EG I. The research had been in process since November 2010 and the Company expects to complete the research and place this asset in service in the second half of 2020. Additional costs to complete the research are expected to be approximately $102,000, which will be expensed as incurred. The timing and cost of additional research may vary from these estimates as the success of the research is subject to many factors outside of the Company’s control.

Note 7: Stockholders’ Equity and Warrants

The Amended and Restated Certificate of Incorporation of the Company dated October 19, 2015 authorized the issuance of 800,000,000 shares of all classes of stock including 780,000,000 shares of Common Stock having a par value of $0.001 per share and 20,000,000 shares of Preferred Stock having a par value of $0.001 per share, 600,000 of which were designated as Series A-1 Convertible Preferred Stock (“Series A-1”) and 200,000 of which were designated as Series A-2 Convertible Preferred Stock (“Series A-2”). The Board of Directors, without a vote of the shareholders, is authorized to issue additional shares of Preferred Stock in series and to establish the characteristics thereof.

Liquidation: Upon any liquidation, dissolution or winding-up of the Company, whether voluntary or involuntary, the holders of the Series A-1 and Series A-2 shall be entitled to receive out of the assets of the Company for each share of Series A-1 and Series A-2 an amount equal to its stated value, $5.25 per share as of March 31, 2020 and December 31, 2019, plus any accrued but unpaid dividends before any distribution or payment shall be made to the holders of any other class or series of stock of the Company that ranks junior to the Series A-1 and Series A-2. The holders shall be entitled to convert their shares of Series A-1 and Series A-2 into Common Stock at any time prior to the consummation of a Liquidation. This is considered a contingent redemption feature.

Conversion: The holders of Series A-1 and Series A-2 may convert their shares into shares of Common Stock, at the option of the holder, on a one-share-for-one-share basis and shall be subject to certain adjustments at any time.

EVOLUTIONARY GENOMICS, INC. AND SUBSIDIARY

NOTES TO CONDENSED AND CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2020 AND 2019 (Unaudited)

Optional Redemption; Sinking Fund Account: The Company may elect to redeem some or all of the then outstanding shares of Series A-1, (i) for cash in an amount equal to the liquidation preference per share, $5.25 per share as of December 31, 2019, subject to adjustment and (ii) by issuing one share, subject to adjustment, of Common Stock for each share of Series A-1 and Series A-2 outstanding being redeemed. 50% of all licensing fees received by the Company will be deposited into a separate sinking fund for use in an optional redemption. As of March 31, 2020, no licensing revenue has been received under these provisions and no sinking fund account has been established.

Dividends: The Company shall pay to the holders of the Series A-1 and Series A-2 dividends at the rate of 8% per annum and the Company has accrued these dividends since issuance of the Series A-1 and Series A-2. The dividend amount shall accrue and shall be payable in shares of Common Stock upon the conversion of the Series A-1 and Series A-2, or upon the redemption of the Series A-1 and Series A-2. No dividends shall be paid on any Common Stock of the Company or any capital stock of the Company that ranks junior to the Series A-1 and Series A-2 until dividends of Series A-1 and Series A-2 been paid. As of March 31, 2020, there were $1,022,052 in accrued stock dividends.

Voting: The holders of the Series A-1 and Series A-2 are entitled to vote on all matters submitted to the stockholders for a vote on an as-if-converted to Common Stock basis, with all stockholders voting as a single class.

Warrants: As of March 31, 2020 and December 31, 2019, the Company had outstanding warrants to purchase 110,856 and 110,884 shares, respectively of the Company’s Common Stock. The following table summarizes the status of the Company’s aggregate warrants outstanding:


	Number of Warrants			Weighted Average Exercise Price		Weighted Average Remaining Term(Years)

Balance, January 1, 2019		110,884		$	6.60		1.87
Granted		—			—		—
Exercised		—			—		—
Expired		—			—		—
Balance, December 31, 2019		110,884		$	6.60		0.87
Granted		—			—		—
Exercised		—			—		—
Expired		(28	)		6.60		—
Balance, March 31, 2020		110,856		$	6.60		0.62

Note 8: Stock-Based Compensation

The Company grants stock-based instruments under the 2015 Stock Incentive Plan (“Plan”) for which 1,400,000 shares of the Company’s Common Stock has been reserved. The Plan allows for the issuance of incentive stock options and non-qualified stock options with a maximum contractual term of 10 years. Shares and options that are cancelled are available for reissuance under the Plan. For the three months ended March 31, 2020 and 2019, the Company recorded compensation costs for stock options of $54,930 and $17,278, respectively. Stock options are generally issued with an exercise price at or above the estimated per-share value of the Company’s Common Stock. The Company granted no options during the three months ended March 31, 2020 and 2019.

Management has valued the options at their date of grant utilizing the Black-Scholes option pricing model. As of the issuance of the outstanding options, there was not a public market for the Company’s shares. Accordingly, the Company utilized the value obtained in equity transactions with unrelated parties to estimate the fair value of the Company’s Common Stock on the date of grant. Volatility of the underlying common shares was determined based on the historical volatility for similar companies that are actively traded in the public markets for a term consistent with the expected life of the options. The risk-free interest rate used in the calculations is based on the implied yield available on U.S. Treasury issues with an equivalent term approximating the expected life of the options on the date of the grant. Due to the lack of sufficient historical activity, the expected life of the options was estimated using the formula set forth in Securities and Exchange Commission SAB 107.

EVOLUTIONARY GENOMICS, INC. AND SUBSIDIARY

NOTES TO CONDENSED AND CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2020 AND 2019 (Unaudited)

The following table summarizes the status of the Company’s aggregate stock options granted:


	Number of Options			Weighted Average Exercise Price		Weighted Average Remaining Term(Years)		Total Intrinsic Value

Balance, January 1, 2019		566,667		$	2.33		5.95
Granted		640,000			1.54		9.83
Exercised		—			—		—
Cancelled		(125,000	)		3.00		7.00

Balance, December 31, 2019		1,081,667		$	1.74		7.85

Balance, January 1, 2020		1,081,667		$	1.74		7.85
Granted		—			—		—
Exercised		—			—		—
Cancelled		—			—		—

Balance, March 31, 2020		1,081,667		$	1.74		7.60	$	—

Exercisable at March 31, 2020		508,333		$	1.96		5.83	$	177,334

During the three months ended March 31, 2020 and 2019, options for 0 and 83,334 shares vested, respectively. As of March 31, 2020, there was $570,238 of unrecognized compensation cost related to share-based compensation arrangements that will be recognized over the next three years.

Note 9: Commitments and Contingencies

Officer Indemnification: Under the Company’s organizational documents, the Company’s officers, employees, and directors are indemnified against certain liabilities arising out of the performance of their duties. The Company’s maximum exposure under these arrangements is unknown, as this would involve future claims that may be made against the Company that have not yet occurred. However, based on experience, the Company expects any risk of loss to be remote. The Company also has an insurance policy for its directors and officers to insure them against liabilities arising from their performance in their positions with the Company.

Lease Commitments: The Company leases its operating facility and pays its rent in monthly installments. The lease was renewed in June 2016 for a period of twelve months and monthly rentals for the period of July 1, 2016 through December 31, 2019 are $2,378 per month which continues on a month-to-month basis. There is no minimum lease commitment as of March 31, 2020. Renewals after June 30, 2017 are by mutual agreement. The Company’s rent expense for the three months ended March 31, 2020 and 2019 was $7,134 and $7,134, respectively.

Royalty: Effective March 1, 2012, the Company entered into an Agreement for Contract Services with SmithBucklin Corporation (the “Contractor”) on behalf of the United Soybean Board. The contract includes the payment of certain royalties, as defined in the Agreement.

The Company is obligated to pay royalties to the United Soybean Board of 10% of the sale of products derived from the soybean genes that were the subject of the research performed by the Contractor or from royalties received by the Company from the sale of products by a third party not to exceed 150% of the total amount paid to the Contractor under this Agreement. The Company has recognized to date grant revenue from the contract of $262,400 as of March 31, 2020, thus limiting any future royalties as of March 31, 2020 to a total of $393,600. The Company has not accrued or paid any royalties under the terms of the Agreement as of and during the three months ended March 31, 2020 and 2019 because it has not received any revenue from the sale of products to date.

EVOLUTIONARY GENOMICS, INC. AND SUBSIDIARY

NOTES TO CONDENSED AND CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2020 AND 2019 (Unaudited)

Note 10: Related Parties and Transactions

Steve B. Warnecke: Mr. Warnecke is the Company’s Chief Executive Officer and Chairman of the Board and owns, directly or indirectly, 1,932,088 shares or 29.9% of the Common Stock outstanding as of March 31, 2020.

Note 11: Concentrations

Considerations of Credit Risk: Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and accounts receivable. The Company maintains its cash balances at high-credit, quality financial institutions. The balances, at times, may exceed federally insured limits. The Company routinely monitors the credit quality of its customers.

Note 12: Liquidity and Going Concern

Sources of funding to meet prospective cash requirements include the Company’s existing cash balances and investments. As of March 31, 2020 we had $10,653 in our bank accounts and $29,694 of trading securities. On April 17, 2020, the Company received $71,268 in funding from the SBA under their Paycheck Protection Program and we expect that most, if not all of this funding will be forgiven. This will not be enough to pay for our expenses for the year ending December 31, 2020 without any additional revenue from grants or licensing revenue or additional capital infusions. We are marketing our banana genes in 2020 which may lead to revenue but may not be able to market our soybean genes until the research is finished. We have flexibility to reduce operating costs and also to delay research projects. We will require additional capital to complete our projects. These factors create substantial doubt as to our ability to continue as a going concern. The accompanying condensed and consolidated financial statements do not include any adjustments that may result if the Company is unable to continue as a going concern.

ITEM 2.

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Caution Regarding Forward-Looking Information

This report includes “forward-looking statements” that are subject to risks, uncertainties and other factors. All statements other than statements of historical fact are statements that could be deemed forward-looking statements including continued compliance with government regulations, changing legislation or regulatory environments; any statements of expectation or belief and any statements of assumptions underlying any of the foregoing. These risks, uncertainties and other factors, and the general risks associated with the businesses of the Company described in the reports and other documents filed with the SEC, could cause actual results to differ materially from those referred to in the forward-looking statements. The Company cautions readers not to rely on these forward-looking statements. All forward-looking statements are based on information currently available to the Company and are qualified in their entirety by this cautionary statement. The Company anticipates that subsequent events and developments may cause its views to change. The information contained in this report speaks as of the date hereof and the Company has or undertakes no obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise unless required by law.

Company Overview

Evolutionary Genomics, Inc. (the "registrant" or "Company") was incorporated under the laws of the state of Minnesota in November 1990 under the name Fonahome Corporation. On March 24, 2009, the Company reincorporated in the state of Nevada and merged with its wholly-owned subsidiary, Fona, Inc., adopting the surviving company’s name, Fona, Inc. The capital structure includes total authorized capital stock of 800,000,000 shares, of which 780,000,000 are common stock and 20,000,000 are blank check preferred stock. The preferred stock may be issued from time to time in one or more series with such designations, preferences and relative participating, optional or other special rights and qualifications, limitations or restrictions thereof, as shall be stated in the resolutions adopted by the Corporation’s Board providing for the issuance of such preferred stock or series thereof.

On June 6, 2014, Evolutionary Genomics, Inc., a Delaware corporation merged with Fona, Inc. treated as a reverse acquisition with Evolutionary Genomics, Inc. as the acquirer and Fona as the acquired party. Subsequent to the Merger, Fona, Inc. was renamed Evolutionary Genomics, Inc. and our subsidiary was renamed from Evolutionary Genomics, Inc. to EG Crop Science, Inc. On May 9, 2016, we formed ICAM Therapeutics, Inc. (a Delaware corporation) as a wholly owned subsidiary of Evolutionary Genomics, Inc. We have not incurred any transactions in this company nor have we established any business plan for the future.

The Company maintains headquarters at the office of its Chief Executive Officer. The Company maintains a website at www.evolgen.com. The Company is not required to deliver an annual report to security holders and at this time does not anticipate the distribution of such a report. The Company will file reports with the SEC.

On August 14, 2000, the Company was issued patent number 6274319, titled “Methods to identify evolutionarily significant changes in polynucleotide and polypeptide sequences in domestic plants and animals”. On June 1, 2004, the Company was issued patent number 6743580, titled “Methods for producing transgenic plants containing evolutionarily significant polynucleotides”. These patents are for the core Adapted Traits Platform that we use for the discovery of genes in humans, animals and commercial crops. The Company has applied the Adapted Traits Platform in research projects including identifying genes believed to be responsible for increases in yield in corn, increases in yield in rice, salt tolerance and sugar content in tomatoes and pest/disease resistance in soybeans and multiple other crops.

In the past century, agriculture has been characterized by enhanced productivity, the use of synthetic fertilizers and pesticides, selective breeding, mechanization, water contamination, and farm subsidies. Proponents of organic farming such as Sir Albert Howard argued in the early 20th century that the overuse of pesticides and synthetic fertilizers damages the long-term fertility of the soil. While this feeling lay dormant for decades, as environmental awareness has increased in the 21st century there has been a movement towards sustainable agriculture by some farmers, consumers, and policymakers.

Advances in genetic research and modification of crop species have led to increased yield, drought tolerance and disease/pest resistance. These advances have also led to an increased concentration within the providers of seed to the industry. The top seed companies control much of the implementation of new seed varieties through patents and licensing agreements. Genetic traits providers, like Evolutionary Genomics, identify and develop genes that impact traits of interest to the industry and market those genes to these seed companies.

On June 26, 2018, the Company was awarded an Advanced Industries Accelerator Grant by the State of Colorado in the amount of $250,000 to identify and validate pathogen resistance genes in bananas and complete validation and marketing tomato and corn genes. The Company maintains ownership of all intellectual property developed from the use of grant funds. The Company has recognized all revenue from this grant.

Evolutionary Genomics intends to continue to pursue grant funding from governmental agencies, industry associations and grant making foundations. These sources of funding are often subject to limitations in available funds, funding priorities in areas other than our area of focus, political uncertainties, long approval processes and competition with other research proposals. If such funding is not available, Evolutionary Genomics may incur the costs of these projects with the prospect of revenue uncertain and likely many years in the future.

The single most valuable step in the process of crop improvement is the identification of the key genes among the 30,000 in the genome that has the desired impact. Evolutionary Genomics’ soybean pest resistance project is an illustration of the evolution of a project from concept through marketing to seed companies. The project has yielded identified genes for pest resistance in soybeans and, in hairy root assays on one of these genes, EG261, at the University of Wisconsin – Madison, proved that EG261 impacted resistance. Evolutionary Genomics has had discussions with seed companies to commercialize the genes and intends to continue those discussions after completion of validation testing with two generation, whole plant validation results. The Company has extended this pest resistance research to other crops including beans, tomatoes, cotton and maize in various stages or progress.

On April 29, 2014, the United States Patent and Trademark Office issued patent 8,710,300 titled EXPRESSION OF DIRIGENT GENE EG261 AND ITS ORTHOLOGS AND PARALOGS ENHANCES PATHOGEN RESISTANCE IN PLANTS. On December 5, 2017, the United States Patent and Trademark Office issued patent 9,834,783 which extended the previous patent to include additional variations of the gene. During 2017, the Company was issued similar patents in Canada, Brazil and China and has additional patents pending in Argentina and India. On January 16, 2020, the Company filed a patent application on its second soybean pest/disease resistance gene, EG19 and has included that gene in its ongoing two generation, whole plant validation research with the University of Missouri and with the Wisconsin Crop Innovation Center. Evolutionary Genomics engaged in discussions with seed companies regarding further validation of the effectiveness of EG261. Based on information received in those discussions, Evolutionary Genomics has engaged in a whole plant validation trial of EG261 and EG19 at the University of Missouri and the Wisconsin Crop Innovation Center.

We previously expected to complete the soybean research in the second quarter of 2020. Subsequent to March 31, 2020, our academic labs have informed us that they are not starting any new projects due to the Covid-19 pandemic and we now believe that the project will be delayed into the second half of 2020. If this research is not completed within a reasonable timeframe or within estimated costs, future licensing revenue, the valuation of our research in progress and the financial condition of the Company could be significantly impacted. The full impact that COVID-19 will have on our business will depend on a number of factors such as the duration and extent of COVID-19, the effect of governmental actions, responses of our third-party research partners, and general economic activity, as described in Part II, Item 1A “Risk Factors” in this Form 10-Q.

As a small company restricted by our limited resources, we cannot afford to generate vast numbers of events. Moderate success is important enough to indicate that further optimization can lead to significantly improved results. We must prove that there is enough evidence to warrant additional trials by companies with vastly more resources to build on our success but the single most valuable step in this process is the identification of the gene that has the desired impact and we have identified two of these genes, EG261 and EG19.

With transgenic change to plants, we use multiple tools to try to land the gene in the right spot in the genome but it is still an imperfect artform. We need to generate enough events in which the gene lands in the right place and is then inherited into the next generation with the right expression level. A low percentage of all attempts result in a testable event and, even then, you cannot be sure that the gene falls into the perfect spot or is expressed at the optimal level. We must generate enough events so that we have a few that genuinely show the impact of the gene. False negatives are the rule and we cannot be discouraged by them. A small number of successes can greatly outweigh a large number of false negatives.

Over the last three years, Dr. Zhang’s lab at the University of Missouri has been attempting to create transgenic events with eleven constructs of EG261 and EG19 along with controls which are tested to confirm that the gene landed in the genome and was inherited into the next generation. Heritable events are then grown to seed and the seeds are tested to see if they are homozygous and are tested to see how many copies of the gene are inherited. The seeds from these homozygous plants are the T2 generation that is tested for resistance impact. Promising T2 lines are grown to seed to generate T3 plants for further resistance testing. When enough data is accumulated, we will present our results to seed companies.

On December 3, 2014, Evolutionary Genomics entered into a Fee for Service Agreement with The Curators of the University of Missouri for the development of transgenic soybean plants with candidate genes for Soybean Cyst Nematode (SCN) resistance. A critical element of the research with the University of Missouri was to generate a large enough number of heritable single copy events to facilitate the next stage of resistance testing with Dr. Nguyen’s lab at the University of Missouri. There have been a small number of events indicating of the impact of both EG261 and EG19 but not nearly enough events were produced to create robust data sets. We continue to process the small number of viable events at the University of Missouri to test for Soybean Cyst Nematode (“SCN”) resistance. No further amounts will be due under this contract.

It is critical to note that the soybean transformation project difficulties at the University of Missouri do not reflect on the efficacy of our genes but, instead, are a reflection of their process not creating enough transgenic events.

We need to generate additional viable events at another institution and have entered into a Service Agreement with Wisconsin Crop Innovation Center (“WCIC”) under which they have transformed soybeans using our genes. WCIC guarantees a minimum number of successful events, have helped to establish the right combinations to achieve a range of expression and will test to assure us of successful events. WCIC has events from seven constructs of EG261 and EG19 growing in their greenhouses. These plants will be harvested in the second quarter of 2020 at which time we planned to begin SCN resistance testing of these lines at the University of Missouri. The lab at the University of Missouri has informed us that they are not starting any new projects due to the Covid-19 pandemic. Our planned project to perform SCN resistance testing of our soybean genes is therefor on indefinite hold.

If we are able to resume SCN resistance testing and results confirm the findings of the University of Wisconsin-Madison for EG261 and the effectiveness of the new gene, EG19, the Company will look to enter into negotiations for a long-term research collaboration and licensing agreement with seed companies. This type of agreement will likely have an upfront payment, milestone payments during their testing and a licensing royalty stream once the genes are incorporated into commercial seed lines. The testing phase includes field trials which may proceed for several years prior to generating licensing revenue. There are many risks in this process including some that are outside of Evolutionary Genomics’ control and there can be no guarantee that we will ever generate any revenue from these potential agreements. If Evolutionary Genomics receives product royalties from the soybean genes, it is required to pay the United Soybean Board a ten percent royalty stream not to exceed 150% of the grant amount of $262,400.

The Company has identified pest/disease resistance genes in other commercially valuable crops. The Company is currently engaged with the University of Missouri to perform two generation, whole plant testing of genes in tomatoes and corn that may lead to increased pest/disease resistance. This project is currently on hold pending results from our soybean project and the availability of funding. If successful, we intend to market them to the seed industry. This strategy will require Evolutionary Genomics to incur significant research costs prior to any confirmation of commercial viability and there can be no guarantee that the desired results can be achieved or that commercialization can be reached.

Evolutionary Genomics has identified a gene in tomatoes that impacts the plant’s ability to tolerate salt and a gene that appears to control sweetness. On January 9, 2018, the United States Patent and Trademark Office issued patent 9,862,962 titled IDENTIFICATION AND USE OF TOMATO GENES CONTROLLING SALT/DROUGHT TOLERANCE AND FRUIT SWEETNESS. Despite discussions with seed companies, the Company has not been able to reach any agreement to license these genes and there can be no assurance that we will ever realize any revenue from these genes.

In 2014, the Company began a project to identify genes in cotton that may impact traits of commercial interest. In particular, we intend to focus on pest resistance and fiber length. We have used our Adapted Traits Platform to identify positively selected candidate genes and intend to further research these genes to confirm that they were positively selected. If any of these genes remain promising, we intend to contract with an independent lab to validate the effectiveness of those genes. These studies can be very costly and there can be no assurance that we will be successful with this project.

During the 1950s the global banana industry was devastated by a disease (caused by Fusarium fungus) that effectively wiped out the predominate variety of commercial bananas know as Gros Michel leading to the development of the Cavendish banana, which makes up well over 90% of the commercial banana market today. Cavendish was resistant to the strain of Fusarium that wiped out the Gros Michel variety but, in recent years, is being challenged by a new race of Fusarium that threatens to once again devastate the global banana industry. This crisis is imminent and has no solution. The recent emergence of Panama Disease TR4 in the Western Hemisphere makes a swift solution to the crisis even more urgent. A substantial part of the banana market consists of exports from Central and South America to the United States. This market is now critically imperiled.

In 2018, the Company began a project to identify genes in wild banana relatives that are resistant to Fusarium. We believe that we are uniquely qualified to provide a solution to this crisis. We have previously used our technology to identify genes in common beans and, in our project for the Bill and Melinda Gates Foundation in common beans, proved that these genes provided increased resistance to Fusarium fungus. We used our platform to isolate a banana gene that controls Fusarium Wilt, aka Panama Disease, Tropical Race 4. The gene, which we have named FusR1 (Fusarium Resistance 1), is a native gene in Musa species, including cultivated bananas. We have found that, for all FW-resistant banana cultivars/species that we have tested, one version of our gene exists while, in all FW-sensitive banana cultivars/species that we have tested, there is a different version of FusR1. And notably, a third version exists in semi-resistant varieties that has allowed us to identify the particular nucleotide changes that are crucial for resistance to Fusarium Wilt.

We believe that this native banana gene can be introduced into cultivated bananas, particularly the Fusarium-sensitive Cavendish cultivar, in order to make these cultivars resistant to Fusarium Wilt. Cavendish cultivars are sterile and seedless, but it should be possible to use MAB (marker assisted breeding), though perhaps difficult and time-consuming, to move FusR1 into Cavendish and other cultivated bananas. We believe that a gene transformation approach would be faster and easier. Given the threat of possible extinction for Cavendish, rapid approaches are not only warranted but essential and minimally genetically edited bananas will be accepted depending upon how the gene transfer is accomplished. Transfer of this native banana gene to cultivated bananas can be best accomplished with CRISPR technology, which allows a targeted, clean, and efficient transfer and which, as compared to more traditional genetic editing techniques, minimizes potential side effects. We believe that Cavendish bananas can be rendered Fusarium Wilt resistant by changing only a few base pairs. These sorts of minimal changes have been allowed by the USDA and FDA in several crops. Even in Europe, use of CRISPR technology has gained substantial traction.

On June 26, 2019, we filed a United States patent application titled IDENTIFICATION AND RESISTANCE GENES FROM WILD RELATIVES OF BANANA AND THEIR USES IN CONTROLLING PANAMA DISEASE. We have also entered into discussions with the largest banana companies in the world. Based on previous experience and common practice in the agriculture industry, we believe that potential agreements with these companies may include some combination of upfront payments for research completed to date, partial or full funding of validation trials, lumpsum milestone payments and/or long term royalty payments upon their use of our gene in production. The Company is engaged in advanced discussions with one of these banana companies regarding a relationship to further develop our banana genes through transformation and validation. We expect to incur significant expenses for the transformation and validation of our banana genes over the next twenty-four months which we expect to be funded by this agreement. There can be no assurance that we will reach such an agreement or that the funding will be available.

If we are able to successfully transform and validate our banana genes, which will likely take 24-36 months, we hope to enter into a long term royalty contract with one or more banana producers based on banana revenue, banana plants produced or acres planted with plants with our gene. There are many risks associated with achieving these desired results including but not limited to:

-We may not reach agreement with any of the banana companies for funding of the transformation/validation;

-We may not be able to adequately establish patent protection for our intellectual property or others may have competing claims;

-Others may develop competitive approaches to compete with our genes;

-Our transformation academic labs may fail to develop enough events for testing;

-Our genes may cause unforeseen and undesirable changes beyond the pest resistance such as yield degradation or changes in the appearance or taste of the fruit;

-Our genes may fail to deliver the desired results of resistance to Fusarium;

-Globally regulations and/or consumer preference may prevent the successful commercial launch of bananas with genetics changed using our methods; and

-We will be dependent on other companies for the successful production and marketing of bananas with our genes and many factors will be outside of our control.

These and other risk factors are discussed in more detail in our 10-K filing dated March 30, 2020.

Evolutionary Genomics has no registered trademarks. The Company had two full time employees and one part-time employee as of March 30, 2020 and leases its operating facility on a month-to-month basis after June 30, 2017. Evolutionary Genomics is not currently involved in or aware of any threatened or actual legal proceedings.

Unaudited Results of Operations


	Three Months Ended March 31,
	2020						2019
	Amount			Percent of Revenue			Amount			Percent of Revenue
Grant revenue	$	12,500			100.0	%	$	32,366			100.0	%
Research and development		93,222			745.8	%		131,684			406.9	%
Salaries and benefits		92,430			739.4	%		54,779			169.2	%
General and administrative		56,665			453.3	%		58,254			180.0	%
Total operating expenses		242,317			1938.5	%		244,717			756.1	%
Operating (loss)		(229,817	)		-1838.5	%		(212,351	)		-656.1	%
Other income and (expenses)		(11,999	)		-96.0	%		11,954			36.9	%
Income Taxes		—			0.0	%		—			0.0	%
Net loss	$	(241,816	)		-1934.5	%	$	(200,397	)		-619.2	%
Preferred stock dividend		(71,391	)		-571.1	%		(60,591	)		-187.2	%
Net loss attributable to common stockholders	$	(313,207	)		-2505.7	%	$	(260,988	)		-806.4	%

Service and Grant Revenue

Service revenue decreased $19,866, or 61.4%, to $12,500 for the three months ended March 31, 2020 from $32,366 for the three months ended March 31, 2019. The decrease was due to decreased revenue recognized from the State of Colorado grant.

Operating Expenses

Operating expenses decreased $2,400, or 1.0% to $242,317 for the three months ended March 31, 2020 from $244,717 for the three months ended March 31, 2019. Changes in these items are described below.

Research and Development

Research and development decreased $38,462, or 29.2%, to $93,222 for the three months ended March 31, 2020 from $131,684 for the three months ended March 31, 2019. The decrease was primarily due to decreased costs for our pest resistance projects.

Salaries and Benefits

Salaries and benefits increased $37,651, or 68.7%, to $92,430 for the three months ended March 31, 2020 from $54,779 for the three months ended March 31, 2019. The increase was primarily due to increased stock compensation costs.

General and Administrative

General and administrative expenses decreased $1,589, or 2.7%, to $56,665 for the three months ended March 31, 2020 from $58,254 for the three months ended March 31, 2019. The decrease was primarily due to decreased professional fees.

Other Income and (Expenses)

Total other income and (expense) decreased $23,953, or 200.4%, to ($11,999) of expense for the three months ended March 31, 2020 from $11,954 of income for the three months ended March 31, 2019. The decrease was primarily due to changes in the market price of marketable securities.

Net (Loss)

Net (loss) increased $41,419, or 20.7%, to $241,816 for the three months ended March 31, 2020 from $200,397 for the three months ended March 31, 2019. The increase was primarily due to decreased revenue from the State of Colorado grant, increased stock compensation costs and unrealized losses on marketable securities and partially offset by decreased costs on our pest resistance projects.

Financial Condition

The Company’s working capital decreased $176,706 to ($77,958) as of March 31, 2020 from $98,748 as of December 31, 2019 primarily due the net loss.

Liquidity and Going Concern

The Company has historically financed operations through cash flows from operations and equity transactions. Net cash used in operating activities was $34,788 for the three months ended March 31, 2020 compared to $124,079 for the three months ended March 31, 2019. The $89,291, or 72.0%, decrease was primarily due to an increase in accounts payable, a decrease in accounts receivable and prepaid expenses, an increase in stock compensation and a unrealized loss on investments compared to an unrealized gain in the prior year partially offset by the increased net operating loss. Net cash flows for investing activities was $0 for the three months ended March 31, 2020 and 2019. Net cash provided from financing activities was $0 for the three months ended March 31, 2020 and 2019.

Sources of funding to meet prospective cash requirements include the Company’s existing cash balances and investments along with grant funds. As of March 31, 2020 we had $10,653 in our bank accounts and $29,694 of trading securities. On April 17, 2020, the Company received $71,268 in funding from the SBA under their Paycheck Protection Program and we expect that most, if not all of this funding will be forgiven. This will not be enough to pay for our expenses for the year ending December 31, 2020 without any additional revenue from grants or licensing revenue or additional capital infusions. We are marketing our banana genes in 2020 which may lead to revenue but may not be able to market our soybean genes until the research is finished at an indefinite date. We have flexibility to reduce operating costs and also to delay research projects. We will require additional capital to complete our projects. These factors create substantial doubt as to our ability to continue as a going concern. The accompanying condensed and consolidated financial statements do not include any adjustments that may result if the Company is unable to continue as a going concern.

The Company is engaged in advanced discussions with one banana company regarding a relationship to further develop our banana genes through transformation and validation. We expect to incur significant expenses for the transformation and validation of our banana genes over the next twenty-four months which we expect to be funded by this agreement. There can be no assurance that we will reach such an agreement or that the funding will be available.

Without additional revenue, we believe that our current resources will not be sufficient to sustain our operations for a period greater than one year. The ability of the Company to continue its operations is dependent on Management's plans, which may include continuing to raise capital through equity or debt based financings and marketing the Company’s genes to obtain licensing revenue. There can be no assurances that such capital will be available to us on acceptable terms, or at all or that we will be successful in our marketing efforts.

The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. These financial statements do not include any adjustments relating to the recovery of the recorded assets or the classification of the liabilities that might be necessary should the Company be unable to continue as a going concern.

Off-Balance Sheet Arrangements

The Company has no off-balance sheet arrangements that have a material current effect, or that are reasonably likely to have a material future effect, on its financial condition, changes in financial condition, revenue or expenses, results of operations, liquidity, capital expenditures, or capital resources.

Contractual Obligations

The Company leases its operating facility and pays its rent in monthly installments. The lease was renewed in June 2016 for a period of twelve months and monthly rentals for the period of July 1, 2016 through December 31, 2019 are $2,378 per month which continues on a month-to-month basis. There is no minimum lease commitment as of March 31, 2020. Renewals after June 30, 2017 are by mutual agreement. The Company’s rent expense for the three months ended March 31, 2020 and 2019 was $7,134 and $7,134, respectively.

On February 21, 2015, Evolutionary Genomics entered into a Sponsored Research Contract with The Curators of the University of Missouri for phenotyping transgenic soybean plants. As amended the contract calls for payments to be made on a per plant basis with no minimum future payments. We expect to continue this contract and will likely have additional amounts payable but the amount is indeterminable.

On May 3, 2018, Evolutionary Genomics entered into a Service Agreement with Wisconsin Crop Innovation Center for the development of transgenic soybean plants with total contract payments, including amendments of $141,631 of which $107,211 has been paid to date. We expect to pay the remaining $34,420 prior to June 30, 2020.

ITEM 3.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not required by smaller reporting companies.

ITEM 4.

CONTROLS AND PROCEDURES

(a) Evaluation of disclosure controls and procedures.

Under the supervision and with the participation of the Company’s management, including the principal executive officer and principal financial officer, as of the end of the period covered by this report, the Company conducted an evaluation of the effectiveness of the design and operation of the Company’s disclosure controls and procedures, as defined in Rule 13a-15(e) and 15d-15(e) under the Exchange Act. The Company’s disclosure controls and procedures are designed to provide reasonable assurance that the information required to be included in the Company’s reports to the Commission is recorded, processed, summarized and reported within the time periods specified in Commission rules and forms and to provide reasonable assurance that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure. Based on this evaluation, the Company’s principal executive officer and principal financial officer concluded that, as of the period covered by this report, our disclosure controls and procedures are not effective at these reasonable assurance levels for the reasons stated below.

Specifically, management identified the following control deficiencies: (1) the Company has not properly segregated duties as one or two individuals initiate, authorize, and complete all transactions. The Company has not implemented measures that would prevent the individuals from overriding the internal control system. The Company does not believe that this control deficiency has resulted in deficient financial reporting because the Chief Financial Officer is aware of his responsibilities under the SEC’s reporting requirements and personally certifies the financial reports. (2) The Company has installed accounting software that does not prevent erroneous or unauthorized changes to previous reporting periods and does not provide an adequate audit trail of entries made in the accounting software. (3) Due to the size of the Company and limited personnel, the Company has not hired an individual with technical accounting expertise within the accounting function.

Our internal control system is designed to provide reasonable cost-effective assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with accounting principles generally accepted in the United States. There is no assurance that our disclosure controls or our internal controls over financial reporting can prevent all errors. An internal control system, no matter how well designed and operated, has inherent limitations, including the possibility of human error. Because of the inherent limitations in a cost-effective control system, misstatements due to error may occur and not be detected. We monitor our disclosure controls and internal controls and make modifications as we believe appropriate given our financial resources and limited level of activities. Our intent in this regard is that our disclosure controls and our internal controls will improve as systems change and conditions warrant.

(b) Changes in internal controls.

Our Certifying Officers have indicated that there were no changes in our internal controls over financial reporting or other factors during the three months ended March 31, 2020, that could significantly affect such controls subsequent to the date of their evaluation, and there were no such control actions with regard to significant deficiencies and material weaknesses.

PART II. OTHER INFORMATION

ITEM 1.

LEGAL PROCEEDINGS

None.

ITEM 1A.

RISK FACTORS

Impacts of COVID-19 on our business

The impact of a novel strain of coronavirus (COVID-19), and measures to prevent its spread are affecting the macroeconomic environment and while the full impact is uncertain, our business and results of operations could be materially adversely affected. We previously expected to complete the soybean research in the second quarter of 2020. Subsequent to March 31, 2020, our academic labs have informed us that they are not starting any new projects due to the Covid-19 pandemic and we now believe that the project will be delayed into the second half of 2020. If this research is not completed within a reasonable timeframe or within estimated costs, future licensing revenue, the valuation of our research in progress and the financial condition of the Company could be significantly impacted. The impact on our business will depend on a number of factors such as the duration and extent of COVID-19, governmental actions, changes in consumer behavior, responses of our third-party business partners that offer our content through their platforms, and general economic activity.

We are attempting to conduct business as usual to the extent possible and are complying with the applicable stay at home orders issued by the Governor of Colorado. The Company has been granted the status of essential operations and our staff continues to work in our lab while staggering working hours to limit exposure.

The impact of the COVID-19 outbreak may also exacerbate other risks discussed in Item 1A. Risk Factors in our Annual Report on Form 10-K, any of which could have a material effect on us.

ITEM 2.

UNREGISTERED SALE OF EQUITY SECURITIES AND USE OF PROCEEDS

None

ITEM 3.

DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4.

MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5.

OTHER INFORMATION

None.

ITEM 6.

EXHIBITS


31.1		Rule 13a-14(a)/15d-14(a) Certification

31.2		Rule 13a-14(a)/15d-14(a) Certification

32.1		Section 1350 Certification

101		XBRL Interactive Data File

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this quarterly report to be signed on its behalf by the undersigned, thereunto duly authorized.


	EVOLUTIONARY GENOMICS, INC.


BY:	/s/ Steve B Warnecke
	Steve B Warnecke
	Chief Executive Officer and Chief Financial Officer

	May 12, 2020

EX-31.1 2 fnam_ex31z1.htm CERTIFICATIONS Certification

EXHIBIT 31.1

CERTIFICATIONS

I, Steve Warnecke, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Evolutionary Genomics, Inc.

2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;

3. Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant and have:

a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared;

b) designed such internal control over financial reporting, or caused such internal control over financial reporting, to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting.

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting,, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):

a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.


	May 12, 2020

BY:	/s/ Steve Warnecke
	Steve Warnecke
	Chief Executive Officer
	(principal executive officer)

EX-31.1 3 fnam_ex31z2.htm CERTIFICATIONS Certification

EXHIBIT 31.2

CERTIFICATIONS

I, Steve Warnecke, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Evolutionary Genomics, Inc.

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.


	May 12, 2020

BY:	/s/ Steve Warnecke
	Steve Warnecke
	Chief Financial Officer
	(principal financial officer)

EX-32.1 4 fnam_ex32z1.htm CERTIFICATION Certification

EXHIBIT 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Evolutionary Genomics, Inc. (the "Company") on Form 10-Q for the period ended March 31, 2020, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Steve B Warnecke, Chief Executive Officer and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. section1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


BY:	/s/ Steve B Warnecke
	Steve B Warnecke
	Chief Executive Officer and Chief Financial Officer
	(principal executive and financial officer)
	May 12, 2020

EX-101.INS 5 fnam-20200331.xml XBRL INSTANCE FILE 0000884363 2015-10-19 0000884363 srt:MinimumMember 2020-01-01 2020-03-31 0000884363 srt:MaximumMember 2020-01-01 2020-03-31 0000884363 us-gaap:ConvertiblePreferredStockMember 2015-10-19 0000884363 us-gaap:ConvertibleDebtSecuritiesMember 2020-01-01 2020-03-31 0000884363 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-03-31 0000884363 fnam:CommonStockAndWarrantsMember 2020-01-01 2020-03-31 0000884363 2020-01-01 2020-03-31 0000884363 srt:ChiefExecutiveOfficerMember 2020-03-31 0000884363 2019-01-01 2019-03-31 0000884363 2019-03-31 0000884363 2018-12-31 0000884363 us-gaap:PatentsMember 2020-01-01 2020-03-31 0000884363 2018-01-01 2018-12-31 0000884363 us-gaap:CommonStockMember 2018-12-31 0000884363 us-gaap:CommonStockMember 2019-03-31 0000884363 us-gaap:PreferredStockMember 2019-01-01 2019-03-31 0000884363 us-gaap:PreferredStockMember 2018-12-31 0000884363 us-gaap:PreferredStockMember 2019-03-31 0000884363 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0000884363 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0000884363 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0000884363 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0000884363 us-gaap:RetainedEarningsMember 2018-12-31 0000884363 us-gaap:RetainedEarningsMember 2019-03-31 0000884363 us-gaap:SubsequentEventMember fnam:ConvertiblePreferredStockSeriesA2Member 2020-05-01 0000884363 us-gaap:ConvertiblePreferredStockMember 2020-01-01 2020-03-31 0000884363 fnam:ConvertiblePreferredStockSeriesA2Member 2020-01-01 2020-03-31 0000884363 us-gaap:CommonStockMember 2019-12-31 0000884363 us-gaap:CommonStockMember 2020-03-31 0000884363 us-gaap:PreferredStockMember 2020-01-01 2020-03-31 0000884363 us-gaap:PreferredStockMember 2019-12-31 0000884363 us-gaap:PreferredStockMember 2020-03-31 0000884363 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0000884363 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0000884363 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0000884363 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0000884363 us-gaap:RetainedEarningsMember 2019-12-31 0000884363 us-gaap:RetainedEarningsMember 2020-03-31 0000884363 2019-12-31 0000884363 2020-03-31 0000884363 us-gaap:SeriesAPreferredStockMember 2020-03-31 0000884363 us-gaap:SeriesAPreferredStockMember 2019-12-31 0000884363 fnam:SeriesA2PreferredStockMember 2020-03-31 0000884363 fnam:SeriesA2PreferredStockMember 2019-12-31 0000884363 us-gaap:FairValueInputsLevel1Member 2020-03-31 0000884363 us-gaap:FairValueInputsLevel2Member 2020-03-31 0000884363 us-gaap:FairValueInputsLevel3Member 2020-03-31 0000884363 us-gaap:FairValueInputsLevel1Member 2019-12-31 0000884363 us-gaap:FairValueInputsLevel2Member 2019-12-31 0000884363 us-gaap:FairValueInputsLevel3Member 2019-12-31 0000884363 us-gaap:EquipmentMember 2019-12-31 0000884363 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2019-12-31 0000884363 us-gaap:FurnitureAndFixturesMember 2019-12-31 0000884363 us-gaap:EquipmentMember 2020-03-31 0000884363 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2020-03-31 0000884363 us-gaap:FurnitureAndFixturesMember 2020-03-31 0000884363 us-gaap:InProcessResearchAndDevelopmentMember 2020-03-31 0000884363 us-gaap:PatentsMember 2020-03-31 0000884363 us-gaap:InProcessResearchAndDevelopmentMember 2019-12-31 0000884363 us-gaap:PatentsMember 2019-12-31 0000884363 us-gaap:PatentsMember 2019-01-01 2019-03-31 0000884363 2019-01-01 2019-12-31 0000884363 us-gaap:ConvertibleDebtSecuritiesMember 2019-01-01 2019-03-31 0000884363 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-03-31 0000884363 fnam:CommonStockAndWarrantsMember 2019-01-01 2019-03-31 0000884363 us-gaap:SubsequentEventMember 2020-04-16 2020-04-17 iso4217:USD iso4217:USD xbrli:shares xbrli:shares xbrli:pure

0.001

780000000

12500

32366

88882

79353

4035592

4034941

93222

131684

92430

54779

56665

58254

242317

244717

-229817

-212351

-11999

11954

10180

54930

17278

-6845

-8073

-8913

3644

114160

56374

-34788

-124079

-34788

-124079

7327

131406

45441

10653

41694

29694

41694

4016596

52045

4016596

52045

651

650

2602

5335

7134

54930

17278

640000

566667

1081667

2.33

1.74

1.54

83334

800000000

20000000

600000

200000

20000000

600000

200000

.001

0.001

110884

110856

6.60 6.60 6.60 P0Y7M13D P1Y10M14D P0Y10M14D

P3Y

P7Y

102000

71391

60591

-313207

-260988

679923

1081667

110856

577063

566667

110884

-0.05

-0.04

5881898

570238

24183

15270

118163

55617

4124474

4114294

4242637

4169911

19415

133575

19415

133575

987353

1006768

1120928

3569594

3029579

540015

5882

12081401

12064940

-13371669

-13613485

220468

403587

5882

681282

741873

12294952

12251639

-12578529

-12778926

5882

950661

1022052

12081401

12064940

-13371669

-13613485

-333725

-520611

4242637

4169911

577063

102860

577063

102860

4013819

577827

5881898

-12000

11943

71391 60591

125000

3.00

1932088 0.299

6845

P20Y

41694

29694

41694

29694

950661

1022052

54930

17278

54930

60591

-60591

71391

-71391

-241816

-200397

-241816

33049

33700

0.08

5881898 EVOLUTIONARY GENOMICS, INC. 0000884363 10-Q 2020-03-31 false --12-31 Non-accelerated Filer true false false Q1 2020 Yes Yes NV 000-54129 0.7516

503665

432499

63179

7987

432499

63179

7987

414783

424312

9529

P10Y

1400000

P3Y

2378 262400 393600

-241816

-200397

6.60 5.25 5.25 5.25 5.25

1022052

508333

177334

1.96

P7Y7M6D

P5Y11M12D

P7Y10M6D

P5Y9M29D

P9Y9M29D P7Y0M0D 71268

Note 1: Business Activity Evolutionary Genomics, Inc. (the Company, We, or Our) has developed a technology platform, the Adapted Traits Platform (ATP), to identify commercially valuable genes that control important traits in animals and plants. We are using the ATP to identify genes to improve crop plant traits such as yield, sugar content, biomass, drought tolerance, and pest/disease resistance. Our platform identifies key genes that have changed successfully to impart new or improved traits. The Company performs its research on behalf of governmental organizations, non-profit foundations, and commercial entities and receives revenue from grants and commercial research contracts. These grants/contracts contain fixed-fee arrangements and may also have licensing provisions upon effective commercialization of research results. Successful commercialization may take many years to produce license royalty payments. Ownership of intellectual property developed in research projects varies from the Company retaining no rights to intellectual property, to joint ownership, to the Company retaining all rights. During 2014, the Company purchased 75.16% of the outstanding stock of Fona, Inc., (Fona) a public shell company. Since Fona was a public shell company which did not constitute a business and the purchase was done in contemplation of a reverse merger, the Company accounted for the payment as a distribution to Fona shareholders. The Company also entered into an Agreement and Plan of Merger (the Merger), which was consummated on October 19, 2015. As a result of the Merger, Evolutionary Genomics, Inc. became a wholly owned subsidiary of Fona. For accounting purposes, the merger was treated as a reverse acquisition with Evolutionary Genomics, Inc. as the acquirer and Fona as the acquired party. Subsequent to the Merger, Fona was renamed Evolutionary Genomics, Inc. and our subsidiary was renamed from Evolutionary Genomics, Inc. to EG Crop Science, Inc.

Note 2: Summary of Significant Accounting Policies Principals of Consolidation: These condensed and consolidated financial statements include the accounts of Evolutionary Genomics, Inc. and its wholly owned subsidiary. All material intercompany transactions and balances have been eliminated. Use of Estimates: The preparation of condensed and consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed and consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ materially from those estimates. Cash: The Company considers all highly liquid investments purchased with an original or remaining maturity of three months or less when purchased to be cash.   Investments: The Companys short-term investments are comprised of equity securities and are carried at their fair value based on the quoted market prices of the securities at March 31, 2020 and December 31, 2019. Net realized and unrealized gains and losses on investments are included in net earnings. For purposes of determining realized gains and losses, the cost of securities sold is based on specific identification. Property and Equipment: Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is provided for by the straight-line method over three- to seven-year estimated useful lives of software, furniture and fixtures and equipment. Maintenance and repairs are expensed as incurred; major renewals and betterments that extend the useful lives of property and equipment are capitalized. When property and equipment are sold or retired, the related cost and accumulated depreciation are removed from the accounts and any gain or loss is recognized. Long-Lived Assets: The long-lived assets held and used by the Company are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. In the event that facts and circumstances indicate that the cost of any long-lived assets may be impaired, an evaluation of recoverability is performed. An impairment is considered to exist if the total estimated undiscounted cash flows are less than the carrying amount of the asset. An impairment loss is measured and recorded to the extent that the carrying amount of the asset exceeds its estimated fair value. No asset impairment was recorded during the three months ended March 31, 2020 and 2019. Intangible Assets: Intangible assets include acquired research in progress and patents on the Companys core technology for gene identification. Patents are amortized over their expected useful life of 20 years using the straight-line method. Acquired research in progress is an indefinite-lived intangible asset until the development is complete at which time the useful life of the asset will be assigned. Costs incurred to renew intangible assets are expensed in the period incurred, while costs incurred to extend the lives of patents are capitalized and amortized over the remaining useful life of the asset. Intangible assets held and used by the Company are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. In the event that facts and circumstances indicate that the cost of any intangible assets may be impaired, an evaluation of recoverability is performed. An impairment is considered to exist if the total estimated undiscounted cash flows are less than the carrying amount of the asset. No impairment was recorded during the three months ended March 31, 2020 and 2019. Realization of this asset is dependent upon the successful completion of the Companys research and development efforts. Revenue Recognition: In May 2014, the FASB issued new guidance related to revenue recognition, which outlines a comprehensive revenue recognition model and supersedes most current revenue recognition guidance. The new guidance requires a company to recognize revenue as control of goods or services transfers to a customer at an amount that reflects the expected consideration to be received in exchange for those goods or services. It defines a five-step approach for recognizing revenue, which may require a company to use more judgment and make more estimates than under the current guidance. The Company adopted this standard on January 1, 2018 using the modified-retrospective method and it did not have a material impact on the condensed and consolidated financial statements. Grant revenue, which is not within the scope of Topic 606, consists of funding under cost reimbursement programs primarily from federal and non-profit foundation sources for qualified research and development activities performed by us, and as such, are not based on estimates that are susceptible to change. Such amounts are invoiced and recorded as revenue as grant-funded activities are performed. Income Taxes: Deferred tax assets and liabilities are recognized for the expected tax consequences of temporary differences between the tax bases of assets and liabilities and their reported amounts. Management regularly assesses the likelihood that deferred tax assets will be recovered from future taxable income, and to the extent management believes that it is more likely than not that a deferred tax asset will not be realized, a valuation allowance is established. When a valuation allowance is established, increased or decreased, an income tax charge or benefit is included in the condensed and consolidated financial statements and net deferred tax assets are adjusted accordingly. As of March 31, 2020 and December 31, 2019, a full valuation allowance has been established on the net deferred tax asset. Under the Income Tax topic of the ASC, in order to recognize an uncertain tax benefit, the taxpayer must be more likely than not of sustaining the position, and the measurement of the benefit is calculated as the largest amount that is more than 50% likely to be realized upon resolution of the benefit. The Company has no accruals for uncertain tax benefits. Stock-Based Compensation: The Company accounts for stock option awards in accordance with ASC 718. The estimated grant-date fair value of stock-based awards is expensed over the requisite service period, which is typically equivalent to the vesting term of the award.   The Companys accounting policy for equity instruments issued to consultants and vendors in exchange for goods and services received follows the provisions of ASC Topic 718. Accordingly, the measurement date for the fair value of the equity instruments issued is determined at the earlier of (i) the date at which a commitment for performance by the consultant or vendor is reached or (ii) the date at which the consultant or vendors performance is complete. In the case of equity instruments issued to consultants, the fair value of the equity instrument is recognized over the term of the consulting agreement. Research and Development: Research and development costs are expensed as incurred. In instances where we enter into agreements with third parties for research and development activities, we may prepay for services at the initiation of the contract. We record the prepayment as a prepaid asset and amortize the asset into research and development expense over the period of time the contracted research and development services are performed. Net Loss Per Common Share: Basic net (loss) income per common share excludes any dilutive effects of equity instruments.  We compute basic net (loss) income per common share using the weighted average number of common shares outstanding during the period.  We compute diluted net (loss) income per common share using the weighted average number of common shares and common stock equivalents outstanding during the period. For the three months ended March 31, 2020, common stock equivalents including 679,923 shares of convertible preferred stock, options for 1,081,667 shares of common stock and warrants for 110,856 shares of common stock were excluded because their effect was anti-dilutive. For the three months ended March 31, 2019, common stock equivalents including 577,063 shares of convertible preferred stock, options for 566,667 shares of common stock and warrants for 110,884 shares of common stock were excluded because their effect was anti-dilutive. Subsequent Events: The Company has evaluated all subsequent events through the date of this filing.  On April 17, 2020, the Company received $71,268 in funding from the SBA under their Paycheck Protection Program and we expect that most, if not all of this funding will be forgiven.

Note 3: New Accounting Standards Recently Issued Accounting Standards In June 2016, the FASB issued ASU 2016-13, Financial Instruments Credit Losses: Measurement of Credit Losses on Financial Instruments, which requires entities to estimate all expected credit losses for certain types of financial instruments, including trade receivables, held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. The updated guidance also expands the disclosure requirements to enable users of financial statements to understand the entitys assumptions, models and methods for estimating expected credit losses over the entire contractual term of the instrument from the date of initial recognition of that instrument. This guidance is effective for fiscal years beginning after December 15, 2020, including interim periods within that reporting period and did not have an impact on the Companys condensed and consolidated financial statements.

Note 4: Fair Value Measurements The Company complies with the provisions of ASC 820, in measuring fair value and in disclosing fair value measurements at the measurement date. ASC 820 defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements required under other accounting pronouncements. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value measurements also reflect the assumptions market participants would use in pricing an asset or liability based on the best information available. Assumptions include the risks inherent in a particular valuation technique (such as a pricing model) and/or the risks inherent in the inputs to the model. ASC 820 provides three levels of the fair value hierarchy as described below: Level 1 Inputs Quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 Inputs Observable market-based inputs, other than quoted prices in active markets for identical assets or liabilities. Level 3 Inputs Unobservable inputs that are supported by little or no market activity. When determining the fair value measurements for assets or liabilities required or permitted to be recorded at and/or marked to fair value, the Company considers the principal or most advantageous market in which it would transact and considers assumptions that market participants would use when pricing the asset or liability. When possible, the Company looks to active and observable markets to price identical assets. When identical assets are not traded in active markets, the Company looks to market observable data for similar assets. The following table presents the Companys financial assets that were accounted for at fair value on a recurring basis as of March 31, 2020 and December 31, 2019, by level within the fair value hierarchy: <table cellpadding="0" cellspacing="0" style="margin-top: 0px; font-size: 10pt; width: 100%"><tr style="height: 0px; font-size: 0"><td></td><td style="width: 4.26px"></td><td style="width: 4.4px"></td><td style="width: 6.66px"></td><td style="width: 82.26px"></td><td style="width: 4.46px"></td><td style="width: 4.46px"></td><td style="width: 6.66px"></td><td style="width: 82.26px"></td><td style="width: 4.46px"></td><td style="width: 4.46px"></td><td style="width: 6.66px"></td><td style="width: 82.26px"></td><td style="width: 4.46px"></td><td style="width: 4.46px"></td><td style="width: 6.66px"></td><td style="width: 82.26px"></td><td style="width: 3.33px"></td></tr> <tr><td style="margin-top: 0px; vertical-align: bottom">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.26px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.4px">  </td><td colspan="2" style="border-bottom: #000000 1.33px solid; margin-top: 0px; vertical-align: bottom; width: 88.93px">Total </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td colspan="2" style="border-bottom: #000000 1.33px solid; margin-top: 0px; vertical-align: bottom; width: 88.93px">Quoted Prices in Active Markets for Identical Items (Level 1) </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td colspan="2" style="border-bottom: #000000 1.33px solid; margin-top: 0px; vertical-align: bottom; width: 88.93px">Significant Other Observable Inputs (Level 2) </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td colspan="2" style="border-bottom: #000000 1.33px solid; margin-top: 0px; vertical-align: bottom; width: 88.93px">Significant Unobservable Inputs (Level 3) </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.33px">  </td></tr> <tr><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom">Balance at December 31, 2019 </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.26px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.4px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.66px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 82.26px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.66px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 82.26px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.66px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 82.26px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.66px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 82.26px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.33px">  </td></tr> <tr><td style="margin-top: 0px; vertical-align: bottom">Investments </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.26px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.4px">  </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; vertical-align: bottom; width: 6.66px">$ </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; vertical-align: bottom; width: 82.26px">41,694 </td><td style="border-bottom: #FFFFFF 1px solid; margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; vertical-align: bottom; width: 6.66px">$ </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; vertical-align: bottom; width: 82.26px">41,694 </td><td style="border-bottom: #FFFFFF 1px solid; margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; vertical-align: bottom; width: 6.66px">$ </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; vertical-align: bottom; width: 82.26px"> </td><td style="border-bottom: #FFFFFF 1px solid; margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; vertical-align: bottom; width: 6.66px">$ </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; vertical-align: bottom; width: 82.26px"> </td><td style="border-bottom: #FFFFFF 1px solid; margin-top: 0px; vertical-align: bottom; width: 3.33px">  </td></tr> <tr><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom">   </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.26px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.4px">  </td><td style="border-bottom: #000000 3px double; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.66px">$ </td><td style="border-bottom: #000000 3px double; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 82.26px">41,694 </td><td style="border-bottom: #FFFFFF 3px double; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="border-bottom: #000000 3px double; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.66px">$ </td><td style="border-bottom: #000000 3px double; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 82.26px">41,694 </td><td style="border-bottom: #FFFFFF 3px double; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="border-bottom: #000000 3px double; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.66px">$ </td><td style="border-bottom: #000000 3px double; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 82.26px"> </td><td style="border-bottom: #FFFFFF 3px double; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="border-bottom: #000000 3px double; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.66px">$ </td><td style="border-bottom: #000000 3px double; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 82.26px"> </td><td style="border-bottom: #FFFFFF 3px double; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.33px">  </td></tr> <tr><td style="margin-top: 0px; vertical-align: bottom">Balance at March 31, 2020 </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.26px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.4px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.66px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 82.26px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.66px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 82.26px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.66px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 82.26px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.66px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 82.26px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.33px">  </td></tr> <tr><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom">Investments </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.26px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.4px">  </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.66px">$ </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 82.26px">29,694 </td><td style="border-bottom: #FFFFFF 1px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.66px">$ </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 82.26px">29,694 </td><td style="border-bottom: #FFFFFF 1px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.66px">$ </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 82.26px"> </td><td style="border-bottom: #FFFFFF 1px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.66px">$ </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 82.26px"> </td><td style="border-bottom: #FFFFFF 1px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.33px">  </td></tr> <tr><td style="margin-top: 0px; vertical-align: bottom">   </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.26px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.4px">  </td><td style="border-bottom: #000000 3px double; margin-top: 0px; vertical-align: bottom; width: 6.66px">$ </td><td style="border-bottom: #000000 3px double; margin-top: 0px; vertical-align: bottom; width: 82.26px">29,694 </td><td style="border-bottom: #FFFFFF 3px double; margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="border-bottom: #000000 3px double; margin-top: 0px; vertical-align: bottom; width: 6.66px">$ </td><td style="border-bottom: #000000 3px double; margin-top: 0px; vertical-align: bottom; width: 82.26px">29,694 </td><td style="border-bottom: #FFFFFF 3px double; margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="border-bottom: #000000 3px double; margin-top: 0px; vertical-align: bottom; width: 6.66px">$ </td><td style="border-bottom: #000000 3px double; margin-top: 0px; vertical-align: bottom; width: 82.26px"> </td><td style="border-bottom: #FFFFFF 3px double; margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="border-bottom: #000000 3px double; margin-top: 0px; vertical-align: bottom; width: 6.66px">$ </td><td style="border-bottom: #000000 3px double; margin-top: 0px; vertical-align: bottom; width: 82.26px"> </td><td style="border-bottom: #FFFFFF 3px double; margin-top: 0px; vertical-align: bottom; width: 3.33px">  </td></tr> </table> For the Companys Level 1 measures, which represent common stock in publicly traded companies, fair value is based on the last closing trade occurring on, or closest to, the respective period end date. The carrying value of financial instruments, including cash, receivables, accounts payable and accrued expenses, approximates their fair value at March 31, 2020 and December 31, 2019 due to the relatively short-term nature of these instruments.

Note 5: Property and Equipment Property and equipment is comprised of the following: <table cellpadding="0" cellspacing="0" style="margin-top: 0px; font-size: 10pt; width: 100%"><tr style="height: 0px; font-size: 0"><td></td><td style="width: 6.73px"></td><td style="width: 6.73px"></td><td style="width: 67.2px"></td><td style="width: 6.73px"></td><td style="width: 6.73px"></td><td style="width: 6.73px"></td><td style="width: 67.2px"></td><td style="width: 6.73px"></td></tr> <tr><td style="margin-top: 0px; vertical-align: bottom">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td colspan="2" style="margin-top: 0px; vertical-align: bottom; width: 73.93px">March 31, </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td colspan="2" style="margin-top: 0px; vertical-align: bottom; width: 73.93px">December 31, </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td></tr> <tr><td style="margin-top: 0px; vertical-align: bottom">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td colspan="2" style="border-bottom: #000000 1.33px solid; margin-top: 0px; vertical-align: bottom; width: 73.93px">2020 </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td colspan="2" style="border-bottom: #000000 1.33px solid; margin-top: 0px; vertical-align: bottom; width: 73.93px">2019 </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td></tr> <tr><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom">Equipment </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">$ </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 67.2px">432,499 </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">$ </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 67.2px">432,499 </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td></tr> <tr><td style="margin-top: 0px; vertical-align: bottom">Software </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 67.2px">63,179 </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 67.2px">63,179 </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td></tr> <tr><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom">Furniture and fixtures </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 67.2px">7,987 </td><td style="border-bottom: #FFFFFF 1px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 67.2px">7,987 </td><td style="border-bottom: #FFFFFF 1px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td></tr> <tr><td style="margin-top: 0px; vertical-align: bottom">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 67.2px">503,665 </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 67.2px">503,665 </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td></tr> <tr><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom">Accumulated depreciation </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 67.2px">(424,312 </td><td style="border-bottom: #FFFFFF 1px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">) </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 67.2px">(414,783 </td><td style="border-bottom: #FFFFFF 1px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">) </td></tr> <tr><td style="margin-top: 0px; vertical-align: bottom">Property and equipment, net </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="border-bottom: #000000 3px double; margin-top: 0px; vertical-align: bottom; width: 6.73px">$ </td><td style="border-bottom: #000000 3px double; margin-top: 0px; vertical-align: bottom; width: 67.2px">79,353 </td><td style="border-bottom: #FFFFFF 3px double; margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="border-bottom: #000000 3px double; margin-top: 0px; vertical-align: bottom; width: 6.73px">$ </td><td style="border-bottom: #000000 3px double; margin-top: 0px; vertical-align: bottom; width: 67.2px">88,882 </td><td style="border-bottom: #FFFFFF 3px double; margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td></tr> </table> Depreciation expense for the three months ended March 31, 2020 and 2019 was $9,529 and $9,529, respectively.

Note 6: Intangible Assets   Intangible assets are comprised of the following:   <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center">March 31,</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">December 31,</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2020</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2019</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCFFCC"> <td style="width: 74%">Acquired research in progress - indefinite lived</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">4,016,596</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">4,016,596</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom"> <td>Patents</td> <td> </td> <td> </td> <td style="text-align: right">52,045</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">52,045</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCFFCC"> <td>Accumulated amortization</td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(33,700</td> <td style="border-bottom: white 1pt solid">)</td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(33,049</td> <td style="border-bottom: white 1pt solid">)</td></tr> <tr style="vertical-align: bottom"> <td>Intangible assets, net</td> <td> </td> <td style="border-bottom: Black 2.25pt double">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right">4,034,941</td> <td style="border-bottom: white 2.25pt double"> </td> <td> </td> <td style="border-bottom: Black 2.25pt double">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right">4,035,592</td> <td style="border-bottom: white 2.25pt double"> </td></tr> </table>   The Company expects to recognize $2,602 of amortization expense related to its patents during each of the next five years and the remaining $5,335 thereafter. Amortization expense for the patents during the three months ended March 31, 2020 and 2019 was $651 and $650, respectively.   In its merger completed on October 19, 2015, the Company acquired research in progress. The value of the acquired research in progress was based upon several factors including, evaluation of other intangible assets, the purchase price, estimated future cash flows, and the amounts expended on the research to date. Acquired research in progress is an indefinite lived intangible asset until the development phase is complete, at which time a useful life of the asset will be determined. The research in progress was the identification and validation of genes to provide pest and disease resistance to plants performed by EG I. The research had been in process since November 2010 and the Company expects to complete the research and place this asset in service in the second half of 2020. Additional costs to complete the research are expected to be approximately $102,000, which will be expensed as incurred. The timing and cost of additional research may vary from these estimates as the success of the research is subject to many factors outside of the Company’s control.   We previously expected to complete the soybean research in the second quarter of 2020. Subsequent to March 31, 2020, our academic labs have informed us that they are not starting any new projects due to the Covid-19 pandemic and we now believe that the project will be delayed into the second half of 2020. If this research is not completed within a reasonable timeframe or within estimated costs, future licensing revenue, the valuation of our research in progress and the financial condition of the Company could be significantly impacted.

Note 7: Stockholders Equity and Warrants The Amended and Restated Certificate of Incorporation of the Company dated October 19, 2015 authorized the issuance of 800,000,000 shares of all classes of stock including 780,000,000 shares of Common Stock having a par value of $0.001 per share and 20,000,000 shares of Preferred Stock having a par value of $0.001 per share, 600,000 of which were designated as Series A-1 Convertible Preferred Stock (Series A-1) and 200,000 of which were designated as Series A-2 Convertible Preferred Stock (Series A-2). The Board of Directors, without a vote of the shareholders, is authorized to issue additional shares of Preferred Stock in series and to establish the characteristics thereof. Liquidation: Upon any liquidation, dissolution or winding-up of the Company, whether voluntary or involuntary, the holders of the Series A-1 and Series A-2 shall be entitled to receive out of the assets of the Company for each share of Series A-1 and Series A-2 an amount equal to its stated value, $5.25 per share as of March 31, 2020 and December 31, 2019, plus any accrued but unpaid dividends before any distribution or payment shall be made to the holders of any other class or series of stock of the Company that ranks junior to the Series A-1 and Series A-2. The holders shall be entitled to convert their shares of Series A-1 and Series A-2 into Common Stock at any time prior to the consummation of a Liquidation. This is considered a contingent redemption feature. Conversion: The holders of Series A-1 and Series A-2 may convert their shares into shares of Common Stock, at the option of the holder, on a one-share-for-one-share basis and shall be subject to certain adjustments at any time. Optional Redemption; Sinking Fund Account: The Company may elect to redeem some or all of the then outstanding shares of Series A-1, (i) for cash in an amount equal to the liquidation preference per share, $5.25 per share as of December 31, 2019, subject to adjustment and (ii) by issuing one share, subject to adjustment, of Common Stock for each share of Series A-1 and Series A-2 outstanding being redeemed. 50% of all licensing fees received by the Company will be deposited into a separate sinking fund for use in an optional redemption. As of March 31, 2020, no licensing revenue has been received under these provisions and no sinking fund account has been established. Dividends: The Company shall pay to the holders of the Series A-1 and Series A-2 dividends at the rate of 8% per annum and the Company has accrued these dividends since issuance of the Series A-1 and Series A-2. The dividend amount shall accrue and shall be payable in shares of Common Stock upon the conversion of the Series A-1 and Series A-2, or upon the redemption of the Series A-1 and Series A-2. No dividends shall be paid on any Common Stock of the Company or any capital stock of the Company that ranks junior to the Series A-1 and Series A-2 until dividends of Series A-1 and Series A-2 been paid. As of March 31, 2020, there were $1,022,052 in accrued stock dividends. Voting: The holders of the Series A-1 and Series A-2 are entitled to vote on all matters submitted to the stockholders for a vote on an as-if-converted to Common Stock basis, with all stockholders voting as a single class. Warrants: As of March 31, 2020 and December 31, 2019, the Company had outstanding warrants to purchase 110,856 and 110,884 shares, respectively of the Companys Common Stock. The following table summarizes the status of the Companys aggregate warrants outstanding: <table cellpadding="0" cellspacing="0" style="margin-top: 0px; font-size: 10pt; width: 100%"><tr style="height: 0px; font-size: 0"><td></td><td style="width: 4.46px"></td><td style="width: 4.46px"></td><td style="width: 4.46px"></td><td style="width: 100.93px"></td><td style="width: 4.46px"></td><td style="width: 4.46px"></td><td style="width: 6.66px"></td><td style="width: 100.8px"></td><td style="width: 4.46px"></td><td style="width: 4.46px"></td><td style="width: 4.46px"></td><td style="width: 100.8px"></td><td style="width: 3.33px"></td></tr> <tr><td style="margin-top: 0px; vertical-align: bottom">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td colspan="2" style="border-bottom: #000000 1.33px solid; margin-top: 0px; vertical-align: bottom; width: 105.4px">Number of Warrants </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td colspan="2" style="border-bottom: #000000 1.33px solid; margin-top: 0px; vertical-align: bottom; width: 107.46px">Weighted Average Exercise Price </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td colspan="2" style="border-bottom: #000000 1.33px solid; margin-top: 0px; vertical-align: bottom; width: 105.26px">Weighted Average Remaining Term(Years) </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.33px">  </td></tr> <tr><td style="margin-top: 0px; vertical-align: bottom">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td colspan="2" style="margin-top: 0px; vertical-align: bottom; width: 105.4px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td colspan="2" style="margin-top: 0px; vertical-align: bottom; width: 107.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td colspan="2" style="margin-top: 0px; vertical-align: bottom; width: 105.26px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.33px">  </td></tr> <tr><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom">Balance, January 1, 2019 </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 100.93px">110,884 </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.66px">$ </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 100.8px">6.60 </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 100.8px">1.87 </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.33px">  </td></tr> <tr><td style="margin-top: 0px; vertical-align: bottom">Granted </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 100.93px"> </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.66px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 100.8px"> </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 100.8px"> </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.33px">  </td></tr> <tr><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom">Exercised </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 100.93px"> </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.66px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 100.8px"> </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 100.8px"> </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.33px">  </td></tr> <tr><td style="margin-top: 0px; vertical-align: bottom">Expired </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="border-bottom: #000000 1.33px solid; margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="border-bottom: #000000 1.33px solid; margin-top: 0px; vertical-align: bottom; width: 100.93px"> </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="border-bottom: #000000 1.33px solid; margin-top: 0px; vertical-align: bottom; width: 6.66px">  </td><td style="border-bottom: #000000 1.33px solid; margin-top: 0px; vertical-align: bottom; width: 100.8px"> </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="border-bottom: #000000 1.33px solid; margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="border-bottom: #000000 1.33px solid; margin-top: 0px; vertical-align: bottom; width: 100.8px"> </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.33px">  </td></tr> <tr><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom">Balance, December 31, 2019 </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 100.93px">110,884 </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.66px">$ </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 100.8px">6.60 </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 100.8px">0.87 </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.33px">  </td></tr> <tr><td style="margin-top: 0px; vertical-align: bottom">Granted </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 100.93px"> </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.66px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 100.8px"> </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 100.8px"> </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.33px">  </td></tr> <tr><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom">Exercised </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 100.93px"> </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.66px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 100.8px"> </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 100.8px"> </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.33px">  </td></tr> <tr><td style="margin-top: 0px; vertical-align: bottom">Expired </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="border-bottom: #000000 1.33px solid; margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="border-bottom: #000000 1.33px solid; margin-top: 0px; vertical-align: bottom; width: 100.93px">(28 </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">) </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="border-bottom: #000000 1.33px solid; margin-top: 0px; vertical-align: bottom; width: 6.66px">  </td><td style="border-bottom: #000000 1.33px solid; margin-top: 0px; vertical-align: bottom; width: 100.8px">6.60 </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="border-bottom: #000000 1.33px solid; margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="border-bottom: #000000 1.33px solid; margin-top: 0px; vertical-align: bottom; width: 100.8px"> </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.33px">  </td></tr> <tr><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom">Balance, March 31, 2020 </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="border-bottom: #000000 3px double; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="border-bottom: #000000 3px double; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 100.93px">110,856 </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="border-bottom: #000000 3px double; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.66px">$ </td><td style="border-bottom: #000000 3px double; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 100.8px">6.60 </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="border-bottom: #000000 3px double; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="border-bottom: #000000 3px double; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 100.8px">0.62 </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.33px">  </td></tr> </table>

Note 8: Stock-Based Compensation The Company grants stock-based instruments under the 2015 Stock Incentive Plan (Plan) for which 1,400,000 shares of the Companys Common Stock has been reserved. The Plan allows for the issuance of incentive stock options and non-qualified stock options with a maximum contractual term of 10 years. Shares and options that are cancelled are available for reissuance under the Plan. For the three months ended March 31, 2020 and 2019, the Company recorded compensation costs for stock options of $54,930 and $17,278, respectively. Stock options are generally issued with an exercise price at or above the estimated per-share value of the Companys Common Stock. The Company granted no options during the three months ended March 31, 2020 and 2019. Management has valued the options at their date of grant utilizing the Black-Scholes option pricing model. As of the issuance of the outstanding options, there was not a public market for the Companys shares. Accordingly, the Company utilized the value obtained in equity transactions with unrelated parties to estimate the fair value of the Companys Common Stock on the date of grant. Volatility of the underlying common shares was determined based on the historical volatility for similar companies that are actively traded in the public markets for a term consistent with the expected life of the options. The risk-free interest rate used in the calculations is based on the implied yield available on U.S. Treasury issues with an equivalent term approximating the expected life of the options on the date of the grant. Due to the lack of sufficient historical activity, the expected life of the options was estimated using the formula set forth in Securities and Exchange Commission SAB 107. The following table summarizes the status of the Companys aggregate stock options granted: <table cellpadding="0" cellspacing="0" style="margin-top: 0px; font-size: 10pt; width: 100%"><tr style="height: 0px; font-size: 0"><td></td><td style="width: 3.33px"></td><td style="width: 3.33px"></td><td style="width: 3.33px"></td><td style="width: 69.46px"></td><td style="width: 4.46px"></td><td style="width: 3.33px"></td><td style="width: 6.66px"></td><td style="width: 69.73px"></td><td style="width: 3.46px"></td><td style="width: 3.53px"></td><td style="width: 3.53px"></td><td style="width: 70.46px"></td><td style="width: 3.53px"></td><td style="width: 3.53px"></td><td style="width: 6.66px"></td><td style="width: 70.46px"></td><td style="width: 3.33px"></td></tr> <tr><td style="margin-top: 0px; vertical-align: bottom"> </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.33px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.33px">  </td><td colspan="2" style="border-bottom: #000000 1.33px solid; margin-top: 0px; vertical-align: bottom; width: 72.8px">Number of Options </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.33px">  </td><td colspan="2" style="border-bottom: #000000 1.33px solid; margin-top: 0px; vertical-align: bottom; width: 76.4px">Weighted Average Exercise Price </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.53px">  </td><td colspan="2" style="border-bottom: #000000 1.33px solid; margin-top: 0px; vertical-align: bottom; width: 74px">Weighted Average Remaining Term(Years) </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.53px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.53px">  </td><td colspan="2" style="border-bottom: #000000 1.33px solid; margin-top: 0px; vertical-align: bottom; width: 77.13px">Total Intrinsic Value </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.33px">  </td></tr> <tr><td style="margin-top: 0px; vertical-align: bottom"> </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.33px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.33px">  </td><td colspan="2" style="margin-top: 0px; vertical-align: bottom; width: 72.8px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.33px">  </td><td colspan="2" style="margin-top: 0px; vertical-align: bottom; width: 76.4px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.53px">  </td><td colspan="2" style="margin-top: 0px; vertical-align: bottom; width: 74px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.53px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.53px">  </td><td colspan="2" style="margin-top: 0px; vertical-align: bottom; width: 77.13px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.33px">  </td></tr> <tr><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom">Balance, January 1, 2019 </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.33px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.33px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.33px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 69.46px">566,667 </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.33px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.66px">$ </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 69.73px">2.33 </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.53px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.53px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 70.46px">5.95 </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.53px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.53px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.66px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 70.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.33px">  </td></tr> <tr><td style="margin-top: 0px; vertical-align: bottom">Granted </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.33px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.33px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.33px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 69.46px">640,000 </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.33px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.66px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 69.73px">1.54 </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.53px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.53px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 70.46px">9.83 </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.53px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.53px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.66px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 70.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.33px">  </td></tr> <tr><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom">Exercised </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.33px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.33px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.33px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 69.46px"> </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.33px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.66px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 69.73px"> </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.53px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.53px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 70.46px"> </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.53px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.53px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.66px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 70.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.33px">  </td></tr> <tr><td style="margin-top: 0px; vertical-align: bottom">Cancelled </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.33px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.33px">  </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; vertical-align: bottom; width: 3.33px">  </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; vertical-align: bottom; width: 69.46px">(125,000 </td><td style="border-bottom: #FFFFFF 1px solid; margin-top: 0px; vertical-align: bottom; width: 4.46px">) </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.33px">  </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; vertical-align: bottom; width: 6.66px">  </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; vertical-align: bottom; width: 69.73px">3.00 </td><td style="border-bottom: #FFFFFF 1px solid; margin-top: 0px; vertical-align: bottom; width: 3.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.53px">  </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; vertical-align: bottom; width: 3.53px">  </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; vertical-align: bottom; width: 70.46px">7.00 </td><td style="border-bottom: #FFFFFF 1px solid; margin-top: 0px; vertical-align: bottom; width: 3.53px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.53px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.66px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 70.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.33px">  </td></tr> <tr><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom"> </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.33px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.33px">  </td><td style="border-bottom: #000000 1.33px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.33px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 69.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.33px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.66px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 69.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.53px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.53px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 70.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.53px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.53px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.66px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 70.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.33px">  </td></tr> <tr><td style="margin-top: 0px; vertical-align: bottom">Balance, December 31, 2019 </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.33px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.33px">  </td><td style="border-bottom: #000000 3px double; margin-top: 0px; vertical-align: bottom; width: 3.33px">  </td><td style="border-bottom: #000000 3px double; margin-top: 0px; vertical-align: bottom; width: 69.46px">1,081,667 </td><td style="border-bottom: #FFFFFF 3px double; margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.33px">  </td><td style="border-bottom: #000000 3px double; margin-top: 0px; vertical-align: bottom; width: 6.66px">$ </td><td style="border-bottom: #000000 3px double; margin-top: 0px; vertical-align: bottom; width: 69.73px">1.74 </td><td style="border-bottom: #FFFFFF 3px double; margin-top: 0px; vertical-align: bottom; width: 3.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.53px">  </td><td style="border-bottom: #000000 3px double; margin-top: 0px; vertical-align: bottom; width: 3.53px">  </td><td style="border-bottom: #000000 3px double; margin-top: 0px; vertical-align: bottom; width: 70.46px">7.85 </td><td style="border-bottom: #FFFFFF 3px double; margin-top: 0px; vertical-align: bottom; width: 3.53px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.53px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.66px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 70.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.33px">  </td></tr> <tr><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom"> </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.33px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.33px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.33px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 69.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.33px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.66px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 69.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.53px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.53px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 70.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.53px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.53px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.66px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 70.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.33px">  </td></tr> <tr><td style="margin-top: 0px; vertical-align: bottom">Balance, January 1, 2020 </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.33px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.33px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.33px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 69.46px">1,081,667 </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.33px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.66px">$ </td><td style="margin-top: 0px; vertical-align: bottom; width: 69.73px">1.74 </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.53px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.53px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 70.46px">7.85 </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.53px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.53px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.66px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 70.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.33px">  </td></tr> <tr><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom">Granted </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.33px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.33px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.33px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 69.46px"> </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.33px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.66px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 69.73px"> </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.53px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.53px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 70.46px"> </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.53px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.53px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.66px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 70.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.33px">  </td></tr> <tr><td style="margin-top: 0px; vertical-align: bottom">Exercised </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.33px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.33px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.33px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 69.46px"> </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.33px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.66px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 69.73px"> </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.53px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.53px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 70.46px"> </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.53px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.53px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.66px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 70.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.33px">  </td></tr> <tr><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom">Cancelled </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.33px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.33px">  </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.33px">  </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 69.46px"> </td><td style="border-bottom: #FFFFFF 1px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.33px">  </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.66px">  </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 69.73px"> </td><td style="border-bottom: #FFFFFF 1px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.53px">  </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.53px">  </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 70.46px"> </td><td style="border-bottom: #FFFFFF 1px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.53px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.53px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.66px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 70.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.33px">  </td></tr> <tr><td style="margin-top: 0px; vertical-align: bottom"> </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.33px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.33px">  </td><td style="border-bottom: #000000 1.33px solid; margin-top: 0px; vertical-align: bottom; width: 3.33px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 69.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.33px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.66px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 69.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.53px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.53px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 70.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.53px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.53px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.66px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 70.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.33px">  </td></tr> <tr><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom">Balance, March 31, 2020 </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.33px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.33px">  </td><td style="border-bottom: #000000 3px double; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.33px">  </td><td style="border-bottom: #000000 3px double; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 69.46px">1,081,667 </td><td style="border-bottom: #FFFFFF 3px double; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.33px">  </td><td style="border-bottom: #000000 3px double; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.66px">$ </td><td style="border-bottom: #000000 3px double; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 69.73px">1.74 </td><td style="border-bottom: #FFFFFF 3px double; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.53px">  </td><td style="border-bottom: #000000 3px double; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.53px">  </td><td style="border-bottom: #000000 3px double; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 70.46px">7.60 </td><td style="border-bottom: #FFFFFF 3px double; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.53px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.53px">  </td><td style="border-bottom: #000000 3px double; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.66px">$ </td><td style="border-bottom: #000000 3px double; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 70.46px"> </td><td style="border-bottom: #FFFFFF 3px double; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.33px">  </td></tr> <tr><td style="margin-top: 0px; vertical-align: bottom"> </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.33px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.33px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.33px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 69.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.33px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.66px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 69.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.53px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.53px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 70.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.53px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.53px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.66px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 70.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.33px">  </td></tr> <tr><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom">Exercisable at March 31, 2020 </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.33px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.33px">  </td><td style="border-bottom: #000000 3px double; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.33px">  </td><td style="border-bottom: #000000 3px double; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 69.46px">508,333 </td><td style="border-bottom: #FFFFFF 3px double; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.33px">  </td><td style="border-bottom: #000000 3px double; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.66px">$ </td><td style="border-bottom: #000000 3px double; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 69.73px">1.96 </td><td style="border-bottom: #FFFFFF 3px double; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.53px">  </td><td style="border-bottom: #000000 3px double; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.53px">  </td><td style="border-bottom: #000000 3px double; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 70.46px">5.83 </td><td style="border-bottom: #FFFFFF 3px double; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.53px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.53px">  </td><td style="border-bottom: #000000 3px double; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.66px">$ </td><td style="border-bottom: #000000 3px double; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 70.46px">177,334 </td><td style="border-bottom: #FFFFFF 3px double; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.33px">  </td></tr> </table> During the three months ended March 31, 2020 and 2019, options for 0 and 83,334 shares vested, respectively. As of March 31, 2020, there was $570,238 of unrecognized compensation cost related to share-based compensation arrangements that will be recognized over the next three years.

Note 9: Commitments and Contingencies Officer Indemnification: Under the Companys organizational documents, the Companys officers, employees, and directors are indemnified against certain liabilities arising out of the performance of their duties. The Companys maximum exposure under these arrangements is unknown, as this would involve future claims that may be made against the Company that have not yet occurred. However, based on experience, the Company expects any risk of loss to be remote. The Company also has an insurance policy for its directors and officers to insure them against liabilities arising from their performance in their positions with the Company. Lease Commitments: The Company leases its operating facility and pays its rent in monthly installments. The lease was renewed in June 2016 for a period of twelve months and monthly rentals for the period of July 1, 2016 through December 31, 2019 are $2,378 per month which continues on a month-to-month basis. There is no minimum lease commitment as of March 31, 2020. Renewals after June 30, 2017 are by mutual agreement. The Companys rent expense for the three months ended March 31, 2020 and 2019 was $7,134 and $7,134, respectively. Royalty: Effective March 1, 2012, the Company entered into an Agreement for Contract Services with SmithBucklin Corporation (the Contractor) on behalf of the United Soybean Board. The contract includes the payment of certain royalties, as defined in the Agreement. The Company is obligated to pay royalties to the United Soybean Board of 10% of the sale of products derived from the soybean genes that were the subject of the research performed by the Contractor or from royalties received by the Company from the sale of products by a third party not to exceed 150% of the total amount paid to the Contractor under this Agreement. The Company has recognized to date grant revenue from the contract of $262,400 as of March 31, 2020, thus limiting any future royalties as of March 31, 2020 to a total of $393,600. The Company has not accrued or paid any royalties under the terms of the Agreement as of and during the three months ended March 31, 2020 and 2019 because it has not received any revenue from the sale of products to date.

Note 10: Related Parties and Transactions Steve B. Warnecke: Mr. Warnecke is the Companys Chief Executive Officer and Chairman of the Board and owns, directly or indirectly, 1,932,088 shares or 29.9% of the Common Stock outstanding as of March 31, 2020.

Note 11: Concentrations Considerations of Credit Risk: Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and accounts receivable. The Company maintains its cash balances at high-credit, quality financial institutions. The balances, at times, may exceed federally insured limits. The Company routinely monitors the credit quality of its customers.

Note 12: Liquidity and Going Concern Sources of funding to meet prospective cash requirements include the Companys existing cash balances and investments. As of March 31, 2020 we had $10,653 in our bank accounts and $29,694 of trading securities. On April 17, 2020, the Company received $71,268 in funding from the SBA under their Paycheck Protection Program and we expect that most, if not all of this funding will be forgiven.  This will not be enough to pay for our expenses for the year ending December 31, 2020 without any additional revenue from grants or licensing revenue or additional capital infusions. We are marketing our banana genes in 2020 which may lead to revenue but may not be able to market our soybean genes until the research is finished. We have flexibility to reduce operating costs and also to delay research projects. We will require additional capital to complete our projects. These factors create substantial doubt as to our ability to continue as a going concern.  The accompanying condensed and consolidated financial statements do not include any adjustments that may result if the Company is unable to continue as a going concern.

Principals of Consolidation: These condensed and consolidated financial statements include the accounts of Evolutionary Genomics, Inc. and its wholly owned subsidiary. All material intercompany transactions and balances have been eliminated.

Use of Estimates: The preparation of condensed and consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed and consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ materially from those estimates.

Cash: The Company considers all highly liquid investments purchased with an original or remaining maturity of three months or less when purchased to be cash.

Investments: The Companys short-term investments are comprised of equity securities and are carried at their fair value based on the quoted market prices of the securities at March 31, 2020 and December 31, 2019. Net realized and unrealized gains and losses on investments are included in net earnings. For purposes of determining realized gains and losses, the cost of securities sold is based on specific identification.

Property and Equipment: Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is provided for by the straight-line method over three- to seven-year estimated useful lives of software, furniture and fixtures and equipment. Maintenance and repairs are expensed as incurred; major renewals and betterments that extend the useful lives of property and equipment are capitalized. When property and equipment are sold or retired, the related cost and accumulated depreciation are removed from the accounts and any gain or loss is recognized.

Long-Lived Assets: The long-lived assets held and used by the Company are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. In the event that facts and circumstances indicate that the cost of any long-lived assets may be impaired, an evaluation of recoverability is performed. An impairment is considered to exist if the total estimated undiscounted cash flows are less than the carrying amount of the asset. An impairment loss is measured and recorded to the extent that the carrying amount of the asset exceeds its estimated fair value. No asset impairment was recorded during the three months ended March 31, 2020 and 2019.

Intangible Assets: Intangible assets include acquired research in progress and patents on the Companys core technology for gene identification. Patents are amortized over their expected useful life of 20 years using the straight-line method. Acquired research in progress is an indefinite-lived intangible asset until the development is complete at which time the useful life of the asset will be assigned. Costs incurred to renew intangible assets are expensed in the period incurred, while costs incurred to extend the lives of patents are capitalized and amortized over the remaining useful life of the asset. Intangible assets held and used by the Company are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. In the event that facts and circumstances indicate that the cost of any intangible assets may be impaired, an evaluation of recoverability is performed. An impairment is considered to exist if the total estimated undiscounted cash flows are less than the carrying amount of the asset. No impairment was recorded during the three months ended March 31, 2020 and 2019. Realization of this asset is dependent upon the successful completion of the Companys research and development efforts.

Revenue Recognition: In May 2014, the FASB issued new guidance related to revenue recognition, which outlines a comprehensive revenue recognition model and supersedes most current revenue recognition guidance. The new guidance requires a company to recognize revenue as control of goods or services transfers to a customer at an amount that reflects the expected consideration to be received in exchange for those goods or services. It defines a five-step approach for recognizing revenue, which may require a company to use more judgment and make more estimates than under the current guidance. The Company adopted this standard on January 1, 2018 using the modified-retrospective method and it did not have a material impact on the condensed and consolidated financial statements. Grant revenue, which is not within the scope of Topic 606, consists of funding under cost reimbursement programs primarily from federal and non-profit foundation sources for qualified research and development activities performed by us, and as such, are not based on estimates that are susceptible to change. Such amounts are invoiced and recorded as revenue as grant-funded activities are performed.

Income Taxes: Deferred tax assets and liabilities are recognized for the expected tax consequences of temporary differences between the tax bases of assets and liabilities and their reported amounts. Management regularly assesses the likelihood that deferred tax assets will be recovered from future taxable income, and to the extent management believes that it is more likely than not that a deferred tax asset will not be realized, a valuation allowance is established. When a valuation allowance is established, increased or decreased, an income tax charge or benefit is included in the condensed and consolidated financial statements and net deferred tax assets are adjusted accordingly. As of March 31, 2020 and December 31, 2019, a full valuation allowance has been established on the net deferred tax asset. Under the Income Tax topic of the ASC, in order to recognize an uncertain tax benefit, the taxpayer must be more likely than not of sustaining the position, and the measurement of the benefit is calculated as the largest amount that is more than 50% likely to be realized upon resolution of the benefit. The Company has no accruals for uncertain tax benefits.

Stock-Based Compensation: The Company accounts for stock option awards in accordance with ASC 718. The estimated grant-date fair value of stock-based awards is expensed over the requisite service period, which is typically equivalent to the vesting term of the award.   The Companys accounting policy for equity instruments issued to consultants and vendors in exchange for goods and services received follows the provisions of ASC Topic 718. Accordingly, the measurement date for the fair value of the equity instruments issued is determined at the earlier of (i) the date at which a commitment for performance by the consultant or vendor is reached or (ii) the date at which the consultant or vendors performance is complete. In the case of equity instruments issued to consultants, the fair value of the equity instrument is recognized over the term of the consulting agreement.

Research and Development: Research and development costs are expensed as incurred. In instances where we enter into agreements with third parties for research and development activities, we may prepay for services at the initiation of the contract. We record the prepayment as a prepaid asset and amortize the asset into research and development expense over the period of time the contracted research and development services are performed.

Net Loss Per Common Share: Basic net (loss) income per common share excludes any dilutive effects of equity instruments.  We compute basic net (loss) income per common share using the weighted average number of common shares outstanding during the period.  We compute diluted net (loss) income per common share using the weighted average number of common shares and common stock equivalents outstanding during the period. For the three months ended March 31, 2020, common stock equivalents including 679,923 shares of convertible preferred stock, options for 1,081,667 shares of common stock and warrants for 110,856 shares of common stock were excluded because their effect was anti-dilutive. For the three months ended March 31, 2019, common stock equivalents including 577,063 shares of convertible preferred stock, options for 566,667 shares of common stock and warrants for 110,884 shares of common stock were excluded because their effect was anti-dilutive.

Subsequent Events: The Company has evaluated all subsequent events through the date of this filing.  On April 17, 2020, the Company received $71,268 in funding from the SBA under their Paycheck Protection Program and we expect that most, if not all of this funding will be forgiven.

The following table presents the Companys financial assets that were accounted for at fair value on a recurring basis as of March 31, 2020 and December 31, 2019, by level within the fair value hierarchy: <table cellpadding="0" cellspacing="0" style="margin-top: 0px; font-size: 10pt; width: 100%"><tr style="height: 0px; font-size: 0"><td></td><td style="width: 4.26px"></td><td style="width: 4.4px"></td><td style="width: 6.66px"></td><td style="width: 82.26px"></td><td style="width: 4.46px"></td><td style="width: 4.46px"></td><td style="width: 6.66px"></td><td style="width: 82.26px"></td><td style="width: 4.46px"></td><td style="width: 4.46px"></td><td style="width: 6.66px"></td><td style="width: 82.26px"></td><td style="width: 4.46px"></td><td style="width: 4.46px"></td><td style="width: 6.66px"></td><td style="width: 82.26px"></td><td style="width: 3.33px"></td></tr> <tr><td style="margin-top: 0px; vertical-align: bottom">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.26px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.4px">  </td><td colspan="2" style="border-bottom: #000000 1.33px solid; margin-top: 0px; vertical-align: bottom; width: 88.93px">Total </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td colspan="2" style="border-bottom: #000000 1.33px solid; margin-top: 0px; vertical-align: bottom; width: 88.93px">Quoted Prices in Active Markets for Identical Items (Level 1) </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td colspan="2" style="border-bottom: #000000 1.33px solid; margin-top: 0px; vertical-align: bottom; width: 88.93px">Significant Other Observable Inputs (Level 2) </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td colspan="2" style="border-bottom: #000000 1.33px solid; margin-top: 0px; vertical-align: bottom; width: 88.93px">Significant Unobservable Inputs (Level 3) </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.33px">  </td></tr> <tr><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom">Balance at December 31, 2019 </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.26px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.4px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.66px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 82.26px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.66px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 82.26px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.66px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 82.26px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.66px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 82.26px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.33px">  </td></tr> <tr><td style="margin-top: 0px; vertical-align: bottom">Investments </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.26px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.4px">  </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; vertical-align: bottom; width: 6.66px">$ </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; vertical-align: bottom; width: 82.26px">41,694 </td><td style="border-bottom: #FFFFFF 1px solid; margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; vertical-align: bottom; width: 6.66px">$ </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; vertical-align: bottom; width: 82.26px">41,694 </td><td style="border-bottom: #FFFFFF 1px solid; margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; vertical-align: bottom; width: 6.66px">$ </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; vertical-align: bottom; width: 82.26px"> </td><td style="border-bottom: #FFFFFF 1px solid; margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; vertical-align: bottom; width: 6.66px">$ </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; vertical-align: bottom; width: 82.26px"> </td><td style="border-bottom: #FFFFFF 1px solid; margin-top: 0px; vertical-align: bottom; width: 3.33px">  </td></tr> <tr><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom">   </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.26px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.4px">  </td><td style="border-bottom: #000000 3px double; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.66px">$ </td><td style="border-bottom: #000000 3px double; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 82.26px">41,694 </td><td style="border-bottom: #FFFFFF 3px double; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="border-bottom: #000000 3px double; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.66px">$ </td><td style="border-bottom: #000000 3px double; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 82.26px">41,694 </td><td style="border-bottom: #FFFFFF 3px double; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="border-bottom: #000000 3px double; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.66px">$ </td><td style="border-bottom: #000000 3px double; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 82.26px"> </td><td style="border-bottom: #FFFFFF 3px double; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="border-bottom: #000000 3px double; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.66px">$ </td><td style="border-bottom: #000000 3px double; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 82.26px"> </td><td style="border-bottom: #FFFFFF 3px double; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.33px">  </td></tr> <tr><td style="margin-top: 0px; vertical-align: bottom">Balance at March 31, 2020 </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.26px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.4px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.66px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 82.26px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.66px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 82.26px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.66px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 82.26px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.66px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 82.26px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.33px">  </td></tr> <tr><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom">Investments </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.26px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.4px">  </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.66px">$ </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 82.26px">29,694 </td><td style="border-bottom: #FFFFFF 1px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.66px">$ </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 82.26px">29,694 </td><td style="border-bottom: #FFFFFF 1px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.66px">$ </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 82.26px"> </td><td style="border-bottom: #FFFFFF 1px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.66px">$ </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 82.26px"> </td><td style="border-bottom: #FFFFFF 1px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.33px">  </td></tr> <tr><td style="margin-top: 0px; vertical-align: bottom">   </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.26px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.4px">  </td><td style="border-bottom: #000000 3px double; margin-top: 0px; vertical-align: bottom; width: 6.66px">$ </td><td style="border-bottom: #000000 3px double; margin-top: 0px; vertical-align: bottom; width: 82.26px">29,694 </td><td style="border-bottom: #FFFFFF 3px double; margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="border-bottom: #000000 3px double; margin-top: 0px; vertical-align: bottom; width: 6.66px">$ </td><td style="border-bottom: #000000 3px double; margin-top: 0px; vertical-align: bottom; width: 82.26px">29,694 </td><td style="border-bottom: #FFFFFF 3px double; margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="border-bottom: #000000 3px double; margin-top: 0px; vertical-align: bottom; width: 6.66px">$ </td><td style="border-bottom: #000000 3px double; margin-top: 0px; vertical-align: bottom; width: 82.26px"> </td><td style="border-bottom: #FFFFFF 3px double; margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="border-bottom: #000000 3px double; margin-top: 0px; vertical-align: bottom; width: 6.66px">$ </td><td style="border-bottom: #000000 3px double; margin-top: 0px; vertical-align: bottom; width: 82.26px"> </td><td style="border-bottom: #FFFFFF 3px double; margin-top: 0px; vertical-align: bottom; width: 3.33px">  </td></tr> </table>

Property and equipment is comprised of the following: <table cellpadding="0" cellspacing="0" style="margin-top: 0px; font-size: 10pt; width: 100%"><tr style="height: 0px; font-size: 0"><td></td><td style="width: 6.73px"></td><td style="width: 6.73px"></td><td style="width: 67.2px"></td><td style="width: 6.73px"></td><td style="width: 6.73px"></td><td style="width: 6.73px"></td><td style="width: 67.2px"></td><td style="width: 6.73px"></td></tr> <tr><td style="margin-top: 0px; vertical-align: bottom">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td colspan="2" style="margin-top: 0px; vertical-align: bottom; width: 73.93px">March 31, </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td colspan="2" style="margin-top: 0px; vertical-align: bottom; width: 73.93px">December 31, </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td></tr> <tr><td style="margin-top: 0px; vertical-align: bottom">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td colspan="2" style="border-bottom: #000000 1.33px solid; margin-top: 0px; vertical-align: bottom; width: 73.93px">2020 </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td colspan="2" style="border-bottom: #000000 1.33px solid; margin-top: 0px; vertical-align: bottom; width: 73.93px">2019 </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td></tr> <tr><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom">Equipment </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">$ </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 67.2px">432,499 </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">$ </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 67.2px">432,499 </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td></tr> <tr><td style="margin-top: 0px; vertical-align: bottom">Software </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 67.2px">63,179 </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 67.2px">63,179 </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td></tr> <tr><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom">Furniture and fixtures </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 67.2px">7,987 </td><td style="border-bottom: #FFFFFF 1px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 67.2px">7,987 </td><td style="border-bottom: #FFFFFF 1px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td></tr> <tr><td style="margin-top: 0px; vertical-align: bottom">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 67.2px">503,665 </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 67.2px">503,665 </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td></tr> <tr><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom">Accumulated depreciation </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 67.2px">(424,312 </td><td style="border-bottom: #FFFFFF 1px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">) </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 67.2px">(414,783 </td><td style="border-bottom: #FFFFFF 1px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">) </td></tr> <tr><td style="margin-top: 0px; vertical-align: bottom">Property and equipment, net </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="border-bottom: #000000 3px double; margin-top: 0px; vertical-align: bottom; width: 6.73px">$ </td><td style="border-bottom: #000000 3px double; margin-top: 0px; vertical-align: bottom; width: 67.2px">79,353 </td><td style="border-bottom: #FFFFFF 3px double; margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="border-bottom: #000000 3px double; margin-top: 0px; vertical-align: bottom; width: 6.73px">$ </td><td style="border-bottom: #000000 3px double; margin-top: 0px; vertical-align: bottom; width: 67.2px">88,882 </td><td style="border-bottom: #FFFFFF 3px double; margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td></tr> </table>

Intangible assets are comprised of the following: <table cellpadding="0" cellspacing="0" style="margin-top: 0px; font-size: 10pt; width: 100%"><tr style="height: 0px; font-size: 0"><td></td><td style="width: 6.73px"></td><td style="width: 6.73px"></td><td style="width: 67.2px"></td><td style="width: 6.73px"></td><td style="width: 6.73px"></td><td style="width: 6.73px"></td><td style="width: 67.2px"></td><td style="width: 6.73px"></td></tr> <tr><td style="margin-top: 0px; vertical-align: bottom">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td colspan="2" style="margin-top: 0px; vertical-align: bottom; width: 73.93px">March 31, </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td colspan="2" style="margin-top: 0px; vertical-align: bottom; width: 73.93px">December 31, </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td></tr> <tr><td style="margin-top: 0px; vertical-align: bottom">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td colspan="2" style="border-bottom: #000000 1.33px solid; margin-top: 0px; vertical-align: bottom; width: 73.93px">2020 </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td colspan="2" style="border-bottom: #000000 1.33px solid; margin-top: 0px; vertical-align: bottom; width: 73.93px">2019 </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td></tr> <tr><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom">Acquired research in progress - indefinite lived </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">$ </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 67.2px">4,016,596 </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">$ </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 67.2px">4,016,596 </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td></tr> <tr><td style="margin-top: 0px; vertical-align: bottom">Patents </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 67.2px">52,045 </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 67.2px">52,045 </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td></tr> <tr><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom">Accumulated amortization </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 67.2px">(33,700 </td><td style="border-bottom: #FFFFFF 1px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">) </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 67.2px">(33,049 </td><td style="border-bottom: #FFFFFF 1px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">) </td></tr> <tr><td style="margin-top: 0px; vertical-align: bottom">Intangible assets, net </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="border-bottom: #000000 3px double; margin-top: 0px; vertical-align: bottom; width: 6.73px">$ </td><td style="border-bottom: #000000 3px double; margin-top: 0px; vertical-align: bottom; width: 67.2px">4,034,941 </td><td style="border-bottom: #FFFFFF 3px double; margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="border-bottom: #000000 3px double; margin-top: 0px; vertical-align: bottom; width: 6.73px">$ </td><td style="border-bottom: #000000 3px double; margin-top: 0px; vertical-align: bottom; width: 67.2px">4,035,592 </td><td style="border-bottom: #FFFFFF 3px double; margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td></tr> </table>

The following table summarizes the status of the Companys aggregate warrants outstanding: <table cellpadding="0" cellspacing="0" style="margin-top: 0px; font-size: 10pt; width: 100%"><tr style="height: 0px; font-size: 0"><td></td><td style="width: 4.46px"></td><td style="width: 4.46px"></td><td style="width: 4.46px"></td><td style="width: 100.93px"></td><td style="width: 4.46px"></td><td style="width: 4.46px"></td><td style="width: 6.66px"></td><td style="width: 100.8px"></td><td style="width: 4.46px"></td><td style="width: 4.46px"></td><td style="width: 4.46px"></td><td style="width: 100.8px"></td><td style="width: 3.33px"></td></tr> <tr><td style="margin-top: 0px; vertical-align: bottom">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td colspan="2" style="border-bottom: #000000 1.33px solid; margin-top: 0px; vertical-align: bottom; width: 105.4px">Number of Warrants </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td colspan="2" style="border-bottom: #000000 1.33px solid; margin-top: 0px; vertical-align: bottom; width: 107.46px">Weighted Average Exercise Price </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td colspan="2" style="border-bottom: #000000 1.33px solid; margin-top: 0px; vertical-align: bottom; width: 105.26px">Weighted Average Remaining Term(Years) </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.33px">  </td></tr> <tr><td style="margin-top: 0px; vertical-align: bottom">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td colspan="2" style="margin-top: 0px; vertical-align: bottom; width: 105.4px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td colspan="2" style="margin-top: 0px; vertical-align: bottom; width: 107.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td colspan="2" style="margin-top: 0px; vertical-align: bottom; width: 105.26px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.33px">  </td></tr> <tr><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom">Balance, January 1, 2019 </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 100.93px">110,884 </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.66px">$ </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 100.8px">6.60 </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 100.8px">1.87 </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.33px">  </td></tr> <tr><td style="margin-top: 0px; vertical-align: bottom">Granted </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 100.93px"> </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.66px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 100.8px"> </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 100.8px"> </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.33px">  </td></tr> <tr><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom">Exercised </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 100.93px"> </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.66px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 100.8px"> </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 100.8px"> </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.33px">  </td></tr> <tr><td style="margin-top: 0px; vertical-align: bottom">Expired </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="border-bottom: #000000 1.33px solid; margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="border-bottom: #000000 1.33px solid; margin-top: 0px; vertical-align: bottom; width: 100.93px"> </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="border-bottom: #000000 1.33px solid; margin-top: 0px; vertical-align: bottom; width: 6.66px">  </td><td style="border-bottom: #000000 1.33px solid; margin-top: 0px; vertical-align: bottom; width: 100.8px"> </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="border-bottom: #000000 1.33px solid; margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="border-bottom: #000000 1.33px solid; margin-top: 0px; vertical-align: bottom; width: 100.8px"> </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.33px">  </td></tr> <tr><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom">Balance, December 31, 2019 </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 100.93px">110,884 </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.66px">$ </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 100.8px">6.60 </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 100.8px">0.87 </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.33px">  </td></tr> <tr><td style="margin-top: 0px; vertical-align: bottom">Granted </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 100.93px"> </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.66px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 100.8px"> </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 100.8px"> </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.33px">  </td></tr> <tr><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom">Exercised </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 100.93px"> </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.66px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 100.8px"> </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 100.8px"> </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.33px">  </td></tr> <tr><td style="margin-top: 0px; vertical-align: bottom">Expired </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="border-bottom: #000000 1.33px solid; margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="border-bottom: #000000 1.33px solid; margin-top: 0px; vertical-align: bottom; width: 100.93px">(28 </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">) </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="border-bottom: #000000 1.33px solid; margin-top: 0px; vertical-align: bottom; width: 6.66px">  </td><td style="border-bottom: #000000 1.33px solid; margin-top: 0px; vertical-align: bottom; width: 100.8px">6.60 </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="border-bottom: #000000 1.33px solid; margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="border-bottom: #000000 1.33px solid; margin-top: 0px; vertical-align: bottom; width: 100.8px"> </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.33px">  </td></tr> <tr><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom">Balance, March 31, 2020 </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="border-bottom: #000000 3px double; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="border-bottom: #000000 3px double; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 100.93px">110,856 </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="border-bottom: #000000 3px double; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.66px">$ </td><td style="border-bottom: #000000 3px double; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 100.8px">6.60 </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="border-bottom: #000000 3px double; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="border-bottom: #000000 3px double; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 100.8px">0.62 </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.33px">  </td></tr> </table>

The following table summarizes the status of the Companys aggregate stock options granted: <table cellpadding="0" cellspacing="0" style="margin-top: 0px; font-size: 10pt; width: 100%"><tr style="height: 0px; font-size: 0"><td></td><td style="width: 3.33px"></td><td style="width: 3.33px"></td><td style="width: 3.33px"></td><td style="width: 69.46px"></td><td style="width: 4.46px"></td><td style="width: 3.33px"></td><td style="width: 6.66px"></td><td style="width: 69.73px"></td><td style="width: 3.46px"></td><td style="width: 3.53px"></td><td style="width: 3.53px"></td><td style="width: 70.46px"></td><td style="width: 3.53px"></td><td style="width: 3.53px"></td><td style="width: 6.66px"></td><td style="width: 70.46px"></td><td style="width: 3.33px"></td></tr> <tr><td style="margin-top: 0px; vertical-align: bottom"> </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.33px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.33px">  </td><td colspan="2" style="border-bottom: #000000 1.33px solid; margin-top: 0px; vertical-align: bottom; width: 72.8px">Number of Options </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.33px">  </td><td colspan="2" style="border-bottom: #000000 1.33px solid; margin-top: 0px; vertical-align: bottom; width: 76.4px">Weighted Average Exercise Price </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.53px">  </td><td colspan="2" style="border-bottom: #000000 1.33px solid; margin-top: 0px; vertical-align: bottom; width: 74px">Weighted Average Remaining Term(Years) </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.53px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.53px">  </td><td colspan="2" style="border-bottom: #000000 1.33px solid; margin-top: 0px; vertical-align: bottom; width: 77.13px">Total Intrinsic Value </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.33px">  </td></tr> <tr><td style="margin-top: 0px; vertical-align: bottom"> </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.33px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.33px">  </td><td colspan="2" style="margin-top: 0px; vertical-align: bottom; width: 72.8px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.33px">  </td><td colspan="2" style="margin-top: 0px; vertical-align: bottom; width: 76.4px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.53px">  </td><td colspan="2" style="margin-top: 0px; vertical-align: bottom; width: 74px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.53px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.53px">  </td><td colspan="2" style="margin-top: 0px; vertical-align: bottom; width: 77.13px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.33px">  </td></tr> <tr><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom">Balance, January 1, 2019 </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.33px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.33px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.33px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 69.46px">566,667 </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.33px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.66px">$ </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 69.73px">2.33 </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.53px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.53px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 70.46px">5.95 </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.53px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.53px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.66px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 70.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.33px">  </td></tr> <tr><td style="margin-top: 0px; vertical-align: bottom">Granted </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.33px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.33px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.33px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 69.46px">640,000 </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.33px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.66px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 69.73px">1.54 </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.53px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.53px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 70.46px">9.83 </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.53px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.53px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.66px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 70.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.33px">  </td></tr> <tr><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom">Exercised </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.33px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.33px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.33px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 69.46px"> </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.33px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.66px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 69.73px"> </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.53px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.53px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 70.46px"> </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.53px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.53px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.66px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 70.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.33px">  </td></tr> <tr><td style="margin-top: 0px; vertical-align: bottom">Cancelled </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.33px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.33px">  </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; vertical-align: bottom; width: 3.33px">  </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; vertical-align: bottom; width: 69.46px">(125,000 </td><td style="border-bottom: #FFFFFF 1px solid; margin-top: 0px; vertical-align: bottom; width: 4.46px">) </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.33px">  </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; vertical-align: bottom; width: 6.66px">  </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; vertical-align: bottom; width: 69.73px">3.00 </td><td style="border-bottom: #FFFFFF 1px solid; margin-top: 0px; vertical-align: bottom; width: 3.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.53px">  </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; vertical-align: bottom; width: 3.53px">  </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; vertical-align: bottom; width: 70.46px">7.00 </td><td style="border-bottom: #FFFFFF 1px solid; margin-top: 0px; vertical-align: bottom; width: 3.53px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.53px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.66px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 70.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.33px">  </td></tr> <tr><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom"> </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.33px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.33px">  </td><td style="border-bottom: #000000 1.33px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.33px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 69.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.33px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.66px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 69.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.53px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.53px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 70.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.53px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.53px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.66px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 70.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.33px">  </td></tr> <tr><td style="margin-top: 0px; vertical-align: bottom">Balance, December 31, 2019 </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.33px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.33px">  </td><td style="border-bottom: #000000 3px double; margin-top: 0px; vertical-align: bottom; width: 3.33px">  </td><td style="border-bottom: #000000 3px double; margin-top: 0px; vertical-align: bottom; width: 69.46px">1,081,667 </td><td style="border-bottom: #FFFFFF 3px double; margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.33px">  </td><td style="border-bottom: #000000 3px double; margin-top: 0px; vertical-align: bottom; width: 6.66px">$ </td><td style="border-bottom: #000000 3px double; margin-top: 0px; vertical-align: bottom; width: 69.73px">1.74 </td><td style="border-bottom: #FFFFFF 3px double; margin-top: 0px; vertical-align: bottom; width: 3.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.53px">  </td><td style="border-bottom: #000000 3px double; margin-top: 0px; vertical-align: bottom; width: 3.53px">  </td><td style="border-bottom: #000000 3px double; margin-top: 0px; vertical-align: bottom; width: 70.46px">7.85 </td><td style="border-bottom: #FFFFFF 3px double; margin-top: 0px; vertical-align: bottom; width: 3.53px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.53px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.66px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 70.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.33px">  </td></tr> <tr><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom"> </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.33px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.33px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.33px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 69.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.33px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.66px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 69.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.53px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.53px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 70.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.53px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.53px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.66px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 70.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.33px">  </td></tr> <tr><td style="margin-top: 0px; vertical-align: bottom">Balance, January 1, 2020 </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.33px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.33px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.33px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 69.46px">1,081,667 </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.33px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.66px">$ </td><td style="margin-top: 0px; vertical-align: bottom; width: 69.73px">1.74 </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.53px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.53px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 70.46px">7.85 </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.53px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.53px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.66px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 70.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.33px">  </td></tr> <tr><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom">Granted </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.33px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.33px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.33px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 69.46px"> </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.33px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.66px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 69.73px"> </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.53px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.53px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 70.46px"> </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.53px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.53px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.66px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 70.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.33px">  </td></tr> <tr><td style="margin-top: 0px; vertical-align: bottom">Exercised </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.33px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.33px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.33px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 69.46px"> </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.33px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.66px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 69.73px"> </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.53px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.53px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 70.46px"> </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.53px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.53px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.66px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 70.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.33px">  </td></tr> <tr><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom">Cancelled </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.33px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.33px">  </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.33px">  </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 69.46px"> </td><td style="border-bottom: #FFFFFF 1px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.33px">  </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.66px">  </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 69.73px"> </td><td style="border-bottom: #FFFFFF 1px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.53px">  </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.53px">  </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 70.46px"> </td><td style="border-bottom: #FFFFFF 1px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.53px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.53px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.66px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 70.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.33px">  </td></tr> <tr><td style="margin-top: 0px; vertical-align: bottom"> </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.33px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.33px">  </td><td style="border-bottom: #000000 1.33px solid; margin-top: 0px; vertical-align: bottom; width: 3.33px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 69.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.33px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.66px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 69.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.53px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.53px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 70.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.53px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.53px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.66px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 70.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.33px">  </td></tr> <tr><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom">Balance, March 31, 2020 </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.33px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.33px">  </td><td style="border-bottom: #000000 3px double; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.33px">  </td><td style="border-bottom: #000000 3px double; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 69.46px">1,081,667 </td><td style="border-bottom: #FFFFFF 3px double; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.33px">  </td><td style="border-bottom: #000000 3px double; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.66px">$ </td><td style="border-bottom: #000000 3px double; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 69.73px">1.74 </td><td style="border-bottom: #FFFFFF 3px double; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.53px">  </td><td style="border-bottom: #000000 3px double; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.53px">  </td><td style="border-bottom: #000000 3px double; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 70.46px">7.60 </td><td style="border-bottom: #FFFFFF 3px double; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.53px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.53px">  </td><td style="border-bottom: #000000 3px double; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.66px">$ </td><td style="border-bottom: #000000 3px double; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 70.46px"> </td><td style="border-bottom: #FFFFFF 3px double; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.33px">  </td></tr> <tr><td style="margin-top: 0px; vertical-align: bottom"> </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.33px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.33px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.33px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 69.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.33px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.66px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 69.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.53px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.53px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 70.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.53px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.53px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.66px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 70.46px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 3.33px">  </td></tr> <tr><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom">Exercisable at March 31, 2020 </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.33px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.33px">  </td><td style="border-bottom: #000000 3px double; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.33px">  </td><td style="border-bottom: #000000 3px double; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 69.46px">508,333 </td><td style="border-bottom: #FFFFFF 3px double; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 4.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.33px">  </td><td style="border-bottom: #000000 3px double; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.66px">$ </td><td style="border-bottom: #000000 3px double; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 69.73px">1.96 </td><td style="border-bottom: #FFFFFF 3px double; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.46px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.53px">  </td><td style="border-bottom: #000000 3px double; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.53px">  </td><td style="border-bottom: #000000 3px double; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 70.46px">5.83 </td><td style="border-bottom: #FFFFFF 3px double; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.53px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.53px">  </td><td style="border-bottom: #000000 3px double; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.66px">$ </td><td style="border-bottom: #000000 3px double; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 70.46px">177,334 </td><td style="border-bottom: #FFFFFF 3px double; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 3.33px">  </td></tr> </table>

EX-101.SCH 6 fnam-20200331.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed and Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed and Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed and Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed and Consolidated Statement of Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Condensed and Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Business Activity link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - New Accounting Standards link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Property and Equipment link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Intangible Assets link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Stockholders' Equity and Warrants link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Related Parties and Transactions link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Concentrations link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Liquidity and Going Concern link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Property and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Stockholders' Equity and Warrants (Tables) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Business Activity (Details) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Summary of Significant Accounting Policies (Other) (Details) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Summary of Significant Accounting Policies (Property and Equipment) (Details) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Summary of Significant Accounting Policies (Intangible Assets) (Details) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Summary of Significant Accounting Policies (Net Loss Per Common Share) (Details) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Fair Value Measurements (Details) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Stockholders' Equity and Warrants (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - Stockholders' Equity and Warrants (Summary of Warrants Activity) (Details) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - Stock-Based Compensation (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - Stock-Based Compensation (Summary of Stock Options Activity) (Details) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - Related Parties and Transactions (Details) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - Liquidity and Going Concern (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 fnam-20200331_cal.xml XBRL CALCULATION FILE EX-101.DEF 8 fnam-20200331_def.xml XBRL DEFINITION FILE EX-101.LAB 9 fnam-20200331_lab.xml XBRL LABEL FILE Range [Axis] Minimum [Member] Maximum [Member] Class of Stock [Axis] Series A-1 Convertible Preferred Stock [Member] Antidilutive Securities [Axis] Convertible Preferred Stock [Member] Stock Options [Member] Common Stock and Warrants [Member] Related Party Transaction [Axis] Chief Executive Officer [Member] Finite-Lived Intangible Assets by Major Class [Axis] Patents [Member] Equity Components [Axis] Common Stock [Member] Preferred Dividend [Member] Additional Paid-In Capital [Member] Accumulated Deficit [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Series A-2 Convertible Preferred Stock [Member] Series A-1 Convertible Preferred Stock [Member] Series A-2 Convertible Preferred Stock [Member] Fair Value, Hierarchy [Axis] Quoted Prices in Active Markets for Identical Items (Level 1) [Member] Significant Other Observable Inputs (Level 2) [Member] Significant Unobservable Inputs (Level 3) [Member] Property, Plant and Equipment, Type [Axis] Equipment [Member] Software [Member] Furniture and fixtures [Member] Acquired research in progress [Member] Document And Entity Information [Abstract] Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Entity Filer Category Entity Small Business Entity Emerging Growth Company Entity Shell Company Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Entity Current Reporting Status Entity Interactive Data Current Entity Incorporation State Country Name Entity File Number Statement [Table] Statement [Line Items] ASSETS Current assets Cash Accounts receivable Investments Prepaid expenses Total current assets Non-current assets Property and equipment, net Intangible assets, net Total non-current assets Total assets LIABILITIES AND STOCKHOLDERS' (DEFICIT) EQUITY Current liabilities Accounts payable and accrued expenses Total current liabilities Long-term liabilities Deferred tax liability Total liabilities Commitments and contingencies Total preferred stock subject to possible redemption Stockholders' equity Preferred Stock Common Stock, $0.001 par value; 780,000,000 shares authorized, 5,881,898 shares issued and outstanding at March 31, 2020 and December 31, 2019 Additional paid-in capital Accumulated deficit Total stockholders' (deficit) equity Total liabilities and stockholders' (deficit) equity Preferred stock, par value Preferred stock, authorized shares Preferred stock, issued shares Preferred stock, outstanding shares Preferred stock, liquidation preference Common stock, par value Common stock, authorized shares Common stock, issued shares Common stock, outstanding shares Income Statement [Abstract] Grant revenue Operating expenses Research and development Salaries and benefits General and administrative Total operating expenses Operating (loss) Other income (expenses): Investment income Unrealized gain or (loss) on investments Total other income (expenses) Loss before income taxes Income taxes Net loss Preferred stock dividend Net loss attributable to common stockholders Net loss per common share, basic and diluted Weighted average common shares outstanding, basic and diluted Balance Balance, shares Stock compensation Preferred stock dividends Net loss Balance Balance, shares Statement of Cash Flows [Abstract] Cash flows from operating activities: Adjustments to reconcile net loss to net cash flows from operating activities Depreciation and amortization Stock-based compensation Unrealized (gain) or loss on investments Deferred income taxes Changes in operating assets and liabilities: Accounts receivable Prepaid expenses Accounts payable and accrued expenses Cash flows from operating activities Cash flows from investing activities: Purchase of trading securities Cash flows from investing activities Cash flows from financing activities: Proceeds from issuance of preferred stock Cash flows from financing activities Net change in cash Cash, beginning of period Cash, end of period Supplemental cash flow information Preferred stock dividend accrual Organization, Consolidation and Presentation of Financial Statements [Abstract] Business Activity Accounting Policies [Abstract] Summary of Significant Accounting Policies Accounting Changes and Error Corrections [Abstract] New Accounting Standards Fair Value Disclosures [Abstract] Fair Value Measurements Property, Plant and Equipment [Abstract] Property and Equipment Goodwill and Intangible Assets Disclosure [Abstract] Intangible Assets Equity [Abstract] Stockholders' Equity and Warrants Share-based Payment Arrangement [Abstract] Stock-Based Compensation Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Related Party Transactions [Abstract] Related Parties and Transactions Risks and Uncertainties [Abstract] Concentrations Liquidity and Going Concern Subsequent Events [Abstract] Subsequent Events Principals of Consolidation Use of Estimates Cash Accounts Receivable Investments Property and Equipment Long-Lived Assets Intangible Assets Billings in Excess of Costs Revenue Recognition Income Taxes Stock-Based Compensation Research and Development Net Loss Per Common Share Subsequent Events Schedule of Assets and Liabilities Measured at Fair Value Schedule of Property and Equipment Schedule of Intangible Assets Summary of Warrants Activity Schedule of Assumptions Used to Value Stock Options Schedule of Stock Option Activity Percentage of outstanding stock purchased during reverse merger with Fona, Inc. Asset impairment charges Funding from SBA Property, Plant and Equipment [Table] Property, Plant and Equipment [Line Items] Statistical Measurement [Axis] Estimated useful lives of property and equipment Schedule of Finite-Lived Intangible Assets [Table] Acquired Finite-Lived Intangible Assets [Line Items] Intangible assets useful lives Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] EX-101.PRE 10 fnam-20200331_pre.xml XBRL PRESENTATION FILE EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

M_ -W/?^;'S$%I5:*-!6H"8&FH+>[8^G+. CX(> T:[V)'1R07P. MP4-=T%TP!!(J%Q2X7ZYP#U(&(6_C9=:D2\E 7._?U3_'WGTO%V[A'N5/4;NN MH+>4U-#P0;HG'+_ W,^!DKGYKW %Z>'!B:]1H;3Q2ZK!.E2SBK>B^.NT"AW7 MYP9&8Z>Q['JYX?TS\V50A&8\B_O/F MK<]>R_TAS=DU",V8TX1)UI@%P;SZ4B+9*G%*_J&GAVU^NFDQC?ST#XO9MD"V M*9!%@>R_/6YA_G;)5H>JP+1QG"RI<-!QE%?996+ODG@IO^'3N#]RTPIMR06= MO]IX 0VB V]E=^-GJ/,O; DD-"YL/_J]F>9L"ASV\Q-BRSLN?P%02P,$% M @ ]V2L4$LPY&"U 0 TP, !D !X;"]W;W)K&UL?5/1CILP$/P5RQ]P3DAR%T6 =+FJ:J56BJYJ^^S M;9++5-N/Y]UX:C MM$5]P=YE9G;67J<#VA?7 'CV:G3K,MYXWYV$<$4#1KH[[*"E/Q5:(SV%MA:N MLR#+2#):))O-O3!2M3Q/8^YB\Q1[KU4+%\M<;XRT/\^@<=K)&KZ _]I=+$5B5BF5@=8I;)F%*N./V]-Y'_ 1\$W!X!9[%CJY(KZ$X&.9 M\4TP!!H*'Q0D+3=X JV#$-GX,6GRN60@+O=OZN]C[]3+53IX0OU=E;[)^)&S M$BK9:_^,PP>8^CEP-C7_"6Z@"1Z<4(T"M8M?5O3.HYE4R(J1K^.JVK@.XY]# M,M'6"$^%;<@-&'.(R998F:$(/6Y1+)6XIS\0]\=UOF[58N[R-_]8?%A76"_*K"/ M OO_]KB&.?Y51"P.U8"MXS@Y5F#?QE%>9.>)?8RW*'[#QW'_+&VM6L>NZ.EJ MXP54B![(RN:.9JBA%S8'&BH?M@^TM^.&UL M?5/MCIP@%'T5P@,LCLY,MQ,UV=FF:9,VF6S3[6]&KTH6N!9PW+Y] 5UK6M,_ MP+V<<^X'EWQ$\V([ $=>E=2VH)US_8DQ6W6@N+W#'K2_:= H[KQI6F9[ [R. M)"59FB1'IKC0M,RC[V+*' H75?0>TIJ:/@@ MW1..GV"NYT#)7/P7N('T\)")CU&AM'$EU6 =JEG%IZ+XZ[0+'?=QNLGN9]HV M(9T)Z4(X3K5,@6+F'[CC96YP)&;J?<_#$^].J>]-%9RQ%?'.)V^]]U;N#N]S M=@M",^8\8=(U9D$PK[Z$2+="G--_Z-EAFY]MIIA%?K8.?TRV!?:; OLHL/]O MC1N8X]]5LE53%9@VCI,E%0XZCO+*NTSL0QH?Y0]\&O>OW+1"6W)%YY\V/D"# MZ,"GDMSY&>K\#UL,"8T+QW?^;*8YFPR'_?R%V/*/R]]02P,$% @ ]V2L M4"-P&Q^U 0 TP, !D !X;"]W;W)K&UL?5/; M;IPP$/T5RQ\0[P*;1"M RJ:J6JF15JG:/GMA "N^4-LLR=]W; BE+>J+[1G/ M.7-F/,Y'8U]--XVQBGLT;09BSHGKX[GD7;^>!@9=[S%KZ" M_]:?+5IL8:F% NV$T<1"4]"'_?&4A?@8\%W Z%9G$BJY&/,2C,]U07=!$$BH M?&#@N%WA$:0,1"CCY\Q)EY0!N#Z_LW^,M6,M%^[@T<@?HO9=0>\IJ:'A@_3/ M9OP$U[FUHS$3KWO>7CB_3'!WE3!&5L1[U"\0^^UW-\F.;L& MHCGF-,4DZY@E@B'[DB+92G%*_H&GAVU\NBDQC?CT#XGI-D&V29!%@NR_-6[% M9'\E8:NF*K!M'"='*C/H.,HK[S*Q#TE\E-_AT[@_<=L*['S:^ "-,1Y0 MRNX&9ZC#'[88$AH?CG=XMM.<388W_?R%V/*/RU]02P,$% @ ]V2L4$&@ M#:FQ 0 TP, !D !X;"]W;W)K&UL?5-M;YLP M$/XKEG] G4"251$@-9VF3MJDJ-.VSPX<8-7V4=N$]M_/-H2A#NT+OCN>Y[D7 MG[,!S8MM 1QY4U+;G+;.=4?&;-F"XO8..]#^3XU&<>==TS#;&>!5)"G)DLWF MP!07FA99C)U-D6'OI-!P-L3V2G'S?@*)0TZW]!9X%DWK0H 56<<;^ 'N9W?2\7;N$1Y6]1N3:G]Y144/->NF<\R P.Q(RS[WBXXNTQ\;,I0S".(O[SQ5L?O1;;PSYCUR T84XC)EEB M9@3SZG.*9"W%*?F'GN[7^>EJB6GDI\OT:;HNL%L5V$6!W7][7,,\DJN7-SI>H-0C++:4GD$Z]II:]G6[AU%NN4WQ8J*'H4C;V5)Q)\#9;S9N=C]V'@IKKDR&RC=UN1*?U#ULSX* MO4*]R[DH:24+7CF"7G;N'F\..#8!5O%:T$8.SAU3RHGS-[/X>MZYGLF(,IHI M8T'TX4Z?*6/&2>?QNS-U>Z8)')Y_N'^VQ>MB3D329\Y^%6>5[]R5ZYSIA=R8 M>N'-%]H5%+E.5_TW>J=,RTTFFI%Q)NVOD]VDXF7GHE,IR7M[+"I[;-HK4=B% MP0%^%^#W 2O+02W(9OZ)*))N!6\^OC>9V;2WPE[3R4N]>T]Q MG&S1W1AUFD.K\8>:7H&T>X_P(<3!GX4'$1P?@"D&-CX8XH,8-@A!@] :A*,: M5Y,:ES4C2 1"(L!@/8$L:T:0&(3$,X-@6LBB9(1(0$0RBP_Q!+$H&2%6(&(U MOPUA.&$L:T:0-0A9SPT2;P)9UHP@V(/;QP/RG/7/LFC,>="F&$AU^EQ D?^ M _;J'ON 13#E0*('#P?#/8V#N44TXP"BY,&K \.MCX&^3N(I9UDTYL#=CX'6 M3F;_@V71F ._ /"\O7$R?07\1]1RT&!"E%1<[6R43L9OE1W,@]U^_NY].V'^ MR=OA_9V(:U%)Y\25GE-VFEPX5U3GXCWIFG/]O= O&+TH-U] M$*#^JR3]"U!+ P04 " #W9*Q0[JUO_;?1=3)GCX*30<#'$#DIQ\^<, M$L>"[NB;XTFTG0L.5N8];^$'N)_]Q7B++2JU4*"M0$T,- 5]V)W.6ZH$E(""14+BAPO]W@$:0,0CZ-W[,F74(&XOK\IOXYUNYK MN7(+CRA_B=IU!3U24D/#!^F>'3'R,"J6-*ZD&ZU#- M*CX5Q5^G7>BXC]/-X3C3M@GI3$@7PC'&85.@F/DG[GB9&QR)F7K?\_#$NU/J M>U,%9VQ%O//)6^^]E;O[CSF[!:$99V(&PO=V]R:W-H M965TZR5 M[D'YFT8;R9PW34ML;X#5D20%H;O=#9&,*USFT7BQP@M\=3[SM7'"0,N]9"S_ _>Q/QEMD4:FY!&6Y5LA 4^#;Y'#, CX"?G$8 M[>J,0B5GK5^"\5@7>!<2 @&5"PK,;Q>X R&"D$_C==;$2\A 7)_?U>]C[;Z6 M,[-PI\4SKUU7X#U&-31L$.Y)CP\PUW.-T5S\-[B \/"0B8]1:6'CBJK!.BUG M%9^*9&_3SE79L,ISNYR]$ MEG]<_@%02P,$% @ ]V2L4*.U99RX 0 TP, !D !X;"]W;W)K&UL;5/;;IPP$/T5RQ\0[P*;K%: E$U5M5(KK5*U??;" M %9\H;99TK_OV!!*4UYLS_B<,Q>/\]'8%]/*JI'8%[;SO3XRYJ@/%W9WI M0>--8ZSB'DW;,M=;X'4D*Z>*2XT+?/HN]@R-X.70L/%$CWO,T@S M%G1/WQS/HNU\<+ R[WD+W\!_[R\6+;:HU$*!=L)H8J$IZ./^=,X"/@)^"!C= MZDQ")5=C7H+QN2[H+B0$$BH?%#AN-W@"*8,0IO%KUJ1+R$!E[DU([%3[WL>GGA_2K W M57#&5L0[3-ZA]U;NCX>!>$K9JJP+9QG!RIS*#C**^\R\0^)O%1 M_L*G,!4=G9L,KSIYR_$ MEG]<_@%02P,$% @ ]V2L4%S*2PBY 0 TP, !D !X;"]W;W)K&UL=5/1;IPP$/P5RQ\0<\"UEQ,@Y1)5K=1*IU1-GWVP M@!6;I;8YTK^O;0BE*7G!WF5F=M9>9R/J9],"6/*B9&=RVEK;'QDS90N*FQOL MH7-_:M2*6Q?JAIE> Z\"24D61]$'IKCH:)&%W%D7&0Y6B@[.FIA!*:Y_GT#B MF-,=?4T\BJ:U/L&*K.<-? ?[HS]K%[%%I1(*.B.P(QKJG-[MCJ?4XP/@272\7 M;N >Y4]1V3:G!THJJ/D@[2..GV'N9T_)W/Q7N()T<._$U2A1FO EY6 LJEG% M65'\95I%%]9Q^I,F,VV;$,^$>"$<0ATV%0K.'[CE1:9Q)'HZ^Y[[*]X=8W;]_TN(&YC=X48:M#5:";,$Z&E#AT8917V65B[^)P M*7_AT[A_X[H1G2$7M.YJPP74B!:C&S5#K7M@22*BMWWYT>SW-V118[.&PO=V]R:W-H M965TI5"VP)US_8$06W4@F;W2 M/2A_TV@CF?.F:8GM#; ZDJ0@=+?[0B3C"I=Y])U,F>O!":[@9) =I&3F[0A" MCP5.\+OCD;>="PY2YCUKX1>XW_W)>(LL*C67H"S7"AEH"GR3'(Y9P$? $X?1 MKLXH5'+6^B48/^H"[T)"(*!R08'Y[0*W($00\FG\F37Q$C(0U^=W]?M8NZ_E MS"S<:O',:]<5^!JC&AHV"/>HQ^\PU[/':"[^)UQ >'C(Q,>HM+!Q1=5@G9:S MBD]%LM=IYRKNXW23I3-MFT!G ET(US$.F0+%S.^88V5N](C,U/N>A2=.#M3W MI@K.V(IXYY.WWGLIDV])3BY!:,8<)PQ=8Q8$\>I+"+H5XDC_HZ?[;7ZZF6(: M^>DZ_#[;%L@V!;(HD/U3(_U4XQ8F_12$K)HJP;1QG"RJ]*#B**^\R\3>T/@H M'_!IW!^8:;FRZ*R=?]KX (W6#GPJNRL_0YW_88LAH''A^-6?S31GD^%T/W\A MLOSC\B]02P,$% @ ]V2L4%+FTF:V 0 TP, !D !X;"]W;W)K&UL;5/;CILP$/T5RQ^P3H!LVPB0-EM5K=1*T5;=/CLP M@+6^4-N$[=]W; BE6U[PS'#.F8O'^6CLB^L /'E54KN"=M[W1\9Z>*2XT+?,8.]LR-X.70L/9$CWO$T@S M%G1/;X$GT78^!%B9][R%[^!_]&>+'EM4:J% .V$TL= 4]&%_/&4!'P'/ D:W MLDGHY&+,2W"^U 7=A8) 0N6# L?C"H\@91#",G[-FG1)&8AK^Z;^*?:.O5RX M@TR_V'+&?7(#1C3A,F66,6!$/U)46RE>*4_$=/#]O\=+/$-/+3 M=?HTW1;(-@6R*)#]T^/A38];F/LW2=AJJ IL&]?)D&PO=V]R:W-H965T M0'J/EJDD: M":J-FF3HD[K?CMP":C^ MH+83NK>?;5P6"*KV!_M>GW-\[K5-U@OYJAH ';PSRE6.&JV[+<:J;( 1=2##-29,2+_/ (5 M?8XB])%X;D^-M@E<9!TYP4_0O[J#-!$>5:J6 5>MX(&$.D=?HNT^M7@'>&FA M5U?SP%9R%.+5!M^J'(76$% HM54@9KC #BBU0L;&F]=$XY:6>#W_4']RM9M: MCD3!3M#?;:6;'&U04$%-SE0_B_XK^'KN4>"+_PX7H 9NG9@]2D&5^P;E66G! MO(JQPLC[,+;T(\$J+T4T+B"K,GFA29 M%'T@A]/MB+U$T38UW2]MTC7;K9GV*).]%-'#.L,7*^0QCP,FGF V4\SN%I/< M3R'[6\CZWT[8N!RMQHM68\=/)S8>9C9N,6DXL_$I9&(C6;21W/#-(UL62!<% MT@6!:-;R ;-R&#[T*HI7F]DV^.J4[3/]0>2IY2HX"FTNC#O66@@-1C&\,W>_ M,7^&,:!0:SM=F[D,S9\X,'N>3 M5$^Z S#H6?!!%[@S9CP2HJL.!--W(=?'(]]VQGG(&4^LA9^@/DYGI6U MR,I2]P(&WNDHN43\[X6A^^-EV!,XQJ:-B5FTU'_PZS2=IMH2% ^@20-< MF]O5,B?RRC\QP\I6^^MI!'-R1W\R&^\ZV3?4W]Y7^'SL_"=J;8?-+I(8T? 7]1&2@-62G1G6][9EV@U.#3& M;5.[5_,\SH:1X_+4D/6]*_\!4$L#!!0 ( /=DK% ]JK);P@$ !0$ 9 M >&PO=V]R:W-H965T<^;,V$,Q*_UH>@"+G@27 MIL2]M>.1$%/W()BY42-(=](J+9AUINZ(&36P)H $)S1)WA'!!HFK(OC.NBK4 M9/D@X:R1F81@^L\)N)I+G.)GQ\/0]=8[2%6,K(/O8'^,9^TLLK$T@P!I!B61 MAK;$=^GQE/OX$/!S@-GL]LA7N!^_\S^*=3N:KDP _>*_QH:VY?X/48-M&SB]D'-GV&M)\=H+?XK7(&[ M<*_$Y:@5-^&+ZLE8)586)T6PIV4=9%CGY>0V6V%Q %T!= .DH3ED2124?V26 M5856,])+[T?FKS@]4M>;VCM#*\*9$V^<]UK1Y$-!KIYHC3DM,707DVX1Q+%O M*6@LQ8F^@F=Y')]%)68!?]A+3),XP2%*< @$V7\$;U201PGRB +ZHDFQF.Q% M$K*[%0&Z"^_1H%I-,LS"SKL]^3L:;O5?^#(OWYCN!FG015GW-L(-MDI9<%*2 M&Z>E=R.Z&1Q:Z[>W;J^7A[H85HWK#)+M1U#]!5!+ P04 " #W9*Q0F3?E M*3L" #4!@ &0 'AL+W=OV.FS 0 M?!7$ YSY-! 1I$NJJI5:*;JJ[6^'; (Z@ZGMA.O;US:$(\17Y4^PEYG9V25> MYSWCKZ("D,Y;0UNQ=BLINQ5"HJR@(>*)=="J-T?&&R+5EI^0Z#B0@R$U% 6> MAU%#ZM8M>F(?SO!BCKUZ[O7@,O]:F2.H"*O",G^ 'R M9[?C:H\9>]>;K8>UZVA%0 M**66(.IQ@2U0JI64CS^CJ#OEU,3Y^JK^V12OBMD3 5M&?]<'6:W=U'4.<"1G M*E]8_P7&@F+7&:O_!A>@"JZ=J!PEH\+\.N592-:,*LI*0]Z&9]V:9S_J7VEV M0C 2@HF@('9Z;43T22(N>L=_CPM3JB_Q3^*E3-+'70],Z\ M4]4*%;T4@1_EZ**%1LQFP 0SC#\AD%*?4@2V%)O@CA[&MQFV]Y DL:<(K56$ MAA_=5!';!2*K0&0$PAL!;!>(K0*QQ4&RZ.. B0VF-1B<9%D0+IIQ#XN3Q,.A MW0ZVVL$6.ZE=(+$*)(\W)+4*I \T)+VKU/=2'^,%;GN/BS&>PV[\9%8_F<5/ M9A?P/?M1\1[OB?_!:?,?Z,H(NFF+ZDN,%UWY )=&"TMH-@L:X"D#%;J MBIDV%(Y2+Q.UYL.<'3:2=>,=@J:+K/@'4$L#!!0 ( /=DK% WN>1K6 ( M #$) 9 >&PO=V]R:W-H965T)NPJ:5Z2/??$M2@P__M,**NW/O3O R_Y)9-Z *1)A2_D)Y&_ MJCU7/="YG/*"E")GI>M_@IL=C'6 4;SFI!:]MJ=3.3#VICO?3EL_T$2$ MDJ/4%E@];F1'*-5.BN-/:^IWW]2!_?;=_8M)7B5SP(+L&/V=GV2V]5>^=R)G M?*7RA=5?29O0PO?:[+^3&Z%*KDG4-XZ,"O/K':]"LJ)U42@%?F^>>6F>=>M_ M#W,'H#8 =0$PF@P(VX!P% :,I/J9RQQFG!6>[RI5H7UGP)N0C691SUHYLZ\ M4]D*-7I+$0H2<--&K>:YT:">)EP,)3N').XD0!%T&,B)@4Q\.," ;H/0:1 : M@ZAG$,%1&HTD-I*R^<8Z7D>C3&Q5!/NJ 4OD9(DL%AB@$4RC63R L543, LG MS,*"00BY#6*G03R_-$NGP?)Q:9:S9L-63 '&P!\7!Z7)ACO ).:(8E[#X!H1G$<(AME4C-$<>\FT-Y. M$/J@MM"]"<#H/TKC7KK07KMV:1P::SXF-4,2]QX XSFEL44VRJ2F00&]LTM? M)GY@?LE+X1V85,>@.:S.C$FB_((GE5JF[B]=AY*SU,VE:O/F$&\ZDE7M!05T MMZ3T'U!+ P04 " #W9*Q09W]AEZ\" "G"0 &0 'AL+W=OA8$:GOD M)5-WHN:5>;,7LF3:3.4A4+7D;.>,RB+ 81@')05?Y"> M.I4ED_]6O!"7A8_\EX4?^>&H[4*PG-?LP']R_:M^D&86="R[O.25RD7E2;Y? M^/=HMD&Q-7"(WSF_J-[8LZ$\"O%D)U]W"S^TBGC!M]I2,/,X\S4O"LMD=/QM M2?W.IS7LCU_8/[O@33"/3/&U*/[D.WU<^*GO[?B>G0K]0UR^\#:@R/?:Z+_Q M,R\,W"HQ/K:B4.[?VYZ4%F7+8J24[+EYYI5[7IHWE+1FL %N#7!G8'R_94!: M _)J0-\TH*T!'1D$32@N-QNFV7(NQ<63S>>MF=U%:$9-]K=VT27;O3/I46;U MO,0XF@=G2]1B5@T&]S"H0P2&O7.!(1 MGT\44X+P2 ^$0S1)"2PH!@7%$T%TO)'BB9\D(Q$9J9FB4O/#L)8$U)( R4E' M8I*)FRS"V6AC)I,O-0 -I*2@E!20X0_D!BX)B#RGL202< Q0.J?0O5R EZMU7)Y<%U LK;BE.E M;*5I6ICO3![R2GF/0IN[U-UX>R$T-R+#.Y.R MH^F:NDG!]]H.$S.63>O03+2HV[8HZ'JSY7]02P,$% @ ]V2L4,6WP8?< M @ XPH !D !X;"]W;W)K&ULE5;;CMHP$/V5 M*._=^):$($!:0%4KM=*J5=OG+!B(-HFI8V#[][4=;S9Q!DI?B.V<.7-FPHQG M=A'RI3EPKH+7JJR;>7A0ZCB-HF9SX%7>/(@CK_6;G9!5KO16[J/F*'F^M495 M&1&$DJC*BSI!_.<-WPERE_% M5AWFX20,MGR7GTKU35P^<1=0' 8N^B_\S$L--TJTCXTH&_L;;$Z-$I5CT5*J M_+5]%K5]7MHW+'5FL %Q!J0ST+YO&5!G0-\-V$T#Y@R89Q"UH=C,IT]C?FT";;OM/I:?3I>4$HF45G0^0PRQ9#>AC<(2+-WKD@ MD(LE&9G3>.AA-8:DZ1"R!E@26 4% Z76G@X"I3 ! PF8)6 # N9EJL4D%E-; MS =*4X2\6$ 88ADL)P;EQ",Y+/'4M)"XYX8ARC*&/3D@+HXS NM)0#T)D)X8 M)DA!@O3^#S0!"2: C\E$R!4G,29AUO_&S<0E(&",D"0][=>9B-'&.FNC6 _ M&,%%C,:>\#6**WT WY]^#-;Y(R9W? 'Z@<<$\2\AK!VL.0J;"@(+GE, 4$3 M7Q ="4IBKT)6#I0,0-<2#+\O2@>YT!'<&G *.1I=4^C^.X Z"@1;"J.]HW!MN.(([ P9: _,O M$P<:U =]=2H=]-77.[M%-4$&W&JE;DO>Z?=I/9(S*3@G2_Q=-7.6^\T[?CW M-9?[HFZ"9Z'T'&*GA9T0BFN1Z$'GX: GSFY3\ITRRU2O93MVM1LECFZDC+JY M=O$74$L#!!0 ( /=DK% ,HZ5+90, "40 9 >&PO=V]R:W-H965T ML^SHEK:1\Y/#XY3;8\T M3ZH9.]%"/-FS,D^X&)8'ISJ5--E)HSQSL.L&3IZDA;U:R+GGJ$D/1UY/.*O%*3G0GY3_.CV78N2T7G9I3HLJ9855 MTOW2?D0/L>?6!A+Q.Z77JG-OU4MY9>RM'GS;+6VW9D0SNN6UBT1<+G1#LZSV M)'C\54[M-F9MV+W_\/Y%+EXLYC6IZ(9E?](=/R[MR+9V=)^<,_["KE^I6A"Q M+;7Z[_1",P&OF8@86Y95\K^U/5>3UVCP) V4&&V!E@%L# M$?N>@:<,O)N!=]? 5P;^S<"_:T"4 =$,G&;MD3COT M0,1Q;>M)>3KRF=C/2LQ>5M@G"^=2.U*8=8/!'0QJ$8[PWH; 4(@U-LP]+<+& MA& _Z&.> #<:)(;@XBV($/.O"E [_G8*ZQ;#!$8@J)B5SU M!X"($2F,]$C-YDY&QE.0/?8!R#XPV ?:/JT;2-B)Y,Y<%VG, M)Z'B,52/<0@R#DW&D<8X-/8&P]L]%1A/ /:H1R#UR*0>:M2C29L]"16;X3 9 MX#L'^ 3YP=7!F26!F"Q$&AHL;",$22LH6R%E87FTU>+86UTU?.$?A6CO@X!OCZ3&_(ZVI)'_["FKL9!==@AXRPC>Z:"Z M"E 89D&-R\9?SO78(UO.Z4E494,>F<=/=8W9OQ6IZ&7A1_[[P%-Y. HU$"SG M+3Z07T0\MX],]H+>95?6I.$E;3Q&]@O_(;K?1*D*T(K?);GP0=M34WFA]%5U MON\6?JB(2$6V0EE@^3B3-:DJY20Y_AI3OW^G"ARVW]V_ZLG+R;Q@3M:T^E/N MQ''A%[ZW(WM\JL03O7PC9D*I[YG9_R!G4DFY(I'OV-**ZU]O>^*"UL9%HM3X MK7N6C7Y>C/][&!R 3 #J Z)\,B V ?%'0#$9D)B I ] .OU!-Q6=FPT6>#EG M].*Q;GE;K'91=)_([&_5H$ZV_D^FA\O1\Q*EV3PX*R.C674:--!$8\7:5: T M[S6!).@Q$(2Q0HY!G%KO "06Z,:5H+2 ,6(P&[$VB$<&,]@@ 0T2;9 ,#;+0 M2F>G2;6FZ=(9A4616/.]*AOAI"!."N!8:[=R-8E%O)Z4C# R$",#,)"%X6H< MC$G)"",',7( ([8P/YAJ6V7MII?4Z,Z,IVN4&T MN2(:$\/7;03=M\[7%!+E-C$D*FQB2&1_KH)!)5 3=M!5%O>V]-0(]:TRX=X+%;).T=7$GE)!)&-X)QF/LB+M.Q79 M"]7,99MU95G7$;0U)6?0U[W+_U!+ P04 " #W9*Q05F=-+6H" "U!P M&0 'AL+W=O@!4QM)VS_OK8AA!AGFX=@#V?.G!F;F;2G[)V7A CG MHZE;OG%+(;JUY_&B) WF3[0CK7QSI*S!0F[9R>,=(_B@G9K: [X?>0VN6C=+ MM>V%92D]B[IJR0MS^+EI,/N;DYKV&S=PKX;7ZE0*9?"RM,,G\I.(7]T+DSMO M8CE4#6EY15N'D>/&?0[6N\!7#AKQ5I&>S]:.2F5/Z;O:?#ML7%\I(C4IA*+ M\G$A6U+7BDGJ^#.2NE-,Y3A?7]F_Z.1E,GO,R9;6OZN#*#=NXCH'GT]B59M8U$:&VF01QQ2[1"00P@@YU:HKWMFG6;/ M,U"]S[#GP7H[3) ;S3#0?F!VJEKN[*F0G57WOR.E@DB-_I.L=REGZ+2IR5&H M92S7;!@DPT;0;AR2WC2ILW]02P,$% @ ]V2L4 SUP#A: P S X !D M !X;"]W;W)K&ULC9==;YLP%(;_"N)^ 1ML($HB M-2'3)FU2M6G;-4V>UZS.[$R:V;\S"KYRX'792;D8WWTFG/-LKT**@L/^S[URBRO MW-5"C3W6JP6_B"*OV&/M-)>RS.I_:U;PZ])%[MO C_QX$NV MUJM^Z?JM M(E:PG6A39/+RPC:L*-I,4L=?G=3M:[:!P_NW[)_5Y.5DGK*&;7CQ)]^+T]*- M76?/#MFE$#_X]0O3$R*NHV?_C;VP0N*M$EECQXM&_7=VET;P4F>14LKLM;OF ME;I>=?ZW,#@ ZP#0^@:GF[N:O%3#.1 MK18UOSIU=Q[.67OLT)S([=JU@VIWU&]R/1LY^K+"4;+P7MI$FEEW#!XP:$RD M-H%)U#.>5-#+P)",-;82!&1<8V,C463( ++0,;*U$4QB6&D +EB@$@3#!+$/ M)PC!!*%*$(X2&.NY[ABBF*I;<3]&E!H3WM@UN5L'+P%U)X#NT-"=V'7\. @"N [R82OT@4K$ M]$(;FCH2:,)Q$5"&FF4ZB Y7.(J"()PH!;KJ \*V65$RD0*V.Q3<85<:BH=J M9Y&Q21N PK/ .(+I1]18-&RQ"/!8RZP R'KQ-).,)D:F-@$V3@0YIVD" &2+ MNF9AO' CA MB3JP>6+ /!/30D!HXJ7%L'-B#*0@9AT \LV/26_P)5ZR^JC:HL;9\4LE6FL> MC/:MUX/JO(SQ-9IO$#">RE:M:ZS>TW=]WO>L/N95XSQQ(?L']95_X%PPJ=V? MR7?W)%O+_J%@!]'>1O*^[OJK[D'PL^X=O;Z!7?T'4$L#!!0 ( /=DK%#/ M\N7'-P( (8& 9 >&PO=V]R:W-H965T4_9*Z\ A//>D)9OW$J(;NUYO*R@P?R!=M#*.R?*&BSDEIT]WC' 1YW4 M$"_T_<1K<-VZ1:YC>U;D]")(W<*>.?S2-)C]VP*A_<8-W(_ AIKNB%2)T_5']2?=N^SE@#GL*/E;'T6U<5>N MT&:I(*PU^-]>ZU=?> MW(G#($ X)X9@@V5\EH"$!?29$NGGC3+?Z#0ME[LELNH]R6DC2U M(Y"U"Z3ST=1A?*= 9"T0Z0+1S3&DLV,PFD1K6J-!ZD5DZZX*!) <-)%QR4H>0> M9V7EK"R<8,99:J([C,S*R"R,<,98:J)9N[LO)<:&-WE]&V!G/>FX4])+*]1[ M,HF.P_11#YA9?"N'K)F)GV7,A/Z%V;ENN7.@0@X7/0).E J0#OT'^2PJ^5$8 M-P1.0BU3N69F-)J-H-TP];WQTU/\!U!+ P04 " #W9*Q0YQO >JX! #! M P &0 'AL+W=O>=)6BGJ[WVX$E6/4'M9W0OOVM#45IQ!_L7<_.S*YQ,1C[ZCH MG[PKJ5U).N_[':6N[D!Q=V=ZT'C2&JNXQ]">J.LM\"86*4E9FMY3Q84F51%S M!UL5YNRET'"PB3LKQ>W''J092K(BGXEG<>I\2-"JZ/D)_H#_VQ\L1G1F:80" M[831B86V)-]7NWT>\!'P(F!P5_LD='(TYC4$OYJ2I,$02*A]8."X7. !I Q$ M:.-MXB2S9"B\WG^R_XR]8R]'[N#!R'^B\5U)MB1IH.5GZ9_-\ A3/VN23,W_ MA@M(A (WJ<_.&S6QH!7%W\=5Z+@.X\EF.Y4M%["I@,T%+.K042@Z M_\$]KPIKAL2.L^]YN.+5CN%LZI",HXAG:-YA]E)E:5;02R":,/L1PZXP;$90 M9)\EV*($B^79%XE\F2!;),@B0?Z%8'WC<<2L(T9'S.I;QM+M=EDH7Q3*%X3N M;X26,)L;$7HU_?!S/W%[$MHE1^/Q(N.X6V,\(%]ZAYX[?$]S(*'U8;O!O1W_ MJC'PII\>#)U?;?4?4$L#!!0 ( /=DK%!X87#H)@( ),& 9 >&PO M=V]R:W-H965T9ZQJZS* M!O;<$]>ZIOS/!BK6K?W0_QAX*2^%U ,HSUIZ@1\@7]L]5Q$:5$YE#8TH6>-Q M.*_]3^%JEVJ\ ?PLH1.COJ>='!A[T\'7T]H/=$)0P5%J!:J:&VRAJK202N.W MU?2')35QW/]0WQGORLN!"MBRZE=YDL7:7_C>"<[T6LD7UGT!ZR?Q/6O^&]R@ M4G"=B5KCR"IAOM[Q*B2KK8I*I:;O?5LVINWZ&;RP-#H_4TGSC+/.X_W_TU+]FX8KHO;WJ ?-=IHY MM0%"C=[R.%ADZ*:%+&;38Z(1)EQ.,-LY)D[N(<\."+F'?)Y#TO0>LIM#HN1? M,DB9'1Q'3L>1$8CO'"_= K%3(#8">"PPK48/(0;2]!4+2!)/"C)'X03C<%*3 M.2J-HVE5' O&(0Z(VQ=V^L(S7]-B3*)?2WF3EDGQE^\F MH^%W/_Z01S_^4/SX,@W*K4P*X2>A>)444;$7;Q)>,TJ3'YX7/_[P'(?R\(EX MER;%)H>AH0R;3]_YV4!,1IX8#\?#?.-G,F\.,?LM6O<3_U@L\R+S@^*_FC/5 MX ]R'>$(6.*]OY7.J)]OWWY\>'/[?O'A[^*G5^]OW[VYN??$F__.E/B,KFXP6L$=(ZKV-_W7RZ\N/<6?&FS#*:$.4!'/;OTL\Z=S\_'XW/ M)Z,.?+V.8IF)&YBW3C,'6>_3Y-P/ @EC8$3(HSM6NM_Z<2Q>E'F4R-RAE"(K MW=OEB:^V,EM'R5K\E*5/Q4;)O[M,:/BND,AJT:-$.O#UDIW#@S2#O9A1<3,I2*)D^U96?/]S#P6)]^5V MZ5(&L-KY]&(TOG+H-P7V3'*@*!14\%>>QE%()/;"C_TDD'C/LLC%N?AX_U*< M/COKE4[.E 95X@L3C[WF5RYT>AD)]WB!GG^4-: &T%O; C MN_:/N,M SV1P:XAW^6L9[1 83R32H1.@)S]91W!6M5;K* 8K.;@QC^M N9H9 M1_XRBJ,B 'R012Y5B4]:S^-DW6Y\ ]V[Y!+^5*PDJA*/S/ M9IPC@7C/GF50-D5, G2( #0PL+M,@I;!O!H0E-HZ1XDF\G+Y3QD4HDC%+LUS MNB)X*K>[-B5/4G"3QJ',\O^@.W>AOC,[T.@VF"MY^FPX& Y'/3C4GXO M+N=##W@=_U^PH2#\LMBD6?2;##TQ]>;SD3>_FNN'49Z7BO?32BH+OQ# U<'& ML#6- %Z6*%PZ^7D1AA$>'#$%''0>)2+P=Q%@KH6*RFT9DYP)Y2H*H@YZSFLX M.U5CSSJPY]PYP?UE:]R#RH&)B_,1BL-'X%&ZUL;%B'^\(UPXYI29/OZJZ("IWEA\@85HPU'GO9!&PF$I7XG8GV5(X3B.[3(KF MQE96J_:X!C^1.Y#)1YFX=ZH 41T2?T/H'U)BN"10E@E3DG).2P#A)UI9EW* M!/C354T_P??H3I"Z";=10MX*VECM0B ]"%YU@-,8A+>#Q5O@K4Q$C*Y3O?9>@G).79>A0=,BC!XCH%;'3]7S07\46;0L"S(00#D&%I<8".3">D0)WAJ3=&A[I(D"'BBP0>X5@"XC'C&\>Y9AUCQG?V-]U MH_KA=<5(Q47XSU+)-90 X*^E M8%B#.$@TH\.W^#DX8G77 P!-&D2L5$DC;-%7_ZV5>(B\SH'O9=A+9):8/D4Y M?8:"FB#M%]/&'>D3NS<;<.'0X$[L Y(31@>P;%8'E&H?B'*Y<\A]N=O%Q%_H\6IP8>?.V&^7<&.OND4,J\">6/"1'0_F-EO[ MB6(&SV)^S2QW&!8!^.@+.,AK1B+ :\F&;JOP?5I(,;H6#ASBU6,**A6U4K87 M8+"EVRC(/0QP#<0IF#'BW_]M=''YO0H9>OC7_'OUY2]2_PU"ZBU9X,!IDA#N(]N3!DN:S!Y@0YM0%IB\&!+(U%M,6H()K%!>\0(4ZC MK1\S'P,T@+V!^ 5D.EABB*(U _9P5]M1K9WBBEGZ"#9+ENYXNEXZ+]%VSL4^ MDC$X[WFY]C,"A )%RRC=@@#Q1)BE)9@_L!8&ATE+$"3 NL_#"$SP'(,2>80V M4" ' M!JD*;A0>O[D]S;)][X"!3Q38B@!'#5JQ+QPT#[60'R^PFO2QTA5( / MQ,-&ZL PL@GN!)BBL)UR"8#REG+CQRLDP#5,SA+%,ZE%O1CI2I-S6!U< K%* MRR34WW/$1M^:P%,8AY^#@S+7K@O+BC5Z,WESHH&(;ACHG<$'G/'XY^9[&H'V M^RKZ+,/SE<0KSA _50QIZ^\%D$+*V(NC )0-4@#B)\K):RMW<':Y6DD.$%>@ MJ#,C0@Q0\*&,$:1[CX%-=_Z> M( 92> *G*M]$.]PT L**8P"KI$B7"D]67 <^!)W*( !(G%8LK3@@*_TL+'A]66@$0POC#C$? 6<"<1 M*BT<*9Z 3=N'B:=-! @+HQ P07($-&H!C@>,7VH)BJ2#T&FH:;TP35AC(<=O MD6,5=?A$UQD,PWR-S.HG]SE "R<'MN-5^;X%P1BBWXR^&2X&.";PR:I4ODR= M>XF8)28TB )@@I^(Q3J3TF0W0<826.\(&%O0\S=&X#(F\&B(A7*[)7L4P+@- MBA3CBJ,KLI*G ['(Z91(_/KFWJFS]BF9I0S\+6+V"0X#D@K)"877,H_"",>K MRQ[ ?S.-*>+/,MNEX%8S*AFM!&D!-B%YEKF%=C\ ;R\G_TL\1<6F%R9<9*/F M9+ JHHR07G\08O2L0*H":.6O)6)7L8 ^N:&T3"9PS+!_6PKI9O;A[:G$L'WS M8>]7/XD;5$KW021)K> #U]Z!>V3,WD?K!%1)@"IL4>'V#JR/MI!ZRY!#5L?X M6AR_']@YP*#1#E4S>CHU.^AC3N;F*V!&),.<'2$K*R1J"9I7.D$C*$/Q-D)M MMV#SW4K/J&\^*+7S 9P> !$WO!:U8)IFAB@GJ8!$!)R.EYT'L"V"]I#N0);, MAC./V 78EHZQ*EEXP3\4*,EQS6B[+($P"4"0JJ"Y0-_N,CA:%@$;L*DL0Q- M:U6J(@=Z"5"8 V_\"@(:S8*PDOF-*)YE<6L=#Z.7>[!Y6#O[;,%X9 CA*=D% M0^UGL$Z6!C[/RSR0.XZ58\"([ Y2>QMT[BCCY%-HZS$%=19J/9]F(7.G5O7P MD13W.2(*'U50XGP#Z4"H2-@#NFOB(Z$3+Z#Z&@#!*U#R9W%_XY'[EM%(=FGA M=G_#%!A<1P#$@M8!)J54$).E"7P!$ACF;,$AAD=BBS&Z./HDT9:"@Q)R8!? M@=9Q)+93%C&>40];L.7*S$2@\"NU$Q)2X,>!"N\HT1+[(#A@3T8@(QL&TOZT M\73X9P-(BJ 9#YBL%+AZ)2 :V]5U!!KGH.65N\+TTXH/M&/(&7]!E'!C.>/V M@J@P9M_G-?F,/+VGE3EK S3[J"RVP #0 **+2]'\P')G R9,=Y[SOU@L,5H MX)4?J[F=Q!"0$LT^C,_J*-H#'+$A\,@LYG4G; M*D(GOWJYIQD5/*1%PE;U&"@&NO&IN)IJ-/,/,0;B 2#,/A/AUMY6<613X0[T'E14@J&L:@$/"158(@+W')VY M%1C)\BG-/A%=M,'#[*K9+;3PY2_3LN@$3G%BJ&QT3N#:QDR6)BD:2"H*\[I: M)T+V@BTCM.,CE"*9W'&X5IN%MC'WE)9QR':;,EZ H7.,/L JE%U 74W5;.A+ M@EV?*['/7 M92FW*UGT$@IQ5D6WQ#$A>49@JH@8#9-+X#9@#:+YLA<4&<^#+%JB^P5F MS-.U>(O3Q @4*VVE]//?RA3E"1%6+D[+Q*<#65?..#>XHAR 'YM0;2[X)BTH#B8Y)6<&B<5^XF M*5UV6&&= L; LN#%*%I4;N-^('[9 ]HBUPS81?K([RM4%9"@6US,-4+9E?F M7N7'%II\" QZ;LNCHB9MDSQ"U:TDK8IUX/I;C KXX2,PDK^6:6DX#!"LX@Y: M=FB&-VJ'E[2YDY#6SZ)/B"/-!XJ[&URJ$*G+).MGB=/T$W&$NGX*7C6I2,6T M(U3K#9)0BSN4HB,/9-B%+GUU0*$.:T$08ADW7FX>;2.4"7I?U'_L,-+1:; 2 MV'F;GJ^4N0*1Y3@(B$;@UJ_I%Y1C2"9@4N(^6,2"ET1AUR,*-3TB\[/\8\K* M8=@.%.1G$SR4<%+;?CRN;%F$I=3J-Y,Q%1$")O,-: 0N/D_\ ETJ5KNY[9BX MEG=[G+AKE$?IDJ(15#Y@?T^ONZ+1[5T$.@8#]H<,C?&@I=2UA:0&;@!CA*!J M ^"MLXHTNK_0_K\L,_#+$&P*SBCX79"M?>E?S2_7? MZ7#BS693\V^]#-RJZ3F]&%]XD]%8G,''T85W.9_ QYZ>"0#O\LJ;3"?P83[W MYO.QJ!4)*1(R$3DVK[;<="X)?)A7=U,5*?I[#C&*74B=;Q'*'( MZ_'[9V-O-AQ3:M7>6M,,R0@VQB*24'R D/U%#)YJA";R,ZAM%)4<8%!!E1,P M#U5@_]G4FTRF^&4F*>@ IG_;GE7NMK;9UY#N;#HZ(<*=38<-L@5".<$CJ82G MCMNV)F6;6>8>(<<\*ZB/%5 ]1^^5Y@ ?OG+&8&5= M&^V00RV9KCQI'3<$V522F*HJ#[T3'?[2N2:ZA[#2G 9L( (5:>@[D7+D':9H M@BHP)!"?4*#+BD'O"&XKDNY9L?B(,MQ@=F,Q2!RM*AS3BB15EM)*(O!UM(+Y MQ)FB$UT&%%158H!HG2S%$AU=KJ0<5"HO4F&N9HD1#:,ZJ'IB\-5/XDT#EHV/ M/JL$*B2@L,0%3&QP0_ :MU&P4GL+W..K7*T!X6'K-BFG1O@8N"=)25_EFOITB0':G4"7:YFJ D60G1)^>%FA5 MO9DI,RB4(*Y$)N"P511H%JNL=Y.X:% #/."PXTE>>7- !1S@!D+N;WQ4K1*X MWR]40.=:1VI(I^G3WN1+MO+E=:TS@SVLMCU)$%''OPJZ?Y 47P_%#3;MD2PD M/JCW9S=0P2'ZIJZT6]PHY&=5.,^'3HLF\CA6C,4^ITM6QL_3'E-+7R>5M%A- M)< *1.55%QX.T2VB !S-4[9!RV+-#L7CUO/$3*T$#Y6,PV!&*)$V=#'"D3V5 MJO:N&FTJ\ CH+]BGO_FRN<]8[G(GO-'796+2P=>FTR@7/Z?A=9L M&PU@F"Z:R"8#9V M7E?053;CC$,*4^'V.U7VN:B*E \%&N;71Q7HZ%+JW.JLL6LZ2E-,1<*021S$ M*-J8H$>I8%3Q('[67(X^#[/VR+MPY%-+V*PA_W(R)872!\KLI>4( M21RC $/QK+-5!&PF#:@53O%$ Q-)/-X;K#MP)N=@MT0I>Y<"W;73HN2?@F<] MX>6>C2Z]\>6\Z4W>US&8<0=%1DT5JJ:$T89^KI(@'-#W*5G@+]-'MALK7PTT MS3EKKIH_V4,) Y=4)=ZE >RK?.D!/$A\Q49(:P0.JW=SXD+%)'71 FTN2G#Q MHM_TEB_ *_ET?A^ WD#"WJG&<"N'2.7/NB3"(M6B4;^>ZL(,4@?DRZ$]:>K0 M51ICU1YS9LYJJ6+3F&.PU1$5\I=84<.9%%6+966,%5.4B0Z84+:H4;337MC5 MQ]C* Z_A= #:"@.WE/]5:Q"'Q!2*KO?_4C%]55)7BXA;M3N/U8IVIL=$UBN6 M]17%6WDE#CA8:%>Y0!8&JH 72U6XJ)JN$*?$# C MTRA58U"KW1-*+T+)B?;Z7[Q B3W97MJC[H6T,!3#C:]&:J#B/TU M.%9K1$)=EBJ)=/W'&%B#^>20K7-C5-?I:#REN6=B @Z"N,3_]%E=WG ^4H",!I<7 M,&$^[8 :3:36X;_'3*M [S<8F[::"PB8;,\:FW("RTE&38=S;S*9T-2K&>!^ M3I\O+^';"]W*]*4Z75,52AO^?CZA]93PPQPFOOJGKJD7+:EC6X\\FUX.O?%D MCJ-0GIL*6\=:L*/CN65]U@;6^N0XXZU")VW%NQ1%9QRP_73HS4TW?6]NZAU\ M?*)%7%V+_J5N49#!$?"%A]ND"J:^I?"H/?>#:L2S[120W2FHC[7&Y<[?JX8] MI4$1,Q\QE P^HXJJ&4]U-#0-;KD?JT9J;/[#*!=XC8^ZX\>.R5F]GN1*<\20 MPX+-B&$MCLNRCNU=H#JLJL2U*VA--9H9S&>L0&@""0-]C(YEJ@V*JS:PUA7[ MQ,5H6AVPX/>7<16<*6VK@Z2-94#JHBKYMM&]\6N%XRJJKPRV6MLH:5FU--G! MX]D8W9/6\@OD(5 (,=@.)N:H@G,5>EKK-K#X19T--YE<3;S9<-C6:%&8O+BN M[2-[WBQ?>0JHO(UVLIKV..*$L?NORBIAEQT5YA4&(G/C[%HTT.=YL0+>+_QM>B9 ^*&^\*L[C-,&TA)S6:F.H32:;4J=+O&LF$:J MC4W;0K*HS+8^+HV6CHS:83:LHJ,U@D^535D9";JNIPD / 4J>> M7V, #L1M(A;@>,6@@BT-:'O(3-//+D?>>#;'??3Y#6G?OUA4# =>S9V_#S9 M*EBK4' ;!W[$CCR=4F!K5I75@0;U1+1BMHYC9E806WHCK2=!^JX!F$05N-/7 MU%.'1?78_Z]U!MH!B U=,V/2] M6VDS]2JB*%F5.3LTZH4([!R1]\I7!O]3F@C0RZ!0" @37+'T0\[4\R;+LJ#O MU<'UVZ5TN1YVN]9T&R57G=07)F3S#<:'?I&<0%K%0(ZJF)BVH[;YZC4K'!6A MBB0L8T;IA1D?MQV>EJ2[47S0AA0[1X8P5Y,?*(VGL]X!M1Y3 R\V16%&)DS+ M)1+V@U@8T*Z9FBF$NL%/UPB MNM>MZH]ZV/^%_81WQL?N1;6_&WMN)_95MQ[RM0K2[C MMG>4M38=NQKQ0 ]R5Z/>Z0-56CO:\1[OJ&3_;%&]C^ZMU;JBUB&JJ98_JB2C M+8;ZK3WB6WM$QYCC:NN/HN6CRO+;B?9;47UW4?W!0O>C+N=0>7S[O3AEWX>J MV@_?27\1[_%5[:*UJEU\256[^,*J]B\NLNN^FK:#8\T/9;.=\Z_MF/K]R\6ORL8V&K]G77?VCM@ M8*SCZWXU?V__YEN@#C;SW=_7LVI35,O.(R=3=JV65W/^A)/@#L"J\+ +X,OV M:5^"1,=*Z\&?MG^Z?WQ &5JOR9I20537>NS#I&O_V1AMCAX/?S\&.MWR.OMT M_33-E__\SP(@H-^E0&?2*E9Z]9D"[RJ+C[JMK-[?_46.Y"B_:UNU51J]?=-;S%"3Z"1O] M04CO3VCU-#OE<*O#>\0!]8;MUUAE.ZM7P3DME'IK9W9+(W1S#/VD9YJT?U\\ MI>W?8VU+ZY-56CJ_EPI&O1 M?MGOZ(G_=E[/VXL$(W.@@._/G+$#??%4NJ7_DP\[\#Q:-S[:]"]OZ5D MN;$=O96_M(18T#\ZXN=/E(_G"%SMW;D/* )Q+ 2]OZMRP"L_.-QRTC&):FROIF:/MPN?@]1TVWX?)A1CI(6K4%0LIW.J;/WE M;RM:X^@Z^_?[(A-<:_VE46N9@V-KZS8;^#K\:6$DQ*R5K_6P2@"TCYOJ<2,C M*,:M VL'.@2D7O5*+SJ^:EU4"?+#"UX=N:"Y]<-+]A?1'V,6(20QUII1 ?B^ M+6CR 9]UF) /=@&Y:=+3)4)N47C[?/-[STYY=_KD$O]"56R;46[\9%^]0;)S MU,&*91M]-YM(KE!-!NSJZ_Z$+K.HLYBZUX"L1$;M%77N3V^J'V-9[H7='NC^ M '8M?/K'K#F^&ERY%F9?R?,19.B:FZU8>I[GQ8__ U!+ P04 " #W9*Q0 MK$XIA#P" " "@ #0 'AL+W-T>6QEU%7*]?.UWR!F$BA52<:..J,FAJ!21O;!)GP30, M%P$G5. T%BV_X;I!F6R%3O!L@)#/OY8Y)/CA[.675NJK%\B/DU>32?AP?G6( MG[G .4:>XT.>X&CQ&@>_3WH1AC\FML$#\OD?DO^,^X!Z8:F#;H/2N)!B?Y\L M8&H3#FA-6(*O":,K16U603AE6P]/+9!))A72YH",ML@BS:,/1]ZS9]?Q<"JD M6N@D[[)Y[EW:\"A>5-.UU.];LQSA M?'MWX$Y!03?.WQ2# ,-.ZIIMWS%:"@Y^,;\L&!U9,(U)7P=54M%'PV>O2F8 M4!BM06F:[2)?%:F7L-']==H4QVJ>GJ#FI][G$@0HPG9%F[O_G'?Y/RN>O?E[ MR>ZOG('+Q_$7.+O^QQJ#K.CNM;:^Q#2A:M91I*CJU%[4^0TY9?NH+CFS/]!E!+ P04 " #W9*Q039/8!(8# "7&@ #P M 'AL+W=O2GS]PT63NW MV1L,;+[F);.?]88KJ%EJ4S('EV8UL!O#66'7G+M2#NAP.!F43*CD8+\=Z](, MP@OM>.Z$5E#H"VX$O[?/]?Z2,&CPBU^SQ309)H153I\*Z;@Y88Z?&5UMA%I- MDS0A2V&LF_NYZY:E4*(4C[RHK^Q:WW_51CQJY9BY@F]=^2)W 7@^ VZCBTOTT0]\S_A%$O MER+G)SJO2JY<$T?#I9]=V;78V(0H5O)ITC8A3!7DBW) 0V:J&0K:^GN!J6=% M@ HS*U(/'@_R6*N"*\N+FA*NK):B ):"'#') DB*0-(>(6]I M )DAD%EOD'- "B!'".2H1\A.),<(Y+A/R"R G""0D[B01Y45BEM+#GT*A+4= M8&TC6-MQL>9563+S0/22S,5*">C&( 4=YKFN( 4%D#L(Y$YYX)UGC?DC MC2R0*U\( ;QDL%'D#>@U/&3+\G]CB1DDC:P0B%T.+4Q3$U)A DDC&^124899I^L5_N$R2A#WY*]AWW>Q R348;9)XML MG[>'/BR$F9J LMH'>Q*S35(B)&2B+?M)!3HUD*\3$#)1%-A!Z;NR^9\8, ME$4V$')"\VDIQ,0,E-4&&K0?0@J^A/U6<0%36"C/F&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'/%V3UNPD 0AN&K(!\@ZYGA M-P*J-+1)+F"9Q4;X3[L;!6X?QTV,!#LIT$=C9!G-O-7#RJS?;96%8]OX\MCY MR;FN&K])RA"Z5V-\7MHZ\R]M9YO^R:%U=1;Z6U>8+LM/66$-I^G MSYSL]IO$[?:43#XS5]BP2S@<<_O6 MYE^U;<*-BK\%B;D=Q/$@A@=)/$C@0=-XT!0>-(L'S>!!\WC0'!ZTB - 2'K2*!ZW@090J,J;X) UKO-:D<$UXKTD!F_!BDT(VX+U9T9OQ>K.B-^/U9D5O MQNO-BMZ,UYL5O1FO-RMZ,UYO5O1FO-ZBZ"UXO4716_!ZBZ*W/.%=B?:R!*^W M*'H+7F]1]!:\WJ+H+7B]1=%;\'J+HK?@]19%;\'K/1WI[F\(\N MN1I^MV8$MP^7RCX^8YAZ=_](Z=!OL6:X/OSG8ICZ&V&N_CK8_@!02P,$% M @ ]V2L4&:LT:"E 0 I1@ !, !;0V]N=&5N=%]4>7!E&ULS9G? M;L(@%(=?Q?1VL0AL[D_4FVVWF\GV JP]M<2V$$"G;S]:=.G21F"?6#,9R75RJ?&4A,CA7&U"K'K%LRJ;*D6Q,1H M-&:9:0(U81C:',EL\D2%6E5A\+@;;U-/$V5MI3,5M&G8NLE_)1WN$Z:.JFZ. M+[7U5W%",GC>Q"P^CDV3&/4).Z+"[X5M/ZY[79-S.J=_H9FBT!GE)EO5<4GJ MK2.5^Y(HU%7J2^4H?PM.-XL][URY\*+JF)AM*O9C0GHYCK"MJ!^@BYRS1YC'J63OQG%ND]NKDE!]5/*:^W(?] M-&[9O?<=^'?0LZXY[=3/QR% ."0(QS4(QPT(QQB$XQ:$XPZ$XQZ$@X]00%", MRE&4RE&ZK/N[\3L"U!+ 0(4 Q0 ( /=DK% ?(\\#P !," + M " 0 !?D !D;V-0&UL4$L! M A0#% @ ]V2L4.9)<-KO *P( !$ ( !F0$ &1O M8U!R;W!S+V-O&UL4$L! A0#% @ ]V2L4)E-S,>9 " ="@ & @ 'X" >&PO=V]R:W-H M965T&UL4$L! A0#% @ ]V2L4#;V-33O P 61( !@ M ( !O@L 'AL+W=O,/ !X;"]W M;W)K@54# !5 M#0 & @ 'I$@ >&PO=V]R:W-H965T&UL M4$L! A0#% @ ]V2L4.OK.-9E P T0T !@ ( !=!8 M 'AL+W=ODI"K$! #3 P & M@ &C'0 >&PO=V]R:W-H965T&UL4$L! A0#% @ ]V2L M4*B.S!&U 0 TP, !@ ( !BA\ 'AL+W=OM@$ -,# 8 M " 74A !X;"]W;W)K&PO=V]R:W-H M965T&UL4$L! M A0#% @ ]V2L4"O7\8NU 0 TP, !D ( !-R< 'AL M+W=O:+0! M #3 P &0 @ $C*0 >&PO=V]R:W-H965TW<@$M $ -,# 9 " M 0XK !X;"]W;W)K&UL4$L! A0#% @ ]V2L M4$LPY&"U 0 TP, !D ( !^2P 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ ]V2L4$&@#:FQ 0 TP, M !D ( !O3( 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ ]V2L4+0C1S^W 0 TP, !D M ( !)SD 'AL+W=O&PO=V]R:W-H965T M&UL4$L! A0# M% @ ]V2L4/WS[$FW 0 TP, !D ( !]#X 'AL+W=O M&PO=V]R:W-H965T&UL4$L! A0#% @ ]V2L4+^A M, 0 ^P0 !D ( !U$0 'AL+W=O&PO=V]R:W-H965T)( !X;"]W;W)K&UL4$L! A0#% @ ]V2L4#>YY&M8 @ ,0D !D M ( !5$L 'AL+W=O&PO M=V]R:W-H965T&UL4$L! A0#% @ ]V2L4 RCI4ME P )1 !D ( ! MW%, 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% M @ ]V2L4 SUP#A: P S X !D ( !#ET 'AL+W=O&PO&PO&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4 M " #W9*Q09JS1H*4! "E& $P @ '^D 6T-O;G1E C;G1?5'EP97-=+GAM;%!+!08 , P (- #4D@ ! end

XML 12 R28.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Intangible Assets) (Details)	3 Months Ended
	Mar. 31, 2020
Patents [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Intangible assets useful lives	20 years

XML 13 R3.htm IDEA: XBRL DOCUMENT

Condensed and Consolidated Balance Sheets (Parenthetical) - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, authorized shares	20,000,000	20,000,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, authorized shares	780,000,000	780,000,000
Common stock, issued shares	5,881,898	5,881,898
Common stock, outstanding shares	5,881,898	5,881,898
Series A-1 Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, authorized shares	600,000	600,000
Preferred stock, issued shares	577,063	577,063
Preferred stock, outstanding shares	577,063	577,063
Preferred stock, liquidation preference	$ 4,013,819
Series A-2 Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, authorized shares	200,000	200,000
Preferred stock, issued shares	102,860	102,860
Preferred stock, outstanding shares	102,860	102,860
Preferred stock, liquidation preference	$ 577,827

XML 14 R24.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation (Tables)

3 Months Ended

Mar. 31, 2020

Share-based Payment Arrangement [Abstract]

Schedule of Stock Option Activity

The following table summarizes the status of the Company’s aggregate stock options granted:


	Number of Options			Weighted Average Exercise Price		Weighted Average Remaining Term(Years)		Total Intrinsic Value

Balance, January 1, 2019		566,667		$	2.33		5.95
Granted		640,000			1.54		9.83
Exercised		—			—		—
Cancelled		(125,000	)		3.00		7.00

Balance, December 31, 2019		1,081,667		$	1.74		7.85

Balance, January 1, 2020		1,081,667		$	1.74		7.85
Granted		—			—		—
Exercised		—			—		—
Cancelled		—			—		—

Balance, March 31, 2020		1,081,667		$	1.74		7.60	$	—

Exercisable at March 31, 2020		508,333		$	1.96		5.83	$	177,334

XML 15 R20.htm IDEA: XBRL DOCUMENT

Fair Value Measurements (Tables)

3 Months Ended

Mar. 31, 2020

Fair Value Disclosures [Abstract]

Schedule of Assets and Liabilities Measured at Fair Value


	Total		Quoted Prices in Active Markets for Identical Items (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Balance at December 31, 2019
Investments	$	41,694	$	41,694	$	—	$	—
	$	41,694	$	41,694	$	—	$	—
Balance at March 31, 2020
Investments	$	29,694	$	29,694	$	—	$	—
	$	29,694	$	29,694	$	—	$	—

XML 16 R7.htm IDEA: XBRL DOCUMENT

Business Activity

3 Months Ended

Mar. 31, 2020

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Business Activity

Note 1: Business Activity

XML 17 R31.htm IDEA: XBRL DOCUMENT

Property and Equipment (Details) - USD ($)	3 Months Ended
Property and Equipment (Details) - USD ($)	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 503,665		$ 503,665
Accumulated depreciation	(424,312)		(414,783)
Property and equipment, net	79,353		88,882
Depreciation expense	9,529	$ 9,529
Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	432,499		432,499
Software [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	63,179		63,179
Furniture and fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 7,987		$ 7,987

XML 18 R35.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation (Narrative) (Details) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Share-based Payment Arrangement [Abstract]
Number of shares reserved for issuance under 2015 Stock Incentive Plan	1,400,000
Expiration period for stock options	10 years
Compensation costs for incentive stock options	$ 54,930	$ 17,278
Stock options granted during period			640,000
Number of shares vested during the period	0	83,334
Unrecognized compensation cost related to share-based compensation arrangements	$ 570,238
Unrecognized compensation cost period of recognition	3 years

XML 19 R39.htm IDEA: XBRL DOCUMENT

Liquidity and Going Concern (Details) - USD ($)	Apr. 17, 2020	Mar. 31, 2020	Dec. 31, 2019	Mar. 31, 2019	Dec. 31, 2018
Subsequent Event [Line Items]
Cash		$ 10,653	$ 45,441	$ 7,327	$ 131,406
Investments		$ 29,694	$ 41,694
Subsequent Event [Member]
Subsequent Event [Line Items]
Funding from SBA	$ 71,268

XML 20 R16.htm IDEA: XBRL DOCUMENT

Related Parties and Transactions

3 Months Ended

Mar. 31, 2020

Related Parties and Transactions

Note 10: Related Parties and Transactions

XML 21 R12.htm IDEA: XBRL DOCUMENT

Intangible Assets

3 Months Ended

Mar. 31, 2020

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible Assets

Note 6: Intangible Assets

Intangible assets are comprised of the following:

	March 31,			December 31,
	2020			2019
Acquired research in progress - indefinite lived	$	4,016,596		$	4,016,596
Patents		52,045			52,045
Accumulated amortization		(33,700	)		(33,049	)
Intangible assets, net	$	4,034,941		$	4,035,592

XML 22 R38.htm IDEA: XBRL DOCUMENT

Related Parties and Transactions (Details) - Chief Executive Officer [Member]	Mar. 31, 2020 shares
Related Party Transaction [Line Items]
Number of common stock shares outstanding owned by related party	1,932,088
Percentage of common stock shares outstanding owned by related party	29.90%

XML 23 R30.htm IDEA: XBRL DOCUMENT

Fair Value Measurements (Details) - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments	$ 29,694	$ 41,694
Total	29,694	41,694
Quoted Prices in Active Markets for Identical Items (Level 1) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments	29,694	41,694
Total	29,694	41,694
Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments
Total
Significant Unobservable Inputs (Level 3) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments
Total

XML 24 R34.htm IDEA: XBRL DOCUMENT

Stockholders' Equity and Warrants (Summary of Warrants Activity) (Details) - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Number of Warrants
Warrants outstanding at beginning of period	110,884	110,884
Granted
Exercised
Expired	(28)
Warrants outstanding at end of period	110,856	110,884	110,884
Weighted Average Exercise Price
Warrants outstanding at beginning of period	$ 6.60	$ 6.60
Granted
Exercised
Expired	6.60
Warrants outstanding at end of period	$ 6.60	$ 6.60	$ 6.60
Weighted Average Remaining Term (Years)	7 months 13 days	10 months 14 days	1 year 10 months 14 days

ZIP 25 0001553350-20-000420-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001553350-20-000420-xbrl.zip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end XML 27 R17.htm IDEA: XBRL DOCUMENT v3.20.1

Concentrations
3 Months Ended

Mar. 31, 2020

Risks and Uncertainties [Abstract]

Concentrations
Note 11: Concentrations

Considerations of Credit Risk: Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and accounts receivable. The Company maintains its cash balances at high-credit, quality financial institutions. The balances, at times, may exceed federally insured limits. The Company routinely monitors the credit quality of its customers.

X

- Definition
The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-URI http://asc.fasb.org/topic&trid=2134479
+ Details

Name: us-gaap_ConcentrationRiskDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_RisksAndUncertaintiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 28 R13.htm IDEA: XBRL DOCUMENT v3.20.1

Stockholders' Equity and Warrants
3 Months Ended

Mar. 31, 2020

Equity [Abstract]

Stockholders' Equity and Warrants
Note 7: Stockholders’ Equity and Warrants

The Amended and Restated Certificate of Incorporation of the Company dated October 19, 2015 authorized the issuance of 800,000,000 shares of all classes of stock including 780,000,000 shares of Common Stock having a par value of $0.001 per share and 20,000,000 shares of Preferred Stock having a par value of $0.001 per share, 600,000 of which were designated as Series A-1 Convertible Preferred Stock (“Series A-1”) and 200,000 of which were designated as Series A-2 Convertible Preferred Stock (“Series A-2”). The Board of Directors, without a vote of the shareholders, is authorized to issue additional shares of Preferred Stock in series and to establish the characteristics thereof.

Liquidation: Upon any liquidation, dissolution or winding-up of the Company, whether voluntary or involuntary, the holders of the Series A-1 and Series A-2 shall be entitled to receive out of the assets of the Company for each share of Series A-1 and Series A-2 an amount equal to its stated value, $5.25 per share as of March 31, 2020 and December 31, 2019, plus any accrued but unpaid dividends before any distribution or payment shall be made to the holders of any other class or series of stock of the Company that ranks junior to the Series A-1 and Series A-2. The holders shall be entitled to convert their shares of Series A-1 and Series A-2 into Common Stock at any time prior to the consummation of a Liquidation. This is considered a contingent redemption feature.

Conversion: The holders of Series A-1 and Series A-2 may convert their shares into shares of Common Stock, at the option of the holder, on a one-share-for-one-share basis and shall be subject to certain adjustments at any time.

Optional Redemption; Sinking Fund Account: The Company may elect to redeem some or all of the then outstanding shares of Series A-1, (i) for cash in an amount equal to the liquidation preference per share, $5.25 per share as of December 31, 2019, subject to adjustment and (ii) by issuing one share, subject to adjustment, of Common Stock for each share of Series A-1 and Series A-2 outstanding being redeemed. 50% of all licensing fees received by the Company will be deposited into a separate sinking fund for use in an optional redemption. As of March 31, 2020, no licensing revenue has been received under these provisions and no sinking fund account has been established.

Dividends: The Company shall pay to the holders of the Series A-1 and Series A-2 dividends at the rate of 8% per annum and the Company has accrued these dividends since issuance of the Series A-1 and Series A-2. The dividend amount shall accrue and shall be payable in shares of Common Stock upon the conversion of the Series A-1 and Series A-2, or upon the redemption of the Series A-1 and Series A-2. No dividends shall be paid on any Common Stock of the Company or any capital stock of the Company that ranks junior to the Series A-1 and Series A-2 until dividends of Series A-1 and Series A-2 been paid. As of March 31, 2020, there were $1,022,052 in accrued stock dividends.

Voting: The holders of the Series A-1 and Series A-2 are entitled to vote on all matters submitted to the stockholders for a vote on an as-if-converted to Common Stock basis, with all stockholders voting as a single class.

Warrants: As of March 31, 2020 and December 31, 2019, the Company had outstanding warrants to purchase 110,856 and 110,884 shares, respectively of the Company’s Common Stock. The following table summarizes the status of the Company’s aggregate warrants outstanding:

Number of
Warrants

Weighted Average Exercise Price

Weighted Average Remaining
Term(Years)

Balance, January 1, 2019

110,884

$

6.60

1.87

Granted

—

—

—

Exercised

—

—

—

Expired

—

—

—

Balance, December 31, 2019

110,884

$

6.60

0.87

Granted

—

—

—

Exercised

—

—

—

Expired

(28

)

6.60

—

Balance, March 31, 2020

110,856

$

6.60

0.62

X

- References
No definition available.
+ Details

Name: us-gaap_EquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI http://asc.fasb.org/topic&trid=2208762
+ Details

Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 29 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 30 R2.htm IDEA: XBRL DOCUMENT v3.20.1

Condensed and Consolidated Balance Sheets - USD ($)

Mar. 31, 2020

Dec. 31, 2019

Current assets

Cash $ 10,653 $ 45,441

Accounts receivable 6,845

Investments 29,694 41,694

Prepaid expenses 15,270 24,183

Total current assets 55,617 118,163

Non-current assets

Property and equipment, net 79,353 88,882

Intangible assets, net 4,034,941 4,035,592

Total non-current assets 4,114,294 4,124,474

Total assets 4,169,911 4,242,637

Current liabilities

Accounts payable and accrued expenses 133,575 19,415

Total current liabilities 133,575 19,415

Long-term liabilities

Deferred tax liability 987,353 987,353

Total liabilities 1,120,928 1,006,768

Commitments and contingencies

Total preferred stock subject to possible redemption 3,569,594 3,569,594

Stockholders' equity

Preferred Stock 1,022,052 950,661

Common Stock, $0.001 par value; 780,000,000 shares authorized, 5,881,898 shares issued and outstanding at March 31, 2020 and December 31, 2019 5,882 5,882

Additional paid-in capital 12,064,940 12,081,401

Accumulated deficit (13,613,485) (13,371,669)

Total stockholders' (deficit) equity (520,611) (333,725)

Total liabilities and stockholders' (deficit) equity 4,169,911 4,242,637

Series A-1 Convertible Preferred Stock [Member]

Long-term liabilities

Total preferred stock subject to possible redemption 3,029,579 3,029,579

Series A-2 Convertible Preferred Stock [Member]

Long-term liabilities

Total preferred stock subject to possible redemption $ 540,015 $ 540,015

X

- Definition
Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19,20)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(3))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section 45
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522
+ Details

Name: us-gaap_AccountsReceivableNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(1))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_AdditionalPaidInCapitalCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(11))
-URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (bb)
-URI http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(12))
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599
+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (bb)
-URI http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.9)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765
+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(11))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(12))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(15))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(17))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(16))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(14))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(10))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (bb)
-URI http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685
+ Details

Name: us-gaap_AssetsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AssetsNoncurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.25)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03.(a),19)
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03.17)
-URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349
+ Details

Name: us-gaap_CommitmentsAndContingencies

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, with jurisdictional netting and classified as noncurrent.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=120406818&loc=d3e31917-109318

Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=120406818&loc=d3e31931-109318

Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=120406818&loc=d3e31958-109318
+ Details

Name: us-gaap_DeferredTaxLiabilitiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 926
-SubTopic 20
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (bb)
-URI http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19-26)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690
+ Details

Name: us-gaap_Liabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(23))
-URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(25))
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(32))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612
+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (bb)
-URI http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.21)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571
+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_LiabilitiesNoncurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6787-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 340
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 340
-SubTopic 10
-Section 05
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316
+ Details

Name: us-gaap_PrepaidExpenseCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(14))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(8))
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(3))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (g)(2)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(23)(a)(4))
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (h)(2)
-URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(i)
-URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641
+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(4))
-URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(5))
-URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(1)(g))
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(2))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_ShortTermInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571
+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.
+ References
No definition available.
+ Details

Name: us-gaap_TemporaryEquityCarryingAmountAttributableToParent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=fnam_SeriesA2PreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 31 R25.htm IDEA: XBRL DOCUMENT v3.20.1

Business Activity (Details)
3 Months Ended

Mar. 31, 2020

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Percentage of outstanding stock purchased during reverse merger with Fona, Inc. 75.16%

X

- Definition
Percentage of outstanding stock purchased during reverse merger with Fona, Inc.
+ References
No definition available.
+ Details

Name: fnam_PercentageOfOutstandingStockPurchasedDuringReverseMerger

Namespace Prefix: fnam_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 32 R21.htm IDEA: XBRL DOCUMENT v3.20.1

Property and Equipment (Tables)
3 Months Ended

Mar. 31, 2020

Property, Plant and Equipment [Abstract]

Schedule of Property and Equipment

Property and equipment is comprised of the following:

March 31,

December 31,

2020

2019

Equipment

$

432,499

$

432,499

Software

63,179

63,179

Furniture and fixtures

7,987

7,987

503,665

503,665

Accumulated depreciation

(424,312

)

(414,783

)

Property and equipment, net

$

79,353

$

88,882

X

- References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229
+ Details

Name: us-gaap_PropertyPlantAndEquipmentTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 33 R6.htm IDEA: XBRL DOCUMENT v3.20.1

Condensed and Consolidated Statements of Cash Flows - USD ($)
3 Months Ended

Mar. 31, 2020

Mar. 31, 2019

Cash flows from operating activities:

Net loss $ (241,816) $ (200,397)

Adjustments to reconcile net loss to net cash flows from operating activities

Depreciation and amortization 10,180 10,180

Stock-based compensation 54,930 17,278

Unrealized (gain) or loss on investments 12,000 (11,943)

Deferred income taxes

Changes in operating assets and liabilities:

Accounts receivable 6,845 8,073

Prepaid expenses 8,913 (3,644)

Accounts payable and accrued expenses 114,160 56,374

Cash flows from operating activities (34,788) (124,079)

Cash flows from investing activities:

Cash flows from investing activities

Cash flows from financing activities:

Proceeds from issuance of preferred stock

Cash flows from financing activities

Net change in cash (34,788) (124,079)

Cash, beginning of period 45,441 131,406

Cash, end of period 10,653 7,327

Supplemental cash flow information

Preferred stock dividend accrual $ 71,391 $ 60,591

X

- Definition
Preferred stock dividend accrual.
+ References
No definition available.
+ Details

Name: fnam_PreferredStockDividendAccretion

Namespace Prefix: fnam_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.
+ References
No definition available.
+ Details

Name: us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.7)
-URI http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.Fact.1)
-URI http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.Fact.2)
-URI http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319
+ Details

Name: us-gaap_DeferredIncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585
+ Details

Name: us-gaap_DepreciationDepletionAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInAccountsReceivable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInPrepaidExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of noncash expense for share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585
+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of unrealized gain (loss) on investment.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585
+ Details

Name: us-gaap_UnrealizedGainLossOnInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 34 R29.htm IDEA: XBRL DOCUMENT v3.20.1

Summary of Significant Accounting Policies (Net Loss Per Common Share) (Details) - shares
3 Months Ended

Mar. 31, 2020

Mar. 31, 2019

Convertible Preferred Stock [Member]

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Antidilutive shares excluded from earnings per share calculation 679,923 577,063

Stock Options [Member]

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Antidilutive shares excluded from earnings per share calculation 1,081,667 566,667

Common Stock and Warrants [Member]

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Antidilutive shares excluded from earnings per share calculation 110,856 110,884

X

- Definition
Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=fnam_CommonStockAndWarrantsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 35 R19.htm IDEA: XBRL DOCUMENT v3.20.1

Summary of Significant Accounting Policies (Policies)
3 Months Ended

Mar. 31, 2020

Accounting Policies [Abstract]

Principals of Consolidation
Principals of Consolidation: These condensed and consolidated financial statements include the accounts of Evolutionary Genomics, Inc. and its wholly owned subsidiary. All material intercompany transactions and balances have been eliminated.

Use of Estimates
Use of Estimates: The preparation of condensed and consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed and consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ materially from those estimates.

Cash
Cash: The Company considers all highly liquid investments purchased with an original or remaining maturity of three months or less when purchased to be cash.

Investments
Investments: The Company’s short-term investments are comprised of equity securities and are carried at their fair value based on the quoted market prices of the securities at March 31, 2020 and December 31, 2019. Net realized and unrealized gains and losses on investments are included in net earnings. For purposes of determining realized gains and losses, the cost of securities sold is based on specific identification.

Property and Equipment

Property and Equipment: Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is provided for by the straight-line method over three- to seven-year estimated useful lives of software, furniture and fixtures and equipment. Maintenance and repairs are expensed as incurred; major renewals and betterments that extend the useful lives of property and equipment are capitalized. When property and equipment are sold or retired, the related cost and accumulated depreciation are removed from the accounts and any gain or loss is recognized.

Long-Lived Assets

Long-Lived Assets: The long-lived assets held and used by the Company are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. In the event that facts and circumstances indicate that the cost of any long-lived assets may be impaired, an evaluation of recoverability is performed. An impairment is considered to exist if the total estimated undiscounted cash flows are less than the carrying amount of the asset. An impairment loss is measured and recorded to the extent that the carrying amount of the asset exceeds its estimated fair value. No asset impairment was recorded during the three months ended March 31, 2020 and 2019.

Intangible Assets
Intangible Assets: Intangible assets include acquired research in progress and patents on the Company’s core technology for gene identification. Patents are amortized over their expected useful life of 20 years using the straight-line method. Acquired research in progress is an indefinite-lived intangible asset until the development is complete at which time the useful life of the asset will be assigned. Costs incurred to renew intangible assets are expensed in the period incurred, while costs incurred to extend the lives of patents are capitalized and amortized over the remaining useful life of the asset. Intangible assets held and used by the Company are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. In the event that facts and circumstances indicate that the cost of any intangible assets may be impaired, an evaluation of recoverability is performed. An impairment is considered to exist if the total estimated undiscounted cash flows are less than the carrying amount of the asset. No impairment was recorded during the three months ended March 31, 2020 and 2019. Realization of this asset is dependent upon the successful completion of the Company’s research and development efforts.

Revenue Recognition
Revenue Recognition: In May 2014, the FASB issued new guidance related to revenue recognition, which outlines a comprehensive revenue recognition model and supersedes most current revenue recognition guidance. The new guidance requires a company to recognize revenue as control of goods or services transfers to a customer at an amount that reflects the expected consideration to be received in exchange for those goods or services. It defines a five-step approach for recognizing revenue, which may require a company to use more judgment and make more estimates than under the current guidance. The Company adopted this standard on January 1, 2018 using the modified-retrospective method and it did not have a material impact on the condensed and consolidated financial statements.

Grant revenue, which is not within the scope of Topic 606, consists of funding under cost reimbursement programs primarily from federal and non-profit foundation sources for qualified research and development activities performed by us, and as such, are not based on estimates that are susceptible to change. Such amounts are invoiced and recorded as revenue as grant-funded activities are performed.

Income Taxes

Income Taxes: Deferred tax assets and liabilities are recognized for the expected tax consequences of temporary differences between the tax bases of assets and liabilities and their reported amounts. Management regularly assesses the likelihood that deferred tax assets will be recovered from future taxable income, and to the extent management believes that it is more likely than not that a deferred tax asset will not be realized, a valuation allowance is established. When a valuation allowance is established, increased or decreased, an income tax charge or benefit is included in the condensed and consolidated financial statements and net deferred tax assets are adjusted accordingly. As of March 31, 2020 and December 31, 2019, a full valuation allowance has been established on the net deferred tax asset.

Under the Income Tax topic of the ASC, in order to recognize an uncertain tax benefit, the taxpayer must be more likely than not of sustaining the position, and the measurement of the benefit is calculated as the largest amount that is more than 50% likely to be realized upon resolution of the benefit. The Company has no accruals for uncertain tax benefits.

Stock-Based Compensation
Stock-Based Compensation: The Company accounts for stock option awards in accordance with ASC 718. The estimated grant-date fair value of stock-based awards is expensed over the requisite service period, which is typically equivalent to the vesting term of the award.

The Company’s accounting policy for equity instruments issued to consultants and vendors in exchange for goods and services received follows the provisions of ASC Topic 718. Accordingly, the measurement date for the fair value of the equity instruments issued is determined at the earlier of (i) the date at which a commitment for performance by the consultant or vendor is reached or (ii) the date at which the consultant or vendor’s performance is complete. In the case of equity instruments issued to consultants, the fair value of the equity instrument is recognized over the term of the consulting agreement.

Research and Development

Research and Development: Research and development costs are expensed as incurred. In instances where we enter into agreements with third parties for research and development activities, we may prepay for services at the initiation of the contract. We record the prepayment as a prepaid asset and amortize the asset into research and development expense over the period of time the contracted research and development services are performed.

Net Loss Per Common Share
Net Loss Per Common Share: Basic net (loss) income per common share excludes any dilutive effects of equity instruments. We compute basic net (loss) income per common share using the weighted average number of common shares outstanding during the period. We compute diluted net (loss) income per common share using the weighted average number of common shares and common stock equivalents outstanding during the period. For the three months ended March 31, 2020, common stock equivalents including 679,923 shares of convertible preferred stock, options for 1,081,667 shares of common stock and warrants for 110,856 shares of common stock were excluded because their effect was anti-dilutive. For the three months ended March 31, 2019, common stock equivalents including 577,063 shares of convertible preferred stock, options for 566,667 shares of common stock and warrants for 110,884 shares of common stock were excluded because their effect was anti-dilutive.

Subsequent Events

Subsequent Events: The Company has evaluated all subsequent events through the date of this filing. On April 17, 2020, the Company received $71,268 in funding from the SBA under their Paycheck Protection Program and we expect that most, if not all of this funding will be forgiven.

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=121583591&loc=d3e4273-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(1))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790
+ Details

Name: us-gaap_CashAndCashEquivalentsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684
+ Details

Name: us-gaap_ConsolidationPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257
+ Details

Name: us-gaap_EarningsPerSharePolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275
+ Details

Name: us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 05
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 5.CC)
-URI http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742
+ Details

Name: us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=120406818&loc=d3e32247-109318

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 954
-SubTopic 740
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=120406818&loc=d3e32280-109318

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319
+ Details

Name: us-gaap_IncomeTaxPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for investment classified as marketable security.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 320
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=120252992&loc=d3e62652-112803
+ Details

Name: us-gaap_MarketableSecuritiesPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 958
-SubTopic 360
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.13(a))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 958
-SubTopic 360
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790
+ Details

Name: us-gaap_PropertyPlantAndEquipmentPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373
+ Details

Name: us-gaap_ResearchAndDevelopmentExpensePolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790
+ Details

Name: us-gaap_RevenueRecognitionPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (b),(f)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901
+ Details

Name: us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for reporting subsequent events.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790
+ Details

Name: us-gaap_SubsequentEventsPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592
+ Details

Name: us-gaap_UseOfEstimates

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 36 R15.htm IDEA: XBRL DOCUMENT v3.20.1

Commitments and Contingencies
3 Months Ended

Mar. 31, 2020

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies
Note 9: Commitments and Contingencies

Officer Indemnification: Under the Company’s organizational documents, the Company’s officers, employees, and directors are indemnified against certain liabilities arising out of the performance of their duties. The Company’s maximum exposure under these arrangements is unknown, as this would involve future claims that may be made against the Company that have not yet occurred. However, based on experience, the Company expects any risk of loss to be remote. The Company also has an insurance policy for its directors and officers to insure them against liabilities arising from their performance in their positions with the Company.

Lease Commitments: The Company leases its operating facility and pays its rent in monthly installments. The lease was renewed in June 2016 for a period of twelve months and monthly rentals for the period of July 1, 2016 through December 31, 2019 are $2,378 per month which continues on a month-to-month basis. There is no minimum lease commitment as of March 31, 2020. Renewals after June 30, 2017 are by mutual agreement. The Company’s rent expense for the three months ended March 31, 2020 and 2019 was $7,134 and $7,134, respectively.

Royalty: Effective March 1, 2012, the Company entered into an Agreement for Contract Services with SmithBucklin Corporation (the “Contractor”) on behalf of the United Soybean Board. The contract includes the payment of certain royalties, as defined in the Agreement.

The Company is obligated to pay royalties to the United Soybean Board of 10% of the sale of products derived from the soybean genes that were the subject of the research performed by the Contractor or from royalties received by the Company from the sale of products by a third party not to exceed 150% of the total amount paid to the Contractor under this Agreement. The Company has recognized to date grant revenue from the contract of $262,400 as of March 31, 2020, thus limiting any future royalties as of March 31, 2020 to a total of $393,600. The Company has not accrued or paid any royalties under the terms of the Agreement as of and during the three months ended March 31, 2020 and 2019 because it has not received any revenue from the sale of products to date.

X

- References
No definition available.
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for commitments and contingencies.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-URI http://asc.fasb.org/topic&trid=2127136

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 440
-URI http://asc.fasb.org/topic&trid=2144648

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 440
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 440
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 37 R11.htm IDEA: XBRL DOCUMENT v3.20.1

Property and Equipment
3 Months Ended

Mar. 31, 2020

Property, Plant and Equipment [Abstract]

Property and Equipment
Note 5: Property and Equipment

Property and equipment is comprised of the following:

March 31,

December 31,

2020

2019

Equipment

$

432,499

$

432,499

Software

63,179

63,179

Furniture and fixtures

7,987

7,987

503,665

503,665

Accumulated depreciation

(424,312

)

(414,783

)

Property and equipment, net

$

79,353

$

88,882

Depreciation expense for the three months ended March 31, 2020 and 2019 was $9,529 and $9,529, respectively.

X

- References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 958
-SubTopic 360
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-URI http://asc.fasb.org/topic&trid=2155823

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 958
-SubTopic 360
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 958
-SubTopic 360
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916
+ Details

Name: us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 38 R32.htm IDEA: XBRL DOCUMENT v3.20.1

Intangible Assets (Details) - USD ($)
3 Months Ended

Mar. 31, 2020

Mar. 31, 2019

Dec. 31, 2019

Finite-Lived Intangible Assets [Line Items]

Intangible assets, accumulated amortization $ (33,700) $ (33,049)

Intangible assets, net 4,034,941 4,035,592

Acquired research in progress [Member]

Finite-Lived Intangible Assets [Line Items]

Intangible assets, gross 4,016,596 4,016,596

Additional expected costs to complete research 102,000

Patents [Member]

Finite-Lived Intangible Assets [Line Items]

Intangible assets, gross 52,045 $ 52,045

Amortization expense 651 $ 650

Year one 2,602

Year two 2,602

Year three 2,602

Year four 2,602

Year five 2,602

After year five $ 5,335

X

- Definition
Additional expected costs to complete research.
+ References
No definition available.
+ Details

Name: fnam_AdditionalExpectedCostsToCompleteResearch

Namespace Prefix: fnam_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585
+ Details

Name: us-gaap_AdjustmentForAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
+ References
No definition available.
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 928
-SubTopic 340
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 926
-SubTopic 20
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 39 R36.htm IDEA: XBRL DOCUMENT v3.20.1

Stock-Based Compensation (Summary of Stock Options Activity) (Details) - USD ($)
3 Months Ended 12 Months Ended

Mar. 31, 2020

Mar. 31, 2019

Dec. 31, 2019

Dec. 31, 2018

Number of Options

Balance, beginning 1,081,667 566,667 566,667

Granted 640,000

Exercised

Cancelled (125,000)

Balance, ending 1,081,667 1,081,667 566,667

Exercisable 508,333

Outstanding, intrinsic value

Exercisable, intrinsic value $ 177,334

Weighted Average Exercise Price

Balance, beginning $ 1.74 $ 2.33 $ 2.33

Granted 1.54

Exercised

Cancelled 3.00

Balance, ending 1.74 $ 1.74 $ 2.33

Exercisable $ 1.96

Outstanding, contractual term 7 years 7 months 6 days 7 years 10 months 6 days 5 years 11 months 12 days

Exercisable, contractual term 5 years 9 months 29 days

Granted, contractual term 9 years 9 months 29 days

Cancelled, contractual term 7 years

X

- Definition
Cancelled, contractual term.
+ References
No definition available.
+ Details

Name: fnam_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsCancelledWeightedAverageRemainingContractualTerm1

Namespace Prefix: fnam_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Granted, contractual term.
+ References
No definition available.
+ Details

Name: fnam_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1

Namespace Prefix: fnam_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(3)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Gross number of share options (or share units) granted during the period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Number of options outstanding, including both vested and non-vested options.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)-(ii)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average price at which option holders acquired shares when converting their stock options into shares.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of share options (or share units) exercised during the current period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(2)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 40 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.1 html 67 252 1 false 23 0 false 4 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://evolutionarygenomicsinc.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - Condensed and Consolidated Balance Sheets Sheet http://evolutionarygenomicsinc.com/role/AndConsolidatedBalanceSheets Condensed and Consolidated Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Condensed and Consolidated Balance Sheets (Parenthetical) Sheet http://evolutionarygenomicsinc.com/role/AndConsolidatedBalanceSheetsParenthetical Condensed and Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Condensed and Consolidated Statements of Operations Sheet http://evolutionarygenomicsinc.com/role/AndConsolidatedStatementsOfOperations Condensed and Consolidated Statements of Operations Statements 4 false false R5.htm 00000005 - Statement - Condensed and Consolidated Statement of Stockholders' Equity Sheet http://evolutionarygenomicsinc.com/role/AndConsolidatedStatementOfStockholdersEquity Condensed and Consolidated Statement of Stockholders' Equity Statements 5 false false R6.htm 00000006 - Statement - Condensed and Consolidated Statements of Cash Flows Sheet http://evolutionarygenomicsinc.com/role/AndConsolidatedStatementsOfCashFlows Condensed and Consolidated Statements of Cash Flows Statements 6 false false R7.htm 00000007 - Disclosure - Business Activity Sheet http://evolutionarygenomicsinc.com/role/NatureOfBusiness Business Activity Notes 7 false false R8.htm 00000008 - Disclosure - Summary of Significant Accounting Policies Sheet http://evolutionarygenomicsinc.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 8 false false R9.htm 00000009 - Disclosure - New Accounting Standards Sheet http://evolutionarygenomicsinc.com/role/NewAccountingStandards New Accounting Standards Notes 9 false false R10.htm 00000010 - Disclosure - Fair Value Measurements Sheet http://evolutionarygenomicsinc.com/role/FairValueMeasurements Fair Value Measurements Notes 10 false false R11.htm 00000011 - Disclosure - Property and Equipment Sheet http://evolutionarygenomicsinc.com/role/PropertyAndEquipment Property and Equipment Notes 11 false false R12.htm 00000012 - Disclosure - Intangible Assets Sheet http://evolutionarygenomicsinc.com/role/IntangibleAssets Intangible Assets Notes 12 false false R13.htm 00000013 - Disclosure - Stockholders' Equity and Warrants Sheet http://evolutionarygenomicsinc.com/role/Disclosure-CommonStock Stockholders' Equity and Warrants Notes 13 false false R14.htm 00000014 - Disclosure - Stock-Based Compensation Sheet http://evolutionarygenomicsinc.com/role/Stock-basedCompensation Stock-Based Compensation Notes 14 false false R15.htm 00000015 - Disclosure - Commitments and Contingencies Sheet http://evolutionarygenomicsinc.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 15 false false R16.htm 00000016 - Disclosure - Related Parties and Transactions Sheet http://evolutionarygenomicsinc.com/role/RelatedPartiesAndTransactions Related Parties and Transactions Notes 16 false false R17.htm 00000017 - Disclosure - Concentrations Sheet http://evolutionarygenomicsinc.com/role/Concentrations Concentrations Notes 17 false false R18.htm 00000018 - Disclosure - Liquidity and Going Concern Sheet http://evolutionarygenomicsinc.com/role/LiquidityAndGoingConcern Liquidity and Going Concern Notes 18 false false R19.htm 00000020 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://evolutionarygenomicsinc.com/role/fnam-soapadobp Summary of Significant Accounting Policies (Policies) Policies http://evolutionarygenomicsinc.com/role/SummaryOfSignificantAccountingPolicies 19 false false R20.htm 00000021 - Disclosure - Fair Value Measurements (Tables) Sheet http://evolutionarygenomicsinc.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://evolutionarygenomicsinc.com/role/FairValueMeasurements 20 false false R21.htm 00000022 - Disclosure - Property and Equipment (Tables) Sheet http://evolutionarygenomicsinc.com/role/PropertyAndEquipmentTables Property and Equipment (Tables) Tables http://evolutionarygenomicsinc.com/role/PropertyAndEquipment 21 false false R22.htm 00000023 - Disclosure - Intangible Assets (Tables) Sheet http://evolutionarygenomicsinc.com/role/IntangibleAssetsTables Intangible Assets (Tables) Tables http://evolutionarygenomicsinc.com/role/IntangibleAssets 22 false false R23.htm 00000024 - Disclosure - Stockholders' Equity and Warrants (Tables) Sheet http://evolutionarygenomicsinc.com/role/StockholdersEquityAndWarrantsTables Stockholders' Equity and Warrants (Tables) Tables http://evolutionarygenomicsinc.com/role/Disclosure-CommonStock 23 false false R24.htm 00000025 - Disclosure - Stock-Based Compensation (Tables) Sheet http://evolutionarygenomicsinc.com/role/Stock-basedCompensationTables Stock-Based Compensation (Tables) Tables http://evolutionarygenomicsinc.com/role/Stock-basedCompensation 24 false false R25.htm 00000026 - Disclosure - Business Activity (Details) Sheet http://evolutionarygenomicsinc.com/role/BusinessActivityDetails Business Activity (Details) Details http://evolutionarygenomicsinc.com/role/NatureOfBusiness 25 false false R26.htm 00000027 - Disclosure - Summary of Significant Accounting Policies (Other) (Details) Sheet http://evolutionarygenomicsinc.com/role/SummaryOfSignificantAccountingPoliciesOtherDetails Summary of Significant Accounting Policies (Other) (Details) Details http://evolutionarygenomicsinc.com/role/fnam-soapadobp 26 false false R27.htm 00000028 - Disclosure - Summary of Significant Accounting Policies (Property and Equipment) (Details) Sheet http://evolutionarygenomicsinc.com/role/SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails Summary of Significant Accounting Policies (Property and Equipment) (Details) Details http://evolutionarygenomicsinc.com/role/fnam-soapadobp 27 false false R28.htm 00000029 - Disclosure - Summary of Significant Accounting Policies (Intangible Assets) (Details) Sheet http://evolutionarygenomicsinc.com/role/SummaryOfSignificantAccountingPoliciesIntangilbeAssetsDetails Summary of Significant Accounting Policies (Intangible Assets) (Details) Details http://evolutionarygenomicsinc.com/role/fnam-soapadobp 28 false false R29.htm 00000030 - Disclosure - Summary of Significant Accounting Policies (Net Loss Per Common Share) (Details) Sheet http://evolutionarygenomicsinc.com/role/SummaryOfSignificantAccountingPoliciesNetLossPerCommonShareDetails Summary of Significant Accounting Policies (Net Loss Per Common Share) (Details) Details http://evolutionarygenomicsinc.com/role/fnam-soapadobp 29 false false R30.htm 00000031 - Disclosure - Fair Value Measurements (Details) Sheet http://evolutionarygenomicsinc.com/role/FairValueMeasurementsDetails Fair Value Measurements (Details) Details http://evolutionarygenomicsinc.com/role/FairValueMeasurementsTables 30 false false R31.htm 00000032 - Disclosure - Property and Equipment (Details) Sheet http://evolutionarygenomicsinc.com/role/PropertyAndEquipmentDetails Property and Equipment (Details) Details http://evolutionarygenomicsinc.com/role/PropertyAndEquipmentTables 31 false false R32.htm 00000033 - Disclosure - Intangible Assets (Details) Sheet http://evolutionarygenomicsinc.com/role/IntangibleAssetsDetails Intangible Assets (Details) Details http://evolutionarygenomicsinc.com/role/IntangibleAssetsTables 32 false false R33.htm 00000034 - Disclosure - Stockholders' Equity and Warrants (Narrative) (Details) Sheet http://evolutionarygenomicsinc.com/role/Disclosure-CommonStockDetails Stockholders' Equity and Warrants (Narrative) (Details) Details http://evolutionarygenomicsinc.com/role/StockholdersEquityAndWarrantsTables 33 false false R34.htm 00000035 - Disclosure - Stockholders' Equity and Warrants (Summary of Warrants Activity) (Details) Sheet http://evolutionarygenomicsinc.com/role/StockholdersEquityAndWarrantsSummaryOfWarrantsActivityDetails Stockholders' Equity and Warrants (Summary of Warrants Activity) (Details) Details http://evolutionarygenomicsinc.com/role/StockholdersEquityAndWarrantsTables 34 false false R35.htm 00000036 - Disclosure - Stock-Based Compensation (Narrative) (Details) Sheet http://evolutionarygenomicsinc.com/role/Stock-basedCompensationNarrativeDetails Stock-Based Compensation (Narrative) (Details) Details http://evolutionarygenomicsinc.com/role/Stock-basedCompensationTables 35 false false R36.htm 00000037 - Disclosure - Stock-Based Compensation (Summary of Stock Options Activity) (Details) Sheet http://evolutionarygenomicsinc.com/role/Stock-basedCompensationSummaryOfStockOptionsActivityDetails Stock-Based Compensation (Summary of Stock Options Activity) (Details) Details http://evolutionarygenomicsinc.com/role/Stock-basedCompensationTables 36 false false R37.htm 00000038 - Disclosure - Commitments and Contingencies (Details) Sheet http://evolutionarygenomicsinc.com/role/CommitmentsAndContingenciesDetails Commitments and Contingencies (Details) Details http://evolutionarygenomicsinc.com/role/CommitmentsAndContingencies 37 false false R38.htm 00000039 - Disclosure - Related Parties and Transactions (Details) Sheet http://evolutionarygenomicsinc.com/role/RelatedPartiesAndTransactionsDetails Related Parties and Transactions (Details) Details http://evolutionarygenomicsinc.com/role/RelatedPartiesAndTransactions 38 false false R39.htm 00000040 - Disclosure - Liquidity and Going Concern (Details) Sheet http://evolutionarygenomicsinc.com/role/LiquidityAndGoingConcernDetails Liquidity and Going Concern (Details) Details http://evolutionarygenomicsinc.com/role/LiquidityAndGoingConcern 39 false false All Reports Book All Reports fnam-20200331.xml fnam-20200331.xsd fnam-20200331_cal.xml fnam-20200331_def.xml fnam-20200331_lab.xml fnam-20200331_pre.xml http://fasb.org/srt/2020-01-31 http://xbrl.sec.gov/dei/2019-01-31 http://fasb.org/us-gaap/2020-01-31 true true XML 41 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 42 R27.htm IDEA: XBRL DOCUMENT v3.20.1

Summary of Significant Accounting Policies (Property and Equipment) (Details)
3 Months Ended

Mar. 31, 2020

Minimum [Member]

Property, Plant and Equipment [Line Items]

Estimated useful lives of property and equipment 3 years

Maximum [Member]

Property, Plant and Equipment [Line Items]

Estimated useful lives of property and equipment 7 years

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.
+ References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentUsefulLife

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Details

Name: srt_RangeAxis=srt_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 43 R23.htm IDEA: XBRL DOCUMENT v3.20.1

Stockholders' Equity and Warrants (Tables)
3 Months Ended

Mar. 31, 2020

Equity [Abstract]

Summary of Warrants Activity
The following table summarizes the status of the Company’s aggregate warrants outstanding:

Number of
Warrants

Weighted Average Exercise Price

Weighted Average Remaining
Term(Years)

Balance, January 1, 2019

110,884

$

6.60

1.87

Granted

—

—

—

Exercised

—

—

—

Expired

—

—

—

Balance, December 31, 2019

110,884

$

6.60

0.87

Granted

—

—

—

Exercised

—

—

—

Expired

(28

)

6.60

—

Balance, March 31, 2020

110,856

$

6.60

0.62

X

- References
No definition available.
+ Details

Name: us-gaap_EquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 50
-Section S99
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775
+ Details

Name: us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 44 R4.htm IDEA: XBRL DOCUMENT v3.20.1

Condensed and Consolidated Statements of Operations - USD ($)
3 Months Ended

Mar. 31, 2020

Mar. 31, 2019

Income Statement [Abstract]

Grant revenue $ 12,500 $ 32,366

Operating expenses

Research and development 93,222 131,684

Salaries and benefits 92,430 54,779

General and administrative 56,665 58,254

Total operating expenses 242,317 244,717

Operating (loss) (229,817) (212,351)

Other income (expenses):

Investment income 1 11

Unrealized gain or (loss) on investments (12,000) 11,943

Total other income (expenses) (11,999) 11,954

Loss before income taxes (241,816) (200,397)

Income taxes

Net loss (241,816) (200,397)

Preferred stock dividend (71,391) (60,591)

Net loss attributable to common stockholders $ (313,207) $ (260,988)

Net loss per common share, basic and diluted $ (0.05) $ (0.04)

Weighted average common shares outstanding, basic and diluted 5,881,898 5,881,898

X

- Definition
The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256
+ Details

Name: us-gaap_EarningsPerShareBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.4)
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227
+ Details

Name: us-gaap_GeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 940
-SubTopic 20
-Section 25
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(10))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(8))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(15))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260
+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeStatementAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.7)
-URI http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 20
-Section 45
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(9))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794
+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.7(b))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599
+ Details

Name: us-gaap_InvestmentIncomeInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(b)(4))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227
+ Details

Name: us-gaap_LaborAndRelatedExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1377-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599
+ Details

Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.7)
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227
+ Details

Name: us-gaap_NonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NonoperatingIncomeExpenseAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OperatingExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The net result for the period of deducting operating expenses from operating revenues.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599
+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders.
+ References
No definition available.
+ Details

Name: us-gaap_PreferredStockDividendsIncomeStatementImpact

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373
+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(1))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227
+ Details

Name: us-gaap_Revenues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of unrealized gain (loss) on investment.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585
+ Details

Name: us-gaap_UnrealizedGainLossOnInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).
+ References
No definition available.
+ Details

Name: us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 45 R8.htm IDEA: XBRL DOCUMENT v3.20.1

Summary of Significant Accounting Policies
3 Months Ended

Mar. 31, 2020

Accounting Policies [Abstract]

Summary of Significant Accounting Policies
Note 2: Summary of Significant Accounting Policies

Principals of Consolidation: These condensed and consolidated financial statements include the accounts of Evolutionary Genomics, Inc. and its wholly owned subsidiary. All material intercompany transactions and balances have been eliminated.

Use of Estimates: The preparation of condensed and consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed and consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ materially from those estimates.

Cash: The Company considers all highly liquid investments purchased with an original or remaining maturity of three months or less when purchased to be cash.

Investments: The Company’s short-term investments are comprised of equity securities and are carried at their fair value based on the quoted market prices of the securities at March 31, 2020 and December 31, 2019. Net realized and unrealized gains and losses on investments are included in net earnings. For purposes of determining realized gains and losses, the cost of securities sold is based on specific identification.

Property and Equipment: Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is provided for by the straight-line method over three- to seven-year estimated useful lives of software, furniture and fixtures and equipment. Maintenance and repairs are expensed as incurred; major renewals and betterments that extend the useful lives of property and equipment are capitalized. When property and equipment are sold or retired, the related cost and accumulated depreciation are removed from the accounts and any gain or loss is recognized.

Long-Lived Assets: The long-lived assets held and used by the Company are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. In the event that facts and circumstances indicate that the cost of any long-lived assets may be impaired, an evaluation of recoverability is performed. An impairment is considered to exist if the total estimated undiscounted cash flows are less than the carrying amount of the asset. An impairment loss is measured and recorded to the extent that the carrying amount of the asset exceeds its estimated fair value. No asset impairment was recorded during the three months ended March 31, 2020 and 2019.

Intangible Assets: Intangible assets include acquired research in progress and patents on the Company’s core technology for gene identification. Patents are amortized over their expected useful life of 20 years using the straight-line method. Acquired research in progress is an indefinite-lived intangible asset until the development is complete at which time the useful life of the asset will be assigned. Costs incurred to renew intangible assets are expensed in the period incurred, while costs incurred to extend the lives of patents are capitalized and amortized over the remaining useful life of the asset. Intangible assets held and used by the Company are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. In the event that facts and circumstances indicate that the cost of any intangible assets may be impaired, an evaluation of recoverability is performed. An impairment is considered to exist if the total estimated undiscounted cash flows are less than the carrying amount of the asset. No impairment was recorded during the three months ended March 31, 2020 and 2019. Realization of this asset is dependent upon the successful completion of the Company’s research and development efforts.

Revenue Recognition: In May 2014, the FASB issued new guidance related to revenue recognition, which outlines a comprehensive revenue recognition model and supersedes most current revenue recognition guidance. The new guidance requires a company to recognize revenue as control of goods or services transfers to a customer at an amount that reflects the expected consideration to be received in exchange for those goods or services. It defines a five-step approach for recognizing revenue, which may require a company to use more judgment and make more estimates than under the current guidance. The Company adopted this standard on January 1, 2018 using the modified-retrospective method and it did not have a material impact on the condensed and consolidated financial statements.

Grant revenue, which is not within the scope of Topic 606, consists of funding under cost reimbursement programs primarily from federal and non-profit foundation sources for qualified research and development activities performed by us, and as such, are not based on estimates that are susceptible to change. Such amounts are invoiced and recorded as revenue as grant-funded activities are performed.

Income Taxes: Deferred tax assets and liabilities are recognized for the expected tax consequences of temporary differences between the tax bases of assets and liabilities and their reported amounts. Management regularly assesses the likelihood that deferred tax assets will be recovered from future taxable income, and to the extent management believes that it is more likely than not that a deferred tax asset will not be realized, a valuation allowance is established. When a valuation allowance is established, increased or decreased, an income tax charge or benefit is included in the condensed and consolidated financial statements and net deferred tax assets are adjusted accordingly. As of March 31, 2020 and December 31, 2019, a full valuation allowance has been established on the net deferred tax asset.

Under the Income Tax topic of the ASC, in order to recognize an uncertain tax benefit, the taxpayer must be more likely than not of sustaining the position, and the measurement of the benefit is calculated as the largest amount that is more than 50% likely to be realized upon resolution of the benefit. The Company has no accruals for uncertain tax benefits.

Stock-Based Compensation: The Company accounts for stock option awards in accordance with ASC 718. The estimated grant-date fair value of stock-based awards is expensed over the requisite service period, which is typically equivalent to the vesting term of the award.

The Company’s accounting policy for equity instruments issued to consultants and vendors in exchange for goods and services received follows the provisions of ASC Topic 718. Accordingly, the measurement date for the fair value of the equity instruments issued is determined at the earlier of (i) the date at which a commitment for performance by the consultant or vendor is reached or (ii) the date at which the consultant or vendor’s performance is complete. In the case of equity instruments issued to consultants, the fair value of the equity instrument is recognized over the term of the consulting agreement.

Research and Development: Research and development costs are expensed as incurred. In instances where we enter into agreements with third parties for research and development activities, we may prepay for services at the initiation of the contract. We record the prepayment as a prepaid asset and amortize the asset into research and development expense over the period of time the contracted research and development services are performed.

Net Loss Per Common Share: Basic net (loss) income per common share excludes any dilutive effects of equity instruments. We compute basic net (loss) income per common share using the weighted average number of common shares outstanding during the period. We compute diluted net (loss) income per common share using the weighted average number of common shares and common stock equivalents outstanding during the period. For the three months ended March 31, 2020, common stock equivalents including 679,923 shares of convertible preferred stock, options for 1,081,667 shares of common stock and warrants for 110,856 shares of common stock were excluded because their effect was anti-dilutive. For the three months ended March 31, 2019, common stock equivalents including 577,063 shares of convertible preferred stock, options for 566,667 shares of common stock and warrants for 110,884 shares of common stock were excluded because their effect was anti-dilutive.

Subsequent Events: The Company has evaluated all subsequent events through the date of this filing. On April 17, 2020, the Company received $71,268 in funding from the SBA under their Paycheck Protection Program and we expect that most, if not all of this funding will be forgiven.

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-URI http://asc.fasb.org/topic&trid=2122149

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-URI http://asc.fasb.org/topic&trid=2197479

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-URI http://asc.fasb.org/topic&trid=2122369

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-URI http://asc.fasb.org/topic&trid=2134479
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 46 R9.htm IDEA: XBRL DOCUMENT v3.20.1

New Accounting Standards
3 Months Ended

Mar. 31, 2020

Accounting Changes and Error Corrections [Abstract]

New Accounting Standards
Note 3: New Accounting Standards

Recently Issued Accounting Standards

In June 2016, the FASB issued ASU 2016-13, “Financial Instruments – Credit Losses: Measurement of Credit Losses on Financial Instruments,” which requires entities to estimate all expected credit losses for certain types of financial instruments, including trade receivables, held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. The updated guidance also expands the disclosure requirements to enable users of financial statements to understand the entity’s assumptions, models and methods for estimating expected credit losses over the entire contractual term of the instrument from the date of initial recognition of that instrument. This guidance is effective for fiscal years beginning after December 15, 2020, including interim periods within that reporting period and did not have an impact on the Company’s condensed and consolidated financial statements.

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingChangesAndErrorCorrectionsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 65
-Paragraph 1
-Subparagraph (g)(2)
-URI http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-URI http://asc.fasb.org/topic&trid=2122394

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 65
-Paragraph 1
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section S99
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=112272810&loc=SL108384541-122693

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 65
-Paragraph 1
-Subparagraph (i)(2)
-URI http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(iii)
-URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(4)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(ii)
-URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(i)
-URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (g)(1)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 65
-Paragraph 1
-Subparagraph (j)
-URI http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(iv)
-URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 926
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (f)(1)
-URI http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section S99
-Paragraph 5
-Subparagraph (SAB Topic 11.M.Q2)
-URI http://asc.fasb.org/extlink&oid=112272810&loc=d3e31137-122693

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 926
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (f)(2)
-URI http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 926
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (f)(3)
-URI http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (h)(2)
-URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (e)(2)
-URI http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(1)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (e)(1)

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (e)(2)

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (e)(3)
+ Details

Name: us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 47 R1.htm IDEA: XBRL DOCUMENT v3.20.1

Document and Entity Information
3 Months Ended

Mar. 31, 2020

shares

Document And Entity Information [Abstract]

Entity Registrant Name EVOLUTIONARY GENOMICS, INC.

Entity Central Index Key 0000884363

Document Type 10-Q

Document Period End Date Mar. 31, 2020

Amendment Flag false

Current Fiscal Year End Date --12-31

Entity Filer Category Non-accelerated Filer

Entity Small Business true

Entity Emerging Growth Company false

Entity Shell Company false

Entity Common Stock, Shares Outstanding 5,881,898

Document Fiscal Period Focus Q1

Document Fiscal Year Focus 2020

Entity Current Reporting Status Yes

Entity Interactive Data Current Yes

Entity Incorporation State Country Name NV

Entity File Number 000-54129

X

- Definition
Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
No definition available.
+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
End date of current fiscal year in the format --MM-DD.
+ References
No definition available.
+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition
Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition
The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.
+ References
No definition available.
+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
No definition available.
+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.
+ References
No definition available.
+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
No definition available.
+ Details

Name: dei_EntityCurrentReportingStatus

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate if registrant meets the emerging growth company criteria.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityEmergingGrowthCompany

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
No definition available.
+ Details

Name: dei_EntityFileNumber

Namespace Prefix: dei_

Data Type: dei:fileNumberItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition
Two-character EDGAR code representing the state or country of incorporation.
+ References
No definition available.
+ Details

Name: dei_EntityIncorporationStateCountryCode

Namespace Prefix: dei_

Data Type: dei:edgarStateCountryItemType

Balance Type: na

Period Type: duration

X

- Definition
Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-T
-Number 232
-Section 405
+ Details

Name: dei_EntityInteractiveDataCurrent

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityShellCompany

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicates that the company is a Smaller Reporting Company (SRC).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntitySmallBusiness

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: fnam_DocumentDocumentAndEntityInformationAbstract

Namespace Prefix: fnam_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 48 R26.htm IDEA: XBRL DOCUMENT v3.20.1

Summary of Significant Accounting Policies (Other) (Details) - USD ($)
3 Months Ended

Apr. 17, 2020

Mar. 31, 2020

Mar. 31, 2019

Asset impairment charges

Subsequent Event [Member]

Funding from SBA $ 71,268

X

- Definition
Funding from SBA.
+ References
No definition available.
+ Details

Name: fnam_FundingFromSBA

Namespace Prefix: fnam_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109226348&loc=d3e2420-110228
+ Details

Name: us-gaap_AssetImpairmentCharges

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 49 R22.htm IDEA: XBRL DOCUMENT v3.20.1

Intangible Assets (Tables)
3 Months Ended

Mar. 31, 2020

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Intangible Assets
Intangible assets are comprised of the following:

March 31,

December 31,

2020

2019

Acquired research in progress - indefinite lived

$

4,016,596

$

4,016,596

Patents

52,045

52,045

Accumulated amortization

(33,700

)

(33,049

)

Intangible assets, net

$

4,034,941

$

4,035,592

X

- References
No definition available.
+ Details

Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275
+ Details

Name: us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 50 R5.htm IDEA: XBRL DOCUMENT v3.20.1

Condensed and Consolidated Statement of Stockholders' Equity - USD ($)

Common Stock [Member]

Preferred Dividend [Member]

Additional Paid-In Capital [Member]

Accumulated Deficit [Member]

Total

Balance at Dec. 31, 2018 $ 5,882 $ 681,282 $ 12,294,952 $ (12,578,529) $ 403,587

Balance, shares at Dec. 31, 2018 5,881,898

Stock compensation 17,278 17,278

Preferred stock dividends 60,591 (60,591)

Net loss (200,397) (200,397)

Balance at Mar. 31, 2019 $ 5,882 741,873 12,251,639 (12,778,926) 220,468

Balance, shares at Mar. 31, 2019 5,881,898

Balance at Dec. 31, 2019 $ 5,882 950,661 12,081,401 (13,371,669) $ (333,725)

Balance, shares at Dec. 31, 2019 5,881,898 5,881,898

Stock compensation 54,930 $ 54,930

Preferred stock dividends 71,391 (71,391)

Net loss (241,816) (241,816)

Balance at Mar. 31, 2020 $ 5,882 $ 1,022,052 $ 12,064,940 $ (13,613,485) $ (520,611)

Balance, shares at Mar. 31, 2020 5,881,898 5,881,898

X

- Definition
Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 20
-Section 55
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 20
-Section 55
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 35
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899
+ Details

Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Value of stock issued to shareholders as a dividend during the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueStockDividend

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571
+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 51 R14.htm IDEA: XBRL DOCUMENT v3.20.1

Stock-Based Compensation
3 Months Ended

Mar. 31, 2020

Share-based Payment Arrangement [Abstract]

Stock-Based Compensation

Note 8: Stock-Based Compensation

The Company grants stock-based instruments under the 2015 Stock Incentive Plan (“Plan”) for which 1,400,000 shares of the Company’s Common Stock has been reserved. The Plan allows for the issuance of incentive stock options and non-qualified stock options with a maximum contractual term of 10 years. Shares and options that are cancelled are available for reissuance under the Plan. For the three months ended March 31, 2020 and 2019, the Company recorded compensation costs for stock options of $54,930 and $17,278, respectively. Stock options are generally issued with an exercise price at or above the estimated per-share value of the Company’s Common Stock. The Company granted no options during the three months ended March 31, 2020 and 2019.

Management has valued the options at their date of grant utilizing the Black-Scholes option pricing model. As of the issuance of the outstanding options, there was not a public market for the Company’s shares. Accordingly, the Company utilized the value obtained in equity transactions with unrelated parties to estimate the fair value of the Company’s Common Stock on the date of grant. Volatility of the underlying common shares was determined based on the historical volatility for similar companies that are actively traded in the public markets for a term consistent with the expected life of the options. The risk-free interest rate used in the calculations is based on the implied yield available on U.S. Treasury issues with an equivalent term approximating the expected life of the options on the date of the grant. Due to the lack of sufficient historical activity, the expected life of the options was estimated using the formula set forth in Securities and Exchange Commission SAB 107.

The following table summarizes the status of the Company’s aggregate stock options granted:

Number of
Options

Weighted Average Exercise Price

Weighted Average Remaining
Term(Years)

Total Intrinsic Value

Balance, January 1, 2019

566,667

$

2.33

5.95

Granted

640,000

1.54

9.83

Exercised

—

—

—

Cancelled

(125,000

)

3.00

7.00

Balance, December 31, 2019

1,081,667

$

1.74

7.85

Balance, January 1, 2020

1,081,667

$

1.74

7.85

Granted

—

—

—

Exercised

—

—

—

Cancelled

—

—

—

Balance, March 31, 2020

1,081,667

$

1.74

7.60

$

—

Exercisable at March 31, 2020

508,333

$

1.96

5.83

$

177,334

During the three months ended March 31, 2020 and 2019, options for 0 and 83,334 shares vested, respectively. As of March 31, 2020, there was $570,238 of unrecognized compensation cost related to share-based compensation arrangements that will be recognized over the next three years.

X

- Definition
The entire disclosure for share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-URI http://asc.fasb.org/topic&trid=2228938
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 52 R10.htm IDEA: XBRL DOCUMENT v3.20.1

Fair Value Measurements
3 Months Ended

Mar. 31, 2020

Fair Value Disclosures [Abstract]

Fair Value Measurements

Note 4: Fair Value Measurements

The Company complies with the provisions of ASC 820, in measuring fair value and in disclosing fair value measurements at the measurement date. ASC 820 defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements required under other accounting pronouncements. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value measurements also reflect the assumptions market participants would use in pricing an asset or liability based on the best information available. Assumptions include the risks inherent in a particular valuation technique (such as a pricing model) and/or the risks inherent in the inputs to the model.

ASC 820 provides three levels of the fair value hierarchy as described below:

Level 1 Inputs – Quoted prices (unadjusted) in active markets for identical assets or liabilities.

Level 2 Inputs – Observable market-based inputs, other than quoted prices in active markets for identical assets or liabilities.

Level 3 Inputs – Unobservable inputs that are supported by little or no market activity.

When determining the fair value measurements for assets or liabilities required or permitted to be recorded at and/or marked to fair value, the Company considers the principal or most advantageous market in which it would transact and considers assumptions that market participants would use when pricing the asset or liability. When possible, the Company looks to active and observable markets to price identical assets. When identical assets are not traded in active markets, the Company looks to market observable data for similar assets.

The following table presents the Company’s financial assets that were accounted for at fair value on a recurring basis as of March 31, 2020 and December 31, 2019, by level within the fair value hierarchy:

Total

Quoted Prices in Active Markets for Identical Items
(Level 1)

Significant Other Observable Inputs
(Level 2)

Significant Unobservable Inputs
(Level 3)

Balance at December 31, 2019

Investments

$

41,694

$

41,694

$

—

$

—

$

41,694

$

41,694

$

—

$

—

Balance at March 31, 2020

Investments

$

29,694

$

29,694

$

—

$

—

$

29,694

$

29,694

$

—

$

—

For the Company’s Level 1 measures, which represent common stock in publicly traded companies, fair value is based on the last closing trade occurring on, or closest to, the respective period end date. The carrying value of financial instruments, including cash, receivables, accounts payable and accrued expenses, approximates their fair value at March 31, 2020 and December 31, 2019 due to the relatively short-term nature of these instruments.

X

- References
No definition available.
+ Details

Name: us-gaap_FairValueDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258
+ Details

Name: us-gaap_FairValueDisclosuresTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 53 R18.htm IDEA: XBRL DOCUMENT v3.20.1

Liquidity and Going Concern
3 Months Ended

Mar. 31, 2020

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Liquidity and Going Concern
Note 12: Liquidity and Going Concern

Sources of funding to meet prospective cash requirements include the Company’s existing cash balances and investments. As of March 31, 2020 we had $10,653 in our bank accounts and $29,694 of trading securities. On April 17, 2020, the Company received $71,268 in funding from the SBA under their Paycheck Protection Program and we expect that most, if not all of this funding will be forgiven. This will not be enough to pay for our expenses for the year ending December 31, 2020 without any additional revenue from grants or licensing revenue or additional capital infusions. We are marketing our banana genes in 2020 which may lead to revenue but may not be able to market our soybean genes until the research is finished. We have flexibility to reduce operating costs and also to delay research projects. We will require additional capital to complete our projects. These factors create substantial doubt as to our ability to continue as a going concern. The accompanying condensed and consolidated financial statements do not include any adjustments that may result if the Company is unable to continue as a going concern.

X

- References
No definition available.
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 40
-URI http://asc.fasb.org/subtopic&trid=51888271
+ Details

Name: us-gaap_SubstantialDoubtAboutGoingConcernTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 54 R33.htm IDEA: XBRL DOCUMENT v3.20.1

Stockholders' Equity and Warrants (Narrative) (Details) - USD ($)
3 Months Ended

Mar. 31, 2020

May 01, 2020

Dec. 31, 2019

Oct. 19, 2015

Class of Stock [Line Items]

Capital stock, authorized shares 800,000,000

Common stock, authorized shares 780,000,000 780,000,000 780,000,000

Common stock, par value $ 0.001 $ 0.001 $ 0.001

Preferred stock, authorized shares 20,000,000 20,000,000 20,000,000

Preferred stock, par value $ 0.001 $ 0.001 $ .001

Dividends accrued $ 1,022,052

Series A-1 Convertible Preferred Stock [Member]

Class of Stock [Line Items]

Preferred stock, authorized shares 600,000

Preferred stock, par value $ 0.001

Dividend rate 8.00%

Series A-2 Convertible Preferred Stock [Member]

Class of Stock [Line Items]

Dividend rate 8.00%

Series A-2 Convertible Preferred Stock [Member] | Subsequent Event [Member]

Class of Stock [Line Items]

Preferred stock, authorized shares 200,000

Series A-1 Convertible Preferred Stock [Member]

Class of Stock [Line Items]

Preferred stock, authorized shares 600,000 600,000

Preferred stock, par value $ 0.001 $ 0.001

Stated per share value of preferred stock $ 5.25 $ 5.25

Series A-2 Convertible Preferred Stock [Member]

Class of Stock [Line Items]

Preferred stock, authorized shares 200,000 200,000

Preferred stock, par value $ 0.001 $ 0.001

Stated per share value of preferred stock $ 5.25 $ 5.25

X

- Definition
Total number of preferred and common stock authorized.
+ References
No definition available.
+ Details

Name: fnam_CapitalStockSharesAuthorized

Namespace Prefix: fnam_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Stated per share value of preferred stock.
+ References
No definition available.
+ Details

Name: fnam_StatedPerShareValueOfPreferredStock

Namespace Prefix: fnam_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ClassOfStockLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Face amount or stated value per share of common stock.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765
+ Details

Name: us-gaap_DividendsPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The percentage rate used to calculate dividend payments on preferred stock.
+ References
No definition available.
+ Details

Name: us-gaap_PreferredStockDividendRatePercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=fnam_ConvertiblePreferredStockSeriesA2Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=fnam_SeriesA2PreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 55 R37.htm IDEA: XBRL DOCUMENT v3.20.1

Commitments and Contingencies (Details) - USD ($)
3 Months Ended

Mar. 31, 2020

Mar. 31, 2019

Commitments and Contingencies Disclosure [Abstract]

Monthly rent payment $ 2,378

Rent expense 7,134 $ 7,134

Total amount of grant revenue recognized to date 262,400

Total possible future royalties owed 393,600

Accrued royalties

Payments for royalties

X

- Definition
Monthly rent payment.
+ References
No definition available.
+ Details

Name: fnam_MonthlyRentPayment

Namespace Prefix: fnam_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total amount of grant revenue recognized to date.
+ References
No definition available.
+ Details

Name: fnam_TotalAmountOfGrantRevenueRecognizedToDate

Namespace Prefix: fnam_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Total possible future royalties owed.
+ References
No definition available.
+ Details

Name: fnam_TotalPossibleFutureRoyaltiesOwed

Namespace Prefix: fnam_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03.15(a))
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03.15(5))
-URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878
+ Details

Name: us-gaap_AccruedRoyaltiesCurrentAndNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
+ References
No definition available.
+ Details

Name: us-gaap_LeaseAndRentalExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of cash paid for royalties during the current period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585
+ Details

Name: us-gaap_PaymentsForRoyalties

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

Condensed and Consolidated Balance Sheets - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Current assets
Cash	$ 10,653	$ 45,441
Accounts receivable		6,845
Investments	29,694	41,694
Prepaid expenses	15,270	24,183
Total current assets	55,617	118,163
Non-current assets
Property and equipment, net	79,353	88,882
Intangible assets, net	4,034,941	4,035,592
Total non-current assets	4,114,294	4,124,474
Total assets	4,169,911	4,242,637
Current liabilities
Accounts payable and accrued expenses	133,575	19,415
Total current liabilities	133,575	19,415
Long-term liabilities
Deferred tax liability	987,353	987,353
Total liabilities	1,120,928	1,006,768
Commitments and contingencies
Total preferred stock subject to possible redemption	3,569,594	3,569,594
Stockholders' equity
Preferred Stock	1,022,052	950,661
Common Stock, $0.001 par value; 780,000,000 shares authorized, 5,881,898 shares issued and outstanding at March 31, 2020 and December 31, 2019	5,882	5,882
Additional paid-in capital	12,064,940	12,081,401
Accumulated deficit	(13,613,485)	(13,371,669)
Total stockholders' (deficit) equity	(520,611)	(333,725)
Total liabilities and stockholders' (deficit) equity	4,169,911	4,242,637
Series A-1 Convertible Preferred Stock [Member]
Long-term liabilities
Total preferred stock subject to possible redemption	3,029,579	3,029,579
Series A-2 Convertible Preferred Stock [Member]
Long-term liabilities
Total preferred stock subject to possible redemption	$ 540,015	$ 540,015

Business Activity (Details)	3 Months Ended
Business Activity (Details)	Mar. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Percentage of outstanding stock purchased during reverse merger with Fona, Inc.	75.16%

Condensed and Consolidated Statements of Cash Flows - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Cash flows from operating activities:
Net loss	$ (241,816)	$ (200,397)
Adjustments to reconcile net loss to net cash flows from operating activities
Depreciation and amortization	10,180	10,180
Stock-based compensation	54,930	17,278
Unrealized (gain) or loss on investments	12,000	(11,943)
Deferred income taxes
Changes in operating assets and liabilities:
Accounts receivable	6,845	8,073
Prepaid expenses	8,913	(3,644)
Accounts payable and accrued expenses	114,160	56,374
Cash flows from operating activities	(34,788)	(124,079)
Cash flows from investing activities:
Cash flows from investing activities
Cash flows from financing activities:
Proceeds from issuance of preferred stock
Cash flows from financing activities
Net change in cash	(34,788)	(124,079)
Cash, beginning of period	45,441	131,406
Cash, end of period	10,653	7,327
Supplemental cash flow information
Preferred stock dividend accrual	$ 71,391	$ 60,591

Summary of Significant Accounting Policies (Net Loss Per Common Share) (Details) - shares	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive shares excluded from earnings per share calculation	679,923	577,063
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive shares excluded from earnings per share calculation	1,081,667	566,667
Common Stock and Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive shares excluded from earnings per share calculation	110,856	110,884

Summary of Significant Accounting Policies (Policies)	3 Months Ended
Summary of Significant Accounting Policies (Policies)	Mar. 31, 2020
Accounting Policies [Abstract]
Principals of Consolidation	Principals of Consolidation: These condensed and consolidated financial statements include the accounts of Evolutionary Genomics, Inc. and its wholly owned subsidiary. All material intercompany transactions and balances have been eliminated.
Use of Estimates	Use of Estimates: The preparation of condensed and consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed and consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ materially from those estimates.
Cash	Cash: The Company considers all highly liquid investments purchased with an original or remaining maturity of three months or less when purchased to be cash.
Investments	Investments: The Company’s short-term investments are comprised of equity securities and are carried at their fair value based on the quoted market prices of the securities at March 31, 2020 and December 31, 2019. Net realized and unrealized gains and losses on investments are included in net earnings. For purposes of determining realized gains and losses, the cost of securities sold is based on specific identification.
Property and Equipment	Property and Equipment: Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is provided for by the straight-line method over three- to seven-year estimated useful lives of software, furniture and fixtures and equipment. Maintenance and repairs are expensed as incurred; major renewals and betterments that extend the useful lives of property and equipment are capitalized. When property and equipment are sold or retired, the related cost and accumulated depreciation are removed from the accounts and any gain or loss is recognized.
Long-Lived Assets	Long-Lived Assets: The long-lived assets held and used by the Company are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. In the event that facts and circumstances indicate that the cost of any long-lived assets may be impaired, an evaluation of recoverability is performed. An impairment is considered to exist if the total estimated undiscounted cash flows are less than the carrying amount of the asset. An impairment loss is measured and recorded to the extent that the carrying amount of the asset exceeds its estimated fair value. No asset impairment was recorded during the three months ended March 31, 2020 and 2019.
Intangible Assets	Intangible Assets: Intangible assets include acquired research in progress and patents on the Company’s core technology for gene identification. Patents are amortized over their expected useful life of 20 years using the straight-line method. Acquired research in progress is an indefinite-lived intangible asset until the development is complete at which time the useful life of the asset will be assigned. Costs incurred to renew intangible assets are expensed in the period incurred, while costs incurred to extend the lives of patents are capitalized and amortized over the remaining useful life of the asset. Intangible assets held and used by the Company are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. In the event that facts and circumstances indicate that the cost of any intangible assets may be impaired, an evaluation of recoverability is performed. An impairment is considered to exist if the total estimated undiscounted cash flows are less than the carrying amount of the asset. No impairment was recorded during the three months ended March 31, 2020 and 2019. Realization of this asset is dependent upon the successful completion of the Company’s research and development efforts.
Revenue Recognition	Revenue Recognition: In May 2014, the FASB issued new guidance related to revenue recognition, which outlines a comprehensive revenue recognition model and supersedes most current revenue recognition guidance. The new guidance requires a company to recognize revenue as control of goods or services transfers to a customer at an amount that reflects the expected consideration to be received in exchange for those goods or services. It defines a five-step approach for recognizing revenue, which may require a company to use more judgment and make more estimates than under the current guidance. The Company adopted this standard on January 1, 2018 using the modified-retrospective method and it did not have a material impact on the condensed and consolidated financial statements. Grant revenue, which is not within the scope of Topic 606, consists of funding under cost reimbursement programs primarily from federal and non-profit foundation sources for qualified research and development activities performed by us, and as such, are not based on estimates that are susceptible to change. Such amounts are invoiced and recorded as revenue as grant-funded activities are performed.
Income Taxes	Income Taxes: Deferred tax assets and liabilities are recognized for the expected tax consequences of temporary differences between the tax bases of assets and liabilities and their reported amounts. Management regularly assesses the likelihood that deferred tax assets will be recovered from future taxable income, and to the extent management believes that it is more likely than not that a deferred tax asset will not be realized, a valuation allowance is established. When a valuation allowance is established, increased or decreased, an income tax charge or benefit is included in the condensed and consolidated financial statements and net deferred tax assets are adjusted accordingly. As of March 31, 2020 and December 31, 2019, a full valuation allowance has been established on the net deferred tax asset. Under the Income Tax topic of the ASC, in order to recognize an uncertain tax benefit, the taxpayer must be more likely than not of sustaining the position, and the measurement of the benefit is calculated as the largest amount that is more than 50% likely to be realized upon resolution of the benefit. The Company has no accruals for uncertain tax benefits.
Stock-Based Compensation	Stock-Based Compensation: The Company accounts for stock option awards in accordance with ASC 718. The estimated grant-date fair value of stock-based awards is expensed over the requisite service period, which is typically equivalent to the vesting term of the award. The Company’s accounting policy for equity instruments issued to consultants and vendors in exchange for goods and services received follows the provisions of ASC Topic 718. Accordingly, the measurement date for the fair value of the equity instruments issued is determined at the earlier of (i) the date at which a commitment for performance by the consultant or vendor is reached or (ii) the date at which the consultant or vendor’s performance is complete. In the case of equity instruments issued to consultants, the fair value of the equity instrument is recognized over the term of the consulting agreement.
Research and Development	Research and Development: Research and development costs are expensed as incurred. In instances where we enter into agreements with third parties for research and development activities, we may prepay for services at the initiation of the contract. We record the prepayment as a prepaid asset and amortize the asset into research and development expense over the period of time the contracted research and development services are performed.
Net Loss Per Common Share	Net Loss Per Common Share: Basic net (loss) income per common share excludes any dilutive effects of equity instruments. We compute basic net (loss) income per common share using the weighted average number of common shares outstanding during the period. We compute diluted net (loss) income per common share using the weighted average number of common shares and common stock equivalents outstanding during the period. For the three months ended March 31, 2020, common stock equivalents including 679,923 shares of convertible preferred stock, options for 1,081,667 shares of common stock and warrants for 110,856 shares of common stock were excluded because their effect was anti-dilutive. For the three months ended March 31, 2019, common stock equivalents including 577,063 shares of convertible preferred stock, options for 566,667 shares of common stock and warrants for 110,884 shares of common stock were excluded because their effect was anti-dilutive.
Subsequent Events	Subsequent Events: The Company has evaluated all subsequent events through the date of this filing. On April 17, 2020, the Company received $71,268 in funding from the SBA under their Paycheck Protection Program and we expect that most, if not all of this funding will be forgiven.

Intangible Assets (Details) - USD ($)	3 Months Ended
Intangible Assets (Details) - USD ($)	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Finite-Lived Intangible Assets [Line Items]
Intangible assets, accumulated amortization	$ (33,700)		$ (33,049)
Intangible assets, net	4,034,941		4,035,592
Acquired research in progress [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, gross	4,016,596		4,016,596
Additional expected costs to complete research	102,000
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, gross	52,045		$ 52,045
Amortization expense	651	$ 650
Year one	2,602
Year two	2,602
Year three	2,602
Year four	2,602
Year five	2,602
After year five	$ 5,335

Summary of Significant Accounting Policies (Property and Equipment) (Details)	3 Months Ended
	Mar. 31, 2020
Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives of property and equipment	3 years
Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives of property and equipment	7 years

Condensed and Consolidated Statements of Operations - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Income Statement [Abstract]
Grant revenue	$ 12,500	$ 32,366
Operating expenses
Research and development	93,222	131,684
Salaries and benefits	92,430	54,779
General and administrative	56,665	58,254
Total operating expenses	242,317	244,717
Operating (loss)	(229,817)	(212,351)
Other income (expenses):
Investment income	1	11
Unrealized gain or (loss) on investments	(12,000)	11,943
Total other income (expenses)	(11,999)	11,954
Loss before income taxes	(241,816)	(200,397)
Income taxes
Net loss	(241,816)	(200,397)
Preferred stock dividend	(71,391)	(60,591)
Net loss attributable to common stockholders	$ (313,207)	$ (260,988)
Net loss per common share, basic and diluted	$ (0.05)	$ (0.04)
Weighted average common shares outstanding, basic and diluted	5,881,898	5,881,898

Document and Entity Information	3 Months Ended
Document and Entity Information	Mar. 31, 2020 shares
Document And Entity Information [Abstract]
Entity Registrant Name	EVOLUTIONARY GENOMICS, INC.
Entity Central Index Key	0000884363
Document Type	10-Q
Document Period End Date	Mar. 31, 2020
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding	5,881,898
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2020
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Incorporation State Country Name	NV
Entity File Number	000-54129

Condensed and Consolidated Statement of Stockholders' Equity - USD ($)	Common Stock [Member]	Preferred Dividend [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]	Total
Balance at Dec. 31, 2018	$ 5,882	$ 681,282	$ 12,294,952	$ (12,578,529)	$ 403,587
Balance, shares at Dec. 31, 2018	5,881,898
Stock compensation			17,278		17,278
Preferred stock dividends		60,591	(60,591)
Net loss				(200,397)	(200,397)
Balance at Mar. 31, 2019	$ 5,882	741,873	12,251,639	(12,778,926)	220,468
Balance, shares at Mar. 31, 2019	5,881,898
Balance at Dec. 31, 2019	$ 5,882	950,661	12,081,401	(13,371,669)	$ (333,725)
Balance, shares at Dec. 31, 2019	5,881,898				5,881,898
Stock compensation			54,930		$ 54,930
Preferred stock dividends		71,391	(71,391)
Net loss				(241,816)	(241,816)
Balance at Mar. 31, 2020	$ 5,882	$ 1,022,052	$ 12,064,940	$ (13,613,485)	$ (520,611)
Balance, shares at Mar. 31, 2020	5,881,898				5,881,898

Stockholders' Equity and Warrants (Narrative) (Details) - USD ($)	3 Months Ended
	Mar. 31, 2020	May 01, 2020	Dec. 31, 2019	Oct. 19, 2015
Class of Stock [Line Items]
Capital stock, authorized shares				800,000,000
Common stock, authorized shares	780,000,000		780,000,000	780,000,000
Common stock, par value	$ 0.001		$ 0.001	$ 0.001
Preferred stock, authorized shares	20,000,000		20,000,000	20,000,000
Preferred stock, par value	$ 0.001		$ 0.001	$ .001
Dividends accrued	$ 1,022,052
Series A-1 Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, authorized shares				600,000
Preferred stock, par value				$ 0.001
Dividend rate	8.00%
Series A-2 Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Dividend rate	8.00%
Series A-2 Convertible Preferred Stock [Member] \| Subsequent Event [Member]
Class of Stock [Line Items]
Preferred stock, authorized shares		200,000
Series A-1 Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, authorized shares	600,000		600,000
Preferred stock, par value	$ 0.001		$ 0.001
Stated per share value of preferred stock	$ 5.25		$ 5.25
Series A-2 Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, authorized shares	200,000		200,000
Preferred stock, par value	$ 0.001		$ 0.001
Stated per share value of preferred stock	$ 5.25		$ 5.25

Commitments and Contingencies (Details) - USD ($)	3 Months Ended
Commitments and Contingencies (Details) - USD ($)	Mar. 31, 2020	Mar. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Monthly rent payment	$ 2,378
Rent expense	7,134	$ 7,134
Total amount of grant revenue recognized to date	262,400
Total possible future royalties owed	393,600
Accrued royalties
Payments for royalties